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Base excision repair (BER) is the major cellular DNA repair pathway that recognises and 
excises damaged DNA bases to help maintain genome stability. Whilst the major enzymes 
and mechanisms co-ordinating BER are well known and established, the process of BER in 
chromatin where DNA is compacted with histones, remains unclear. Using reconstituted 
mononucleosomes containing a site-specific synthetic abasic site (tetrahydrofuran, THF), we 
have previously demonstrated that the DNA damage is less efficiently incised by recombinant 
AP endonuclease 1 (APE1) when the DNA backbone is facing the histone core (THF-IN) 
compared to that orientated away (THF-OUT). However, when utilising HeLa whole cell 
extracts, the difference in incision of THF-IN versus THF-OUT is less pronounced suggesting 
the presence of chromatin remodelling factors that stimulate THF accessibility to APE1. 
Therefore, adopting an unbiased purification scheme involving the separation of proteins in 
HeLa cell extracts by different ion-exchange and size exclusion chromatography columns, a 
chromatin remodelling activity was purified from HeLa cell extracts and was identified as the 
E3 ubiquitin ligase, HECTD1.  
I have subsequently, cloned and purified a truncated form of HECTD1 and demonstrated in 
my established in vitro mononucleosome model that HECTD1 stimulates incision of THF-IN 
by APE1. Furthermore, I also provide evidence that HECTD1 ubiquitylates histones H2B/H3, 
which may stimulate chromatin remodelling. Additionally, I have elucidated that HECTD1 
appears to play a broader role at multiple stages of the BER pathway via demonstration that 
a recombinant truncated form of HECTD1 can stimulate incision by the DNA glycosylase 
NTH1 of occluded thymine glycol sites within mononucleosome substrates (TG-IN) in vitro. 
Furthermore, utilising siRNA-mediated depletion of HECTD1 in alkaline comet assays and 
clonogenic survival assays, I observed deficiencies in DNA damage repair, and decreased cell 
survival following x-ray irradiation, hydrogen peroxide and methyl methanesulfonate 
treatment, particularly in normal fibroblasts versus non-targeting siRNA control-treated 
cells. However, in neutral comet assays, assessing double strand break repair, no difference 
in DNA damage repair between siRNA-mediated depleted HECTD1 versus non-targeting 
siRNA control-treated cells is observed. Thus, I have now identified HECTD1 as a novel and 
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Chapter 1: Introduction 
 
 
1.1 Genome stability and instability 
The cell comprises all living organisms, forming the basic biological, functional and structural 
building blocks of life. Animal cells, enclosed within a phospholipid bilayer membrane, 
consists of an aqueous cytosol called the cytoplasm, providing the environment for housing 
the cells membrane-bound organelles. There are a variety of organelles with a range of 
responsibilities from producing adenosine triphosphate (ATP), for the use and storage of 
energy, hormones and enzymes, all of which are vital for performing all the biological 
functions of that specific cell type.  The majority of organisms are single cells, however, 
others including humans are composed of extensive multicellular systems made up of a 
myriad of specialised groups of cells that communicate through elaborate systems to form 
complex biological systems which preform specialised functions. The human body consists 
of more than 1013 cells, all of which originate from embryonic cells that house all of the 
organisms genetic material [1]. The resulting whole organism is maintained through the 
action of a cascade of countless cell divisions and differentiations.  
Within the nucleus of all living cells the heritable genetic information is stored in the form of 
double stranded biological polymers called deoxyribose nucleic acid (DNA). In human cells, 
the genome is composed of identical copies of DNA that is distributed between 23 pairs of 
chromosomes. Double stranded DNA consists of two complementary linear unbranched 
polynucleotide chains made up of four types of nitrogenous monomers called nucleotides; 
adenine (A), cytosine (C), guanine (G) and thymine (T). These polynucleotide chains are held 
by hydrogen bonding between bases as well as the specific complementary base pairing 
displayed between A pairing with T and C pairing with G. The order in which nucleotides are 
arranged forms a long sequence encoding the cells genetic information. The machinery 
required to read this genetic information as well as successfully duplicate the DNA during 
DNA replication is all contained within the cell.  
A gene is a functional unit of DNA, which encodes all the instructions required to create a 
protein. Humans have around 20-25,000 protein coding genes, which remarkably only 
accounts for 2 % of the human genome. Proteins are made up of long polypeptide chains 
which are built from 20 types of amino acids, the type and order of which is coded for by the 
specific DNA sequence. Within the amino acid sequence, known as the DNA triplet code, 
20 
 
three DNA bases (codon) encode for a specific amino acid. The amino acids are joined 
together by peptide bonds and resulting polypeptide chains are folded into three 
dimensional proteins. With the amino acids providing different properties, interactions and 
functional groups, the amino acid sequence and thus DNA sequence has a huge impact on 
the function of the protein, of which there are a vast array. These include proteins that 
stimulate generation of ATP, cell mobility and structure, inter/intra cellular signal 
transductions and DNA repair. 
Maintaining genome stability is fundamental for cellular survival, function and propagation 
of life. However, genomic variation can be generated from DNA replication infidelity and 
aberrant chromosome segregation. In addition to this, DNA is constantly under attack from 
both endogenous sources, such as reactive oxygen species (ROS) generated through cellular 
oxidation, and exogenous genotoxic agents including, ultraviolet (UV) radiation and ionising 
radiation (IR). Such DNA damaging events can result in changes to the nucleotide sequence, 
called a mutation. In some instances, mutations can be silent and have no significant impact 
on the cell if it falls within a non-coding region of the DNA. However, a mutation within a 
gene can have significant implications leading to alterations in the amino acid sequence of a 
protein. This can cause alterations in the protein structure and therefore its function, 
regulation and/or activity which can have detrimental effects on the cell and ultimately the 
organism. To prevent an accumulation of DNA damage compromising genome integrity and 
having a negative effect on the whole organism, the cell has developed complex systems 
called DNA repair pathways, the number of which and the many different DNA repair 
enzymes involved highlights the importance of DNA repair within a cell. In the vast majority 
of cases, DNA damage is signalled and repaired by the DNA damage response (DDR). 
However, in cases where DNA damage persists, genome instability ensues and which has 
been implicated in many human diseases, including premature ageing, neurodegenerative 
diseases and multiple types of cancer. In fact, genome instability underlies the six definable 
hallmarks of cancer; sustaining proliferative signalling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion 
and metastasis [2]. Furthermore, with 367,000 new cancer cases in the UK every year, 
leading to 165,000 cancer deaths per year (2015-2017) (Cancer Research UK), cancer and the 
DNA damage associated with the development of the disease is a major UK and worldwide 
issue. Additionally, the current gold standard of care is adjuvant chemo and/or radiotherapy, 
which works by inducing extensive DNA damage in cancer cells, thereby acting through DNA 
damage for effective treatment, overwhelming the ability of the cell to repair the DNA, 
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resulting in cell death. Therefore, it is imperative that research into the basic biology of DNA 
repair continues as DNA damage is not only a driver of disease but also vital for its treatment.  
 
1.2 DNA 
DNA is the predominant genetic material, fundamental for all living organisms. The three 
dimensional structure was discovered nearly 70 years ago, where complementary base 
pairing across two polymers emphasised the double-helical structure of DNA [3]. Watson and 
Crick’s molecular explanation built upon the ‘transforming principle’ theory that DNA 
provided the vehicle for the transfer of genetic material [4] and supported the discovery of 
equal A and T and G and C bases in double stranded DNA [5]. Furthermore, the 
complementary nature of DNA proposed in the 1950’s suggested that genetic information 
could be copied, forming the basis of our understanding of genetics and fundamental for the 
heritability of genetic material.  
The structure of DNA comprises of repeating sugar-phosphate components making up the 
fixed backbone of DNA, with bases lying within the DNA helix. Each 2’-deoxyribose is joined 
to its neighbouring pentose sugar by phosphate groups via phosphodiester bonds on the 3’-
hydroxyl residue of the 2’-deoxyribose. As this bonding only occurs in the 5’ to 3’ direction, 
the ends of the sugar-phosphate DNA backbone are easily discernible, a 5’-phosphate at one 
end with a 3’-hydroxyl at the other. The single units of DNA consist of one of the bases; A, T, 
G or C covalently linked to a deoxyribose sugar by a glycosidic bond (shown in red in Figure 
1.1A). This 2’-deoxyribonucleoside is then attached via a phosphodiester bond at the 5’-
position of the pentose sugar (shown in yellow in Figure 1.1A) to form a 
2’deoxyribonucleotide. Of the four bases, two are bulky two ring bases, purines (A and G) 
which pair with the pyrimidines (T and C), which are single ring bases. This complementary 
base pairing by hydrogen bonds (shown by the dashed lines in Figure 1.1B), two between A 
and T and three shared between G and C, join the two DNA polymers, creating double 
stranded DNA. Due to this base pairing, by nature these two DNA polymers are 
complementary but antiparallel to each other. Furthermore, as the two strands possess 




Figure 1.1: The chemical structure of the four DNA bases and an example of nucleotide 
structure 
A Adenosine monophosphate (AMP) molecular structure, as an example of a nucleotide. The 
base, A, is covalently attached by a glycosidic bond (red bond) to a pentose deoxyribose sugar 
(yellow). This 2’-deoxyribonucleoside is linked via a phosphodiester bond (green bond) to a 
phosphate group to form the nucleotide. B The chemical structure of the four DNA 
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nitrogenous bases, T (green), A (blue), G (purple) and C (red). Hydrogen bonds indicated by 
black dashed lines for complementary base pairing between A and T and C and G.  
The sheer number of hydrogen bonds, although much weaker than the covalent bonds which 
connect the structure of the individual nucleotides, provide sufficient stability to maintain 
the DNA double helix. Yet, hydrogen bonds are weak enough for allowing key biological 
processes, such as transcription and translation, essential for the cells survival. Further 
protection to the integrity of the DNA structure is achieved through stacking interactions. 
Firstly, through hydrophobic effects due to the arrangement of non-polar, hydrophobic 
bases in the interior of the helix and the hydrophilic polar DNA backbone. Through this 
hydrophobic effect, the nitrogenous bases are attracted to one another and spaced based 
upon their van der Waals distance. Although these single interactions are very weak, the net 
effect of several van de Waals forces provide considerable stability to DNA. However, the 
nature of the negatively charged phosphate residues within the DNA backbone can make 
DNA unstable. To remedy this, ionic interactions between positively charged, magnesium 
ions, arginine or lysine residues provide further strength and stability to DNA, protecting the 
genetic information and ultimately its heritability.  
DNA must be tightly organised into small volumes so it can fit within the nucleus of the cell.  
Therefore, the compaction of genetic material into chromatin (see section 1.5) is essential 
for the organisation of DNA within the nucleus and involves co-ordinated levels of folding 
amongst histones and non-histone chromosomal proteins. Through reducing the surface 
area of DNA, this arrangement provides protection from endogenous and exogenous sources 
of DNA damage, but also limits free access to the DNA. Via multiple mechanisms, DNA within 
compacted regions is then made accessible to the complex machinery of essential biological 
processes including gene transcription, DNA replication and DNA repair. 
 
1.3 DNA damage 
DNA is under constant attack both endogenously, from normal cellular metabolism and from 
exogenous sources, such as IR. By design the double helix provides a degree of protection, 
but DNA is still susceptible to damage from spontaneous chemical reactions [6]. 
Endogenously DNA is threatened by spontaneous reactions, causing base loses 
(depurinations/depyrimidinations or apurinic/apyrimidinic (AP) site formation) and through 
cellular metabolism generating ROS, reactive nitrogen species and alkylating agents which 
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produce alkylated base damage (e.g. N7-methylguanine (7meG)), oxidised base damage (e.g. 
8-oxoguanine (8-oxoG)), DNA single strand breaks (SSBs) and DNA double strand breaks 
(DSBs). This is exacerbated by damage induced by environmental stresses and toxins (e.g. IR 
and UV), leading to estimates of the total DNA damage as 105 lesions per cell per day [7], [8]. 
If left unrepaired, accumulation of DNA damage can lead to mutations, blocked transcription 
and translation, incomplete DNA replication or segregation of chromosomes leading to 
chromosomal abnormalities and cell cycle delay, arrest or even apoptosis [6]. This resulting 
genomic instability is the hallmark of all forms of cancer [2] and has been implicated in the 
development of neurodegenerative diseases, including; Huntington’s and Alzheimer’s 
disease [9] as well as premature ageing [10].  
 
1.3.1 Endogenous DNA damage 
The majority of DNA damage within a cell is endogenous in origin, mainly due to oxygen and 
water in the cellular environment [11]. Endogenous DNA damage can arise from a range of 
events, including; hydrolysis, exposure to ROS and other reactive metabolites [12]. 
Hydrolysis is the simplest form of endogenous damage DNA is subject to, and occurs when 
the N-glycosidic bond between the DNA base and the 2’-deoxyribose sugar is labile in certain 
conditions, including; heating or the action of N-glycosylases, where, for example, cleavage 
of this glycosidic bond produces AP sites [13]. ROS, a by-product of normal cellular 
metabolism are also a major type of endogenous DNA damaging agents. For example, 
hydroxyl radicals (•OH) can result from a series of chain reactions, the consequence of 
electron leakage from the electron transport chain during mitochondrial respiration [14].  
 
1.3.1.1 Oxidation 
ROS are unavoidably produced through normal cellular physiology, including respiration, 
metabolism, the inflammatory response and phagocytosis. Similarly, ROS may also be 
generated by exogenous sources, such as UV radiation or IR [15], [16]. Types of ROS include 
superoxide (O2•-), hydrogen peroxide (H2O2), ozone (H3), singlet oxygen (1O2) and hydroxyl 
radicals (•OH) [12], [17]. Accumulation of ROS can lead to the development of oxidative 
stress, which occurs when the production of ROS exceeds the body's natural antioxidant 
defence mechanisms, resulting in damage to macromolecules such as DNA, proteins and 
lipids [18], [19]. Damage to DNA, including oxidised bases, SSBs and DSBs, is the most 
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frequently occurring damage by ROS, of which there is a huge potential for. In fact, each 
human cell metabolises 1012 molecules of oxygen per day, with an estimated 1-2 % of the 
oxygen metabolised converted into ROS [20], [21].  
One such source of ROS generation is during mitochondrial respiration where 1-5 % of the 
oxygen undergoes single electron transfer, resulting in O2•- production [22]. Further sources 
of O2•- include, leakage of electrons from NADPH cytochrome P450 reductase in the 
endoplasmic reticulum, as well as being generated as a direct enzymatic by-product of 
xanthine oxidase, NADPH oxidase and cyclooxygenase [23]. O2•- itself has little reactivity but 
is reduced to H2O2 through a rapid dismutation reaction, either spontaneously or by 
superoxide dismutase. Additionally H2O2 is also a by-product of lipid metabolism in 
peroxisomes [24]. The majority of H2O2 is degraded to H2O by glutathione peroxidase and 
catalase. However, in the presence of transition metals such as iron (Fe2+)and copper (Cu2+), 
H2O2 can be reduced to highly reactive •OH via a Fenton reaction (H2O2 + Fe2+ → •OH + OH- 
+ Fe3+) [12], [24]. The •OH have a very short half-life, only diffusing one or two molecular 
diameters before damaging local cellular structures [25], therefore it must be generated in 
close proximity to cause any damage. Thus, it is assumed that H2O2 acts as a latent form of 
the radical which can diffuse to the vicinity of the DNA molecule before reacting with the 
metal ion [26]. The inflammatory response is a further generator of ROS, with immune cells 
such as neutrophils, producing O2•-and H2O2 to be used at sites of infection against the 
bacterial threat. These can subsequently interact to produce •OH via the Haber-Weiss 
reaction (O2•- + H2O2 → O2 + •OH + OH-) [11].  
Following exposure of DNA to ROS, multiple alterations can be induced, including SSBs, DSBs, 
abasic sites and a range of nucleotide modifications [27]. Guanine has the smallest oxidation 
potential (1.29 V), therefore is the most frequently modified base by ROS [28]. Its most 
abundant oxidatively modified base, formed by the hydroxylation in the C8 position of the 
guanine ring by a •OH. is 8-oxoG (Figure 1.2) [29]. Estimates of 8-oxoG steady-state levels 
are of 103 lesions per cell/per day, and it is often used as a measurement of oxidative DNA 
damage [30]. This lesion is highly mutagenic, due to the incorrect incorporation of adenine 
by DNA polymerases during replication, leading to a GC to TA transversion mutations [31]. 
This in turn can give rise to diseases such as cancer [32], where up to 105 8-oxoG lesions per 
cell/per day has been reported [30]. It can also be further oxidised by various ROS to other, 
stable, and sometimes more mutagenic lesions, for example, 8-oxoG reacts with 




Figure 1.2: Molecular structure of 8-Oxoguanine 
Schematic diagram of the formation of 8-oxoG from the oxidation of guanine in the C8 
position of the ring by a •OH.  
Whilst 8-oxoG is the most prevalent oxidative base damage, thymine glycol (Tg) is the most 
abundant form of an oxidised pyrimidine [35]. Tg is generated via a reaction of the 5,6-double 
bond of thymine with •OH, resulting in the addition of hydroxyl groups at the C5 and C6 
positions (Figure 1.3) [36]. The biological implications of Tg sites include potential TA to GC 
transversions, although Tg generally pairs with adenine, it is weakly mutagenic resulting in T 
to C transitions [37]. More importantly, Tg is known to block DNA polymerases, stalling 
replication inferring lethality, but it can also be by-passed by translesion synthesis (TLS), 
leading to possible base misincorporations and again TA to GC transversions [38], [39]. 
Similarly to 8-oxoG, the presence of Tg sites in DNA has been used as a marker for oxidative 







Figure 1.3: Molecular structure of Thymine Glycol 
Schematic diagram of the formation of Tg, generated via a reaction of the 5,6 double bond 
of thymine with •OH and the addition of hydroxyl groups at the C5 and C6 positions. 
 
1.3.1.2 Hydrolysis 
Within DNA the N-glycosidic bond between bases and the deoxyribose sugar is labile under 
certain conditions, including hydrolysis, heating, base alkylation, oxidation and the action of 
N-glycosylases during BER. This results in the separation of the nitrogenous base from the 
phosphodiester backbone, generating an AP site (Figure 1.4) [13], [43], [44]. These reactions 
are often referred to as depurinations, as in DNA purines are lost at a 20 times faster rate 
than pyrimidines [45]. AP sites are among the most frequent endogenous lesions found in 
DNA, with an estimated 10,000 lesions/per cell/per day [7], with 50,000-200,000 AP 
sites/genome found in many human and rodent tissues [46]. If these lesions are by-passed 
by TLS, they can be highly mutagenic as the DNA polymerase would preferentially 
incorporate adenine opposite the AP site, causing G to T or A to T transversions and 
frameshift mutations [11]. These single-base substitutions are found in many oncogenes 
[47], but can also be highly cytotoxic, due to stalled replication and transcription as well as 
to contribute to the formation of DNA strand breaks [48].   
Another common lesion generated by hydrolysis is the hydrolytic deamination of cytosine to 
uridine or 5-methylcytidine to thymidine, which occurs at a rate of 100-500 events per 
cell/per day [7]. Although this is 1/500th  the rate of depurination events, hydrolytic 
deamination do result in mutagenic nucleotide sequence changes [49]. Uracil generated 
from cytosine deamination is rapidly excised by uracil-DNA glycosylase, and the resulting AP 
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site easily repaired. However, the resulting thymidine from the deamination of 5-
methylcytidine forms a GT base pair, which requires correction via the very slow mismatch 
repair system [7]. Consequentially, these transition sites account for a third of the single 
point mutations causing inherited diseases in humans [50], and is frequently present at CpG 
sites in a variety of cancer-associated genes, including the p53 tumour suppressor gene [51], 
[52].  
 
Figure 1.4: Apurinic/apyrimidinic site in DNA 
Schematic diagram shows an AP site in DNA with the colours showing the bases and DNA 
backbone in black. The AP site is shown where there is no base due to separation of the 
nitrogenous base from the phosphodiester backbone. 
 
1.3.1.3 Errors from DNA processing 
The importance of the fidelity of cellular DNA polymerases is evidenced by the mutator 
phenotype, resulting from mutations in these enzymes [53]. The error rate in vitro has been 
demonstrated to range from 2x10-4 for DNA polymerase β involved in base damage repair, 
to 1x10-7 for DNA polymerases δ and ε associated with DNA replication [54]–[56]. The vast 
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majority of mispaired bases overlooked by DNA polymerase proof-reading are repaired by 
the DNA mismatch repair system [57]. However, in some cases mutations do occur. Factors 
which contribute to increased mutation frequencies include, the sequence context of DNA 
with repetitive segments having the potential to form secondary DNA structures, and stalling 
replication leading to increased nucleotide misincorporation, as demonstrated with the 
d(CGG)n nucleotide repeats associated with fragile X syndrome [58]. Accuracy of base 
incorporation is also dependent on a balanced pool of nucleotides, with alterations in the 
relative concentrations being shown to increase spontaneous mutation rates in cells [11]. 
Errors can also arise during the DNA repair process, in particular the repair of DNA DSBs, 
which have a high mutagenic potential due do both complimentary strands being 
compromised. Non-homologous end joining in particular is known to be error prone, 
resulting in base changes proximal to the DSB, whereas homologous recombination which is 
thought to be error free, has been shown to highly mutagenic, particularly when DSBs are 
clustered [59] or large sections of DNA needs to be synthesised [60]. This inaccurate repair 
of DSBs gives rise to a vast array of genetic diversity found in cancers, such as chromosomal 
rearrangements and translocations, point mutations and copy number variations [61]–[63].  
 
1.3.2 Exogenous DNA damage 
Exogenous damage to DNA is a result of the action of environmental sources, which can be 
physical or chemical in nature. Exogenous agents include UV and IR, physical genotoxins 
which occur naturally from the sun and cosmic irradiation, as well as artificial sources, in the 
case of medical irradiation. Chemical sources, such as alkylating agents found in diesel 
pollutants also cause exogenous DNA damage, including SSBs (Figure 1.5A), DSBs (Figure 




Figure 1.5 DNA strand breaks 
Schematic diagram of the formation of DNA strand breaks with the colours showing the 
bases and DNA backbone in black. A DNA SSB is a break in one side of phosphodiester 
backbone B DNA DSB is a break in opposite sites of phosphodiester backbone.  
 
1.3.2.1 Alkylation 
Alkylation is a process when alkylating agents transfer an alkyl group to the DNA, modifying 
the structure and therefore disrupting its function. Alkylating agents are ubiquitous, 
therefore human exposure is inevitable. They arise endogenously during metabolism, and 
exogenously in air, food, water, tobacco smoke and fuel pollutants. Furthermore, alkylating 
drugs are commonly used as a cancer treatment, thereby these patients are exposed to high 
doses of alkylating agents [44]. All the nitrogen sites within DNA bases (Figure 1.1) and the 
oxygen atoms in the base as well as the phosphodiester bonds are subject to alkylation. In 
general, the effects of base alkylation are genotoxic and cytotoxic, with O-alkylation being 
highly genotoxic and mutagenic and N-alkylation more cytotoxic [64]–[66].  Alkylating agents 
may be monofunctional (one chemical moiety) or bifunctional (two chemical moieties) and 
fall into two groups based upon their reactivity. SN1-type (e.g. N-methyl-N-nitrosourea 
(MNU)) agents target both oxygens and nitrogens, whereas the SN2 type (e.g. methyl 
methanesulfonate (MMS)) alkylate nitrogens [67], [68].  
The types of DNA damage generated by alkylating agents can be primary products, 
methylations for example, or secondary damage through abasic sites, strand breaks and 
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interstrand crosslinks (ICLs) [44]. The most well defined endogenous source, S-
adenosylmethionine (SAM), donates a methyl group in most enzymatic transmethylation 
reactions but can also non-enzymatically methylate DNA [7], [69], [70]. Primary products can 
also arise from exposure to exogenous agents, such as the highly carcinogenic, tobacco-
specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [71]. These 
agents give rise to methylated bases including N7-methylguanine (7meG) and O6-
methylguanine (O6meG) (Figure 1.6) [44], [72]. 7meG is the most common methylated base 
(75 %) being produced at a rate of 4000 residues/human genome/day [68], [70], yet is not 
mutagenic due to maintained coding specificity. However, it is susceptible to depurination, 
forming mutagenic AP sites [73]. O6meG lesions, although much less common (10-30 per cell 
per day), are prone to mismatch with thymine by MMR, resulting in mutagenic effects 
including cytotoxic DSBs [12], [44], [69]. This resulting cytotoxic effect is one reason 
monofunctional alkylating agents, such as MMS and temozolomide, are attractive options as 
anti-cancer drugs [74]. Additionally, bifunctional agents, chlorambucil or carmustine for 
example, are also commonly used in treating cancer, as these give rise to complex lesions, 




Figure 1.6: Molecular structure of N7-methylguanine and O6-methylguanine 
Schematic diagram of the formation of the alkylated base 7meG and O6meG from guanine 
due to the transfer of a methyl group.  
 
1.3.2.2 Ionising Radiation 
IR is an exogenous source of DNA damage which has both natural (cosmic and gamma 
radiation) and artificial (medical X-ray/radiotherapy) origins. IR passes through material, such 
as cells, along a radiation track in which energy is deposited resulting in damage to 
biomolecules [8]. DNA is damaged in one of two ways, directly by 1-electron oxidation 
generating oxidative base lesions, of which 70 types of radiation-induced lesions have been 
characterised [75], or indirectly via water radiolysis radicals, resulting in the formation of 
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DNA base damage, abasic sites, DNA strand breaks and complex/clustered DNA damage 
(CDD) [8], [76], [77]. The most abundant lesions generated by IR are DNA base damage, 
abasic sites and DNA SSBs, with 1 Gy γ-radiation estimated to induce approximately 850 
pyrimidine (e.g. Tg sites), 450 purine lesions (e.g. 8-oxoG) and 1000 DNA SSBs per cell. In 
contrast, only 20-40 DNA DSBs per cell are induced [78].  
DNA DSBs, a break in both strands of the DNA phosphodiester backbone (Figure 1.5B), 
separated by 10 bp or less [79], are the most harmful lesion produced by IR, leading to 
apoptosis if not repaired. As well as being cytotoxic they are highly mutagenic if improperly 
repaired, leading to genomic instability via chromosomal rearrangements, insertions or 
deletions [77]. In addition to DSBs, CDD is also a major contributor to the cell killing effect of 
IR. Non-DSB CDD is defined as two or more lesions induced in close proximity (within 1 to 2 
helical turns of the DNA), which arises due to the spatial deposition of energy along highly 
structured radiation tracks [80]. Furthermore the incidence complexity of non-DSB CDD 
increases with the radiation ionisation density, estimated from 30 % for low linear energy 
transfer (LET) IR up to 90 % for high-LET α-particles (α-IR) [81]–[84]. The base excision repair 
(BER) pathway is responsible for the majority of the repair of non-DSB CDD, but at a reduced 
efficiency [85], the extent of which is determined by the complexity, type, separation and 
orientation of the lesions [77]. This results in a reported persistence of CDD in cells and 
tissues several hours post-IR and an associated cell killing effect [80], [86], [87]. 
 
1.3.2.3 Ultraviolet Radiation 
UV radiation, due to solar exposure, is an unavoidable source of exogenous DNA damage, 
with a day of sun exposure inducing up to 105 UV photoproducts per exposed skin cell [6]. 
The UV spectrum is characterised according to wavelength, UVA (315-400 nm), UVB (280-
315 nm) and UVC (100-280 nm). UVC is fortunately absorbed by the Earth’s atmosphere, 
thereby is a negligible source of DNA damage [88]. However, UVA and UVB exposure, either 
from the sun or artificial sources (e.g. sun beds) are the most important etiological factor 
associated with the development of skin cancer [89], and the International Agency for the 
Research on Cancer has classified both UVA and UVB as a Class I carcinogen [90].   
UV radiation induces DNA damage by providing the energy to modify the covalent bonds 
between pyrimidine residues. UVB induced mutations are well understood and can be 
accounted by two major DNA lesions, both with atypical covalent bonds between 
pyrimidines. Cyclobutane pyrimidine dimer (CPD), accounting for 75 % of UV photoproducts 
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and the pyrimidine-(6-4)-pyrimidone photoproduct (6-4 PP) the remaining 25 % [91]–[94]. 
These bulky DNA adducts distort the DNA helix by 7-9o for CPDs and 44o for 6-4 PP lesions, 
interfering with transcription and replication, therefore compromising genomic integrity 
[93], [95]. Furthermore, the mutagenic potential of these lesions is highlighted in the high 
incidence of C-T and CC-TT transition mutations at dipyrimidine sequences within unrepaired 
UVB lesions [91], referred to as ‘UV-signature mutations’ in skin cancer [96], [97].  
In contrast, UVA is poorly absorbed by DNA, therefore damages DNA through indirect 
mechanisms of action [98], [99]. It is through absorption by chromophores that UVA exerts 
its DNA damaging effects, and these so-called photosensitizers are involved in 
photoreactions to generate ROS, such as, O2•-, H2O2, 1O2 and •OH. This can result in oxidative 
DNA damage, including base oxidation (8-oxoG and Tg), AP site and SSB formation [75], [98]. 
Furthermore, UVA is known to be a source of CPDs, in particular TT-CPDs, formed via a 
photosensitized triplet energy transfer mechanism [100].  
 
1.4 DNA repair 
Maintenance of genomic integrity and stability is integral for the survival of an organism, 
essential for ensuring proper cellular function, and for the successful replication and passage 
of genetic material to progeny. Conversely, the role of accumulated DNA damage, induced 
via endogenous and exogenous sources, compromises genomic integrity and has been well 
documented to be heavily implicated in human disease development, including cancer, 
neurodegenerative diseases and premature ageing [2], [9], [10]. Fortunately, cells possess a 
high fidelity system consisting of a complexity of damage sensors, DNA repair pathways, cell 
cycle checkpoints and damage tolerance mechanisms. This system, collectively known as the 
DNA damage response consists of ∼450 genes [101], encoding for a vast number of 
pathways and proteins, indicative of the range of DNA damaging genotoxic events the cell is 
subject too. The four major DNA repair pathways, double strand break (DSB) repair, 
nucleotide excision repair (NER), mismatch repair (MMR) and base excision repair (BER) have 
evolved to recognise and repair specific types of DNA damage and restore DNA to its 




1.4.1 Double Strand Break Repair 
DSBs are considered the most cytotoxic form of DNA damage, arising from both endogenous 
(e.g. ROS) and exogenous (e.g. IR) sources. The repair of DSBs is imperative for cellular 
survival as they can result in cell death, or genomic rearrangements, such as insertions, 
deletions and chromosomal translocations, which are a primary initiation step in the 
development of many cancers [102]. Conversely, generation of DSBs are also key for certain 
biological processes, such as increasing genetic diversity during meiosis and in the 
diversification of the antigen receptors and immunoglobulins of immune cells via the breaks 
which occur during the process of V(D)J recombination and immunoglobulin heavy chain 
(IgH) class switch recombination [103], [104]. Whether detrimental or biologically vital, DSBs 
nevertheless require efficient processing and repair to avoid induction of major 
chromosomal aberrations. Two major types of DSB repair pathways have been identified, 
non-homologous end joining (NHEJ) and homologous recombination (HR).  
 
1.4.1.1 Non-Homologous End Joining 
NHEJ is the predominant method for the repair of DSBs throughout the cell cycle, repairing 
nearly all DSBs outside of the S and G2 phase of the cell cycle and around 80 % of DSBs which 
are not proximal to a replication fork within these phases [105]. NHEJ is not restricted within 
the cell cycle, as it does not require a template for repair. However, this renders the pathway 
error prone due to the repair mechanism reattaching DNA with no regard for homology and 
modifying break sites with insertions/deletions (indels), linking NHEJ to mutations and 
chromosomal aberrations [102].  
The process of classical NHEJ is divided into three main stages, firstly DSB recognition, 
followed by the processing of non-ligatable DNA ends and finally the joining of suitable DSBs 
(Figure 1.7). Additionally, and of note, NHEJ can directly religate broken DNA ends without 
the need for DNA end resection to initiate repair. Within NHEJ, repair is initiated by 
recognition and binding of the DSB by the Ku70/80 heterodimer, which encircles the DNA 
duplex, structurally supporting broken DNA ends. This also acts as a scaffold for the assembly 
of other NHEJ proteins and recruitment of the DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs) forming the DNA-PK holoenzyme [106]. Activated DNA-PKcs acts as a 
major regulator within NHEJ [107], one such role is through activation of the endonuclease 
activity of Artemis at DNA ends, resulting in the endonucleolytic removal of 5′ and 3′ DNA 
overhangs, to facilitate ligation of the DNA ends by the XRCC4–DNA ligase IV complex [108], 
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[109]. Additional proteins such as, polynucleotide kinase/phosphatase (PNKP) [110] and 
MRE11-RAD50-NBS1 (MRN complex) [111] may also be recruited by DNA-PKcs to further 
process the DNA ends if they are not able to be directly ligated. Following DSB end 
processing, nucleotide addition can occur by the Pol X family polymerases, Pol μ and Pol λ, 
before ligation by DNA ligase IV in complex with XRCC4, XLF, and sometimes PAXX to resolve 
the strand break [112]. In addition to this pathway, a further mode of DSB repair is via 
alternative NHEJ, a poly(ADP-ribose) polymerase (PARP)-dependent sub pathway of NHEJ 
which involves MRN DNA end resection, followed by PARP-1 binding to DNA ends, and 
completion of repair by X-ray repair cross-complementing protein 1-DNA ligase IIIα (XRCC1-





Figure 1.7: Schematic of the non-homologous end joining pathway 
The DSB is recognised by the Ku 70/80 heterodimer encircling the DNA duplex as a scaffold. 
DNA-PKcs is recruited forming the DNA-PK holoenzyme, which acts as a major regulator in 
NHEJ. DNA ends are processed by Artemis, PNKP and the MRN complex. Nucleotide addition 
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can then occur by the Pol X family polymerases and the strand break resolved by ligase 
IV/XRCC4/XLF/PAXX. Adapted from [113], [114].  
 
1.4.1.2 Homologous Recombination 
In contrast to NHEJ, HR requires a homologous sequence, usually the sister chromatid as a 
template for repair [115]. This restricts HR to the S and G2 phases of the cell cycle, where the 
sister chromatid is available, but which allows for the restoration of any missing genetic 
material, proximal to the DSB, resulting in a largely accurate repair system [116].  
DNA end resection initiates HR (Figure 1.8) and is catalysed by the recruitment and binding 
of the MRE11-RAD50-NBS1 (MRN) complex to the DSB. The resection of the 5’-terminated 
end through the 3’-5’-exonuclease activity is achieved through the action of the MRE11 
subunit in combination with CtIP (carboxy-terminal binding protein (CtBP)- interacting 
protein) and generates a 3’-ssDNA overhang [117], [118]. In some instances, long range 
resection enzymes such as exonuclease 1 (EXO1) or DNA2 are required to catalyze 
bidirectional resection in the 5′-3′ direction, away from the DNA end, generating extended 
ssDNA overhangs [119], [120]. The 3’ ssDNA overhang is initially coated by replication protein 
A (RPA), which functions protectively to prevent the self-annealing of ssDNA. RPA is then 
replaced by RAD51 to form a nucleoprotein filament or presynaptic filament. Formation of 
the nucleoprotein filament triggers homology search, template pairing and strand invasion 
[121]. All these steps are positively and negatively mediated by several recombination 
regulators (breast cancer gene 1  and 2 (BRCA1 and BRCA2) and RAD51 paralogs), which often 
promote recombination within the proper context via direct interaction with RAD51 [122]–
[124].  Although the exact mechanism of homology searching is unknown, it is thought that 
the presynaptic filament locates homology by randomly probing the genome with multiple 
temporary contacts, and that when a region of 7 nucleotides of homology is located, strand 
invasion occurs [125], [126]. Following strand invasion, a displacement loop (D-loop) is 
generated due to the invasion of the presynaptic filament into the homologous donor 
template. The 3’-ssDNA strand within the D-loop is then used to prime DNA synthesis, using 
the invaded strand as a template, DNA synthesis occurs down the length of the paired duplex 
and thus repairs the broken DNA [127]. The majority of DNA synthesis during HR is catalysed 
by DNA polymerase δ and polymerase ε [128]–[130], although translesion polymerases have 
been implicated in this role [131], [132]. The repair process can then be completed by one 
of two recombination sub-pathways, synthesis-dependent strand annealing (SDSA) or DSB 
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repair (DSBR). In SDSA, the invading strand is separated from the undamaged template DNA 
and anneals to the end of the DNA break. Repair is completed by DNA synthesis and ligation, 
generating non-crossover intact DNA [115], [127]. During DSBR, both 3’-ssDNA overhangs 
are paired with the template DNA and the D-loop is processed into double Holliday junctions. 
These are then processed via cleavage and ligation into crossover or non-crossover restored 





Figure 1.8: Schematic of the Homologous Recombination pathway 
HR is initiated via the recruitment of the MRN complex to the DNA ends which catalyses DNA 
end resection, generating 3’ ssDNA overhangs which are coated with RPA. RPA is then 
replaced by RAD51 to form a nucleoprotein filament, triggering homology search, template 
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pairing and strand invasion. Following strand invasion, a D-loop is generated and the 3’-
ssDNA strand is used to prime DNA synthesis, using the invaded strand as a template. The 
repair process is then completed via the DSBR pathway (left arm) or the SDSA pathway (right 
arm). In SDSA, the invading strand is separated from the undamaged template DNA and 
anneals to the end of the DNA break. Repair is completed by DNA synthesis and ligation, 
generating non-crossover intact DNA. During DSBR, both 3’-ssDNA overhangs are paired with 
the template DNA and the D-loop is processed into double Holliday junctions. These are then 
processed via cleavage and ligation into crossover or non-crossover restored DNA. Adapted 
from [134], [135]. 
 
 
1.4.2 Nucleotide excision repair 
NER has a wide ranging specificity, processing various helix-distorting DNA lesions. These 
include 6-4PPs and CPDs which form upon exposure to UV radiation, and many bulky DNA 
adducts induced by mutagenic environmental chemicals or cytotoxic drugs such as cisplatin 
[136]. In humans, hereditary defects in NER have been implicated in several diseases 
including xeroderma pigmentosum (XP) [137], where extreme sensitivity to sunlight is seen 
with a 1000-fold increase in the risk of developing skin cancer, and the UV sensitivity disorder 
Cockayne syndrome associated with premature ageing [138]. There are two distinct sub-
pathways of DNA damage detection in NER, global genome NER (GG-NER) and transcription 
coupled NER (TC-NER).  GG-NER, as the name suggests, detects and remove lesions 
throughout the genome, whereas TC-NER detects the blockage of transcription elongation, 




Figure 1.9: Schematic of the NER pathway  
Shown is the two sub-pathways of NER; GG-NER (left arm) and TC-NER (right arm). GG-NER 
is initiated via lesion recognition and binding by the XPC-RAD23B-CETN2 and UV-DDB 
complex. TC-NER is initiated by translocation of stalled RNAPII by CSA and CSB. Following 
lesion recognition, TFIIH and the DNA helicases XPB and XPD unwind the DNA around the 
lesion. RPA then coats and protects the ssDNA, and XPF-ERCC1 and XPG incise the backbone 
removing the damaged DNA. PCNA is the loaded onto the DNA directing the recruitment of 
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replicative polymerases and DNA ligase to fill and seal the gap, completing repair. Adapted 
from [139]. 
 
1.4.2.1 Global Genomic NER 
GG-NER (Figure 1.9, left arm) is initiated by DNA damage sensing by the GG-NER specific 
factor xeroderma pigmentosum complementation group C (XPC) in complex with UV excision 
repair protein RAD23 homolog B (RAD23B) and centrin 2 (CETN2), which provides 
stabilisation. This complex scans the DNA for helical distortions, binding to ssDNA which has 
developed due to thermodynamic destabilisation of the DNA by the lesion [140], [141]. 
Following this initial recognition, a lesion verification step follows where at the junction 
between the ssDNA and dsDNA (created by the lesion), the C-terminal double β-hairpin 
domain of XPC-RAD23B is inserted [142] and it is this non-specific binding which explains the 
broad range of damage targeted by GG-NEC [143]. In certain cases, as with UV-radiation-
induced CPDs which only produce mild helical destabilisation, the XPC complex cannot 
initiate repair [144], [145]. Therefore, the UV radiation-DNA damage-binding protein (UV-
DDB) complex is required. This comprises of the DNA damage-binding protein 1 (DDB1) and 
2 (DDB2) which recruit and form a larger complex with the Cullin-RING ubiquitin ligase (CRL) 
containing cullin 4A (CUL4a) and regulator of cullins 1 (ROC1). DDB2 binds to the DNA 
damage, UV-DDB complex kinks the DNA and ROC1 ubiquitylates XPC facilitating its DNA 
binding [146]–[148]. Following recognition of the lesion by XPC, the ten protein subunit 
transcription initiation and repair factor, transcription initiation factor IIH (TFIIH), is recruited 
[149]. Within TFIIH the two DNA helicases, XPB and XPD, which have opposing polarities, 
unwind the DNA around the lesion [150]. The lesion is then excised by two endonucleases, 
XPF-ERCC1, 5’ to the lesion and XPG, 3’ to the lesion, resulting in a ∼30 nucleotide single 
strand gap. Facilitating this process is XPA which coordinates accurate incision, and RPA 
which coats and protects the ssDNA [151]. Finally, DNA gap filling synthesis and ligation is 
directed by the replication proteins proliferating cell nuclear antigen (PCNA), replication 
factor C (RFC), replicative polymerases DNA Pol δ, DNA Pol ɛ or DNA Pol κ, and DNA ligase I 




1.4.2.2 Transcription coupled NER 
Despite the activity of UV-DDB within GG-NER, the processing of lesions, such as CPDs, is 
often of poor quality and can lead to replication stalling. To avoid negative outcomes 
associated with this, including generation of DSBs or triggering of cell death [154], the TC-
NER pathway has evolved to selectively repair transcription blocking lesions [155]. TC-NER 
(Figure 1.9, right arm) is indirectly initiated due to lesion stalling of RNA polymerase II 
(RNAPII) during transcription elongation, which recruits Cockayne syndrome proteins A (CSA) 
and B (CSB), triggering translocation of RNAPII and further assembly of the TC-NER machinery 
[156]. This includes binding of specific TC-NER factors such as, UV stimulated scaffold protein 
A (UVSSA) and ubiquitin specific processing protease 7 (USP7) which act to stabilise CSB 
[157]. Following this recognition step, it is thought that the stalling of transcript elongation 
induces lesions recognised by the GG-NER sub-pathway and repair proceeds with the same 
steps as GG-NER, starting with the binding of TFIIH [139]. 
 
 
1.4.3 DNA Mismatch Repair 
MMR processes nucleotide misincorporation during DNA synthesis or mismatches with the 
DNA helix, which risk becoming fixed as mutations following DNA replication [158]. The 
pathway also acts to prevent mutations arising due to the natural error rate of replicative 
polymerases [159] and errors associated with strand slippage or unusual secondary DNA 
structures within repetitive sequences [160], [161]. The biological implications of inactive 
MMR is a 1000-fold elevation in spontaneous mutation rate [162], which has been implicated 
in human cancer development, including being a known cause of hereditary non-polyposis 
colon cancer (HNPCC) [163], [164]. MMR has been most extensively characterised in 
Escherichia coli (E. coli), however the pathway is evolutionarily conserved from prokaryotes 
to eukaryotes and substantial information is now available on the yeast and human systems 
[165]. In eukaryotes, MMR is initiated by mismatch recognition by the heterodimers MutSα 
or MutSβ. MutSα repairs mismatched base pairs and short indel loops of 1-2 bp, whereas 
MutSβ repairs longer indels of 1-15 bp. Utilising ATP, MutSα and MutSβ act as sliding clamps 
to search for mismatches, once located and bound, MutLα is recruited. The endonuclease 
activity of MutLα, coupled with the activity of PCNA and EXO1, removes the mismatch 
containing stretch of DNA. RPA provides protection to the ssDNA whilst gap filling by 
replicative polymerases completes repair [166]. 
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1.4.4 Base Excision Repair 
Base excision repair (BER), a sophisticated cellular mechanism first reported in the 1970s by 
Thomas Lindahl, detects small, non-helical distorting lesions [167]. Sites of DNA damage 
processed by BER include SSBs, apurinic/apyrimidinic (AP) sites, alkylated and oxidised DNA 
bases, which are generated at a rate of over 10,000 DNA base lesions and SSB per cell per 
day. This is largely as a result of DNA hydrolysis, cellular oxidation and environmental factors, 
such as IR [7]. If left unrepaired, accumulation of these types of DNA damage compromises 
genomic integrity and have been implicated in human disease development, including 
premature ageing, neurodegenerative diseases and several cancers. The BER pathway is 
highly conserved from prokaryotes to eukaryotes, with functional homologs existing 
between bacteria, yeast and humans [168]. The pathway can be broadly divided into four 
distinct steps; DNA base damage excision, AP site incision, DNA end processing and DNA 
ligation. Following BER initiation, subsequent repair can follow one of two sub pathways, 
short patch repair (Figure 1.10, central branch), the dominant pathway where a single 
nucleotide gap is created and filled, or the lesser utilised long patch repair (Figure 1.10, right 




Figure 1.10: Schematic of the BER pathway 
A damage-specific DNA glycosylase initially detects the lesion in the DNA and excises the 
damaged base through catalysing the cleavage of the N-glycosidic bond, leaving an AP site, 
which recruits both APE1 and PARP1. APE1 cleaves the AP site, yielding a 3’-hydroxyl group 
adjacent to a 5’-deoxyribosephosphate (dRP) which is removed by Pol β that simultaneously 
fills in the gap with a new nucleotide (central branch). Alternatively, if BER is initiated by the 
NEIL DNA glycosylases (left branch), a single nucleotide gap containing 3’- and 5’-phosphate 
ends is created via β,δ- elimination. The 3’-phosphate is subsequently removed by PNKP prior 
to the activity of Pol β that fills in the gap. In short-patch BER, the nick in the phosphodiester 
backbone enhances PARP1 poly (ADP-ribosyl)ation activity allowing for the recruitment of 
XRCC1-Lig IIIα, which seals the nick and completes repair. If there is resistance of the 5’-dRP 
moiety to Pol β dRP lyase activity, long-patch BER (right branch) is initiated in which there is 
a polymerase switch to Pol δ/ε which adds 2-8 more nucleotides into the single nucleotide 
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gap, creating a 5’-flap which is excised by FEN-1. The remaining nick is then repaired by Lig I 
in association with PCNA to complete the BER process. Taken from [170].   
 
1.4.4.1 DNA base damage excision 
The DNA base damage is recognised by a DNA glycosylase, of which 11 damage-specific 
enzymes (Table 1.1) exist that detect and excise the damaged base [171], [172]. These 
enzymes utilise a ‘base flipping’ mechanism whereby the damaged base is flipped 180 
degrees from the sugar phosphate backbone, breaking the hydrogen bonds between the 
bases, and which then places the damaged base in the active site of the DNA glycosylase for 
excision. Yet, within the glycosylases there are two different types, monofunctional and 
bifunctional, that contrast in terms of their activities. 
The monofunctional DNA glycosylases (uracil DNA glycosylase [UNG], single-strand-selective 
monofunctional uracil DNA glycosylase [SMUG1], thymine DNA glycosylase [TDG], N-
methylpurine DNA glycosylase [MPG], methyl-CpG binding domain protein 4 [MBD4] and 
MutY homologue [MUTYH]) only possess DNA glycosylase activity and will therefore only 
remove the damaged base by severing the N-glycosidic bond. This yields an AP site which 
recruits AP endonuclease 1 (APE1) whose activity incises the DNA backbone, forming a 3’-
hydroxyl group adjacent to a 5’-deoxyribosephosphate (dRP) moiety [173], [174]. 
Whereas the bifunctional DNA glycosylases (8-oxoguanine DNA glycosylase 1 [OGG1], 
endonuclease III-like protein 1 [NTH1] and endonuclease VIII-like proteins 1, 2 and 3 [NEIL1, 
NEIL2 and NEIL3]) in addition to their DNA base excision activity are also able to cleave the 
DNA backbone. The activity of the DNA glycosylases OGG1 and NTH1 form a resulting single 
nucleotide gap with flanking 5’-phosphate and 3’-α,β-unsaturated aldehyde (PUA) ends (β 
elimination). Similar to the monofunctional DNA glycosylases, this action is followed by 
cleavage of the 3’-aldehyde residue by APE1 generating the same 3’-hydroxyl end. However, 
due the cellular abundance of APE1 and relatively low activities of these bifunctional 
glycosylases, it is generally thought that APE1 circumvents this step and directly cleaves the 
AP site itself [175]. Alternatively, bifunctional DNA glycosylase action by the NEIL DNA 
glycosylases creates a single nucleotide gap with a flanking 5’-phosphate and 3’-phosphate 
ends (β,δ-elimination). The 3’-phosphate moiety requires removal by polynucleotide kinase 
phosphatase (PNKP), as the lesion is incompatible for DNA polymerase β (Pol β) activity 
(Figure 1.10, left branch) [176]. Irrespective of these different branches of the BER pathway, 
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a single nucleotide gap with a 3’-hydroxyl end, which acts as a substrate for a DNA 
polymerase is produced. 
Table 1.1: The human DNA glycosylases. Adapted from [177].  
Name Abbreviation Classes  Major type of DNA 











III-like 1  




Oxidative damage to 
pyrimidines, including 




VIII-like 1  





with preference for 
pyrimidines 
Endonuclease 
VIII-like 2  







VIII-like 3  









protein 4  




MYH HhH DNA 
glycosylases 
Monofunctional Mispaired adenine 
N-methylpurine 















TDG UNGs Monofunctional Thymine or uracil from 




UNG UNGs Monofunctional Uracil residues 
 
 
1.4.4.2 AP site incision  
In the initial step of BER, DNA glycosylase mediated reactions often generate an AP site, 
which is recognised and cleaved by APE1 on the 5’-side, producing a SSB with a 3’-hydroxyl 
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group and 5′-dRP termini [178]. Structurally, APE1 consists of a flexible N-terminal domain 
and a rigid globular C-terminal nuclease domain, the latter of which provides APE1 with its 
DNA binding and backbone cleavage activity [179], [180]. The nuclease domain binds APE1 
to DNA and allows for AP site searching by sliding along the strand via interactions with the 
DNA phosphate backbone [181]. The AP site is identified via substrate specificity provided by 
the active site, APE1 kinks the DNA forcing the AP site into a ‘flipped out’ position within the 
active site [180], and cleaves the DNA phosphodiester bond through a catalysed acid-base 
reaction which is stabilised by magnesium ion (Mg2+) binding [182]. The resulting SSB is then 
bound by PARP1 which becomes activated upon SSB binding, essential for its role in 
promoting resolution of the DNA damage in the end processing stages of BER [183]. In 
addition to its endonuclease activity, APE1 also possesses weak 3’-5’-exonuclease activity to 
remove 3’-end groups however, this role of APE1 remains inadequately understood [184]. 
Yet, the biological relevance has been demonstrated several times. This includes 
compromised exonuclease APE1 variants association with carcinogenesis [185], [186] 
indicating  a vital proofreading role for APE1, removing ligation stalling DNA polymerase β 
mismatches [184], [187] and the removal of bi-functional glycosylase generated PUA groups 
[176]. 
 
1.4.4.3 DNA end processing 
To fill the gap generated during BER, DNA polymerases are utilised that require a single 
nucleotide gap with a 3’-hydroxyl end and an undamaged template to act as a substrate. 
Four DNA polymerases are involved in BER, DNA Pol β, δ, ɛ and λ, with BER predominantly 
employing Pol β [188]–[190]. Pol β consists of two catalytic domains, an 8 kDa N-terminal 
DNA binding and dRP lyase domain and a 31 kDa C-terminal polymerase domain. There are 
three subdomains, the fingers, the thumb and the palm which facilitate catalysis [191], [192]. 
Pol β is recruited to DNA via interaction with APE1, PARP1 or the SSB. At the gap site, its C-
terminal polymerase domain bends the ssDNA 90 degrees, whilst the dRP lyase activity of 
Pol β removes the 5’-dRP moieties and simultaneously inserts the correct undamaged 
nucleotide into the repair gap [190], [193]. Pol β also initiates long-patch BER (Figure 1.10, 
right branch) by adding the first nucleotide into the repair gap. In fact in certain 
circumstances, often due to resistance by the 5’-dRP moiety to Pol β dRP lyase activity, a 
polymerase switch to Pol δ/ε triggers long-patch BER. Pol δ/ε typically add 2-8 more 
nucleotides into the single nucleotide gap. This process creates a 5’-flap structure that is 
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excised by flap endonuclease-1 (FEN-1) which acts in a proliferating cell nuclear antigen 
(PCNA)-dependent process, with DNA ligase I (Lig I) finally completing repair [194], [195]. The 
fourth DNA polymerase in BER, Pol λ, with 32 % amino acid homology [196], has been 
suggested to be a back-up polymerase for Pol β. Although a less efficient alternative, Pol λ 
has been shown to catalyse background repair activity in Pol β-deficient mouse embryonic 
fibroblast extracts [189].  
 
1.4.4.4 DNA ligation 
Polymerase gap filling produces a resulting nick, this enhances PARP1’s ADP-ribosylation 
activity, allowing for the auto-modification of PARP1 by the addition of negatively charged 
poly ADP-ribose (PAR) chains, which act as a scaffold to DNA repair proteins including the X-
ray cross-complementing protein 1-DNA ligase IIIα (XRCC1-Lig IIIα) complex [197]. At which 
point the accumulation of sufficient negative charges allows for repulsion of PARP1 from the 
lesion allowing for ligation by the XRCC1-Lig IIIα complex. Ligases act by utilising ATP or 
nicotinamide adenine dinucleotide (NAD+) to catalyse a phosphodiester bond between the 
3’- hydroxyl and 5’-phosphate groups. This completes the predominant mode of BER, also 
known as short-patch BER (Figure 1.10, central branch) [198], [199]. The alternative pathway, 






1.5.1 Chromatin structure 
In eukaryotes, the vast majority of DNA within the cell is located within the nucleus. 
However, if all the DNA contained within the 46 chromosomes was laid out end to end, it 
would span 2 metres in length. Therefore, to fit in the 6 µm nucleus, cellular DNA must be 
folded and condensed into a highly organised structure. This is called chromatin and consists 
of a number of loops and coils, organised by histones and non-histone chromosomal proteins 
which bind to DNA and structure chromosomes. The first order of chromatin arrangement is 
the nucleosome, a histone-DNA complex, which link to form nucleosome arrays. These are 
further folded on top of one another to condense DNA to form chromatin fibres, which are 
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coiled and condensed to form chromosomes. This compaction into chromatin allows DNA to 
be packaged into small regions, but also serves to protect it from damage, control gene 
expression and strengthen DNA to allow for mitosis or meiosis when entering anaphase. 
Heterochromatin is the term for tightly packed chromatin, the structure of which turns off 
genes. Conversely, euchromatin is a relaxed area of chromatin and is typically the location of 
frequently expressed genes. Nevertheless, chromatin is dynamic, and can be arranged and 
regulated to accommodate for a range of biological processes, such as DNA transcription, 
replication, and repair. 
 
1.5.1.1 Chromatin organisation 
The compaction of chromosomes into chromatin is vital for DNA organisation within the 
nucleus and involves co-ordinated levels of folding amongst histones and non-histone 
chromosomal proteins. Conversely, the accessibility of DNA within compacted regions is 
modulated via multiple mechanisms to allow for essential biological processes including gene 
transcription, DNA replication and DNA repair. The nucleosome is the first order of DNA 
packaging [200], which consists of ∼145-147 base pairs of DNA wrapped ∼1.7 times around 
a histone octamer. The octamer consists of two copies of the four core histone proteins, H2A, 
H2B, H3 and H4, which are then separated by ∼20-90 bp of linker DNA associated with the 
linker histones, H1 and H5 [201]. Initiation of nucleosome formation involves the wrapping 
of recently replicated or repaired DNA around the H3-H4 tetramer, followed by the addition 
of two H2A-H2B dimers [201]. Stability is provided to the nucleosome via 14 weak histone-
DNA bonds, generated through interactions between the positively charged residues in the 
histone octamer and the DNA phosphate backbone in the minor groove [202]. Short sections 
of DNA, often associated with the linker histones (H1 and H5), also referred to as ‘linker DNA’, 
joins nucleosomes together to form nucleosomal arrays (10 nm beads-on-a-
string like structures; Figure 1.11). These structures are packaged with neighbouring 
nucleosomes into 30 nm chromatin fibres, which following a high degree of compaction due 
to fibre-fibre interactions leads to the formation of a highly ordered tertiary structure 
observed in condensed chromatin [203].  
Protruding out from the nucleosomes are the N-terminal tails of the histones that present 
lysine residues to be targeted for the addition, but also removal, of chemical moieties 
through histone post-translational modifications (PTMs). These PTMs, which include 
phosphorylation, ubiquitiylation, acetylation, methylation, SUMOylation and PARylation, 
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alter chromatin composition and function [204], [205]. In particular, these function to 
promote DNA accessibility either through direct destabilisation of the chromatin structure, 
or via stimulation of the recruitment of chromatin remodelling enzymes. Increasing 
evidence, at least acquired in vitro, suggests that histone PTMs and/or recruitment of 
chromatin remodelling factors may be integral in the processing of DNA damage through the 




Figure 1.11: The primary and secondary structures that form chromatin 
DNA is wrapped ∼1.7 times around a histone octamer consisting of two copies each of 
histones H2A, H2B, H3 and H4 and linked to adjacent nucleosomes via linker DNA to form 
the primary structure of chromatin, the 10 nm fibre. These structures undergo packaging 
with neighbouring nucleosomal arrays and associate with architectural proteins (shown as 
green triangles) to form the 30 nm chromatin fibre, the secondary structure of chromatin. 
Taken from [170].  
 
1.5.1.2 Nucleosome structure 
The crystal structure of the nucleosome, determined in 1997, gives our clearest depiction 
that 146 bp of human DNA wrapped 1.65 times in a left-handed superhelix around a central 
histone octamer (Figure 1.12) [201].  The nucleosome itself is symmetrical, with the dyad, 
centred on a single DNA base defining the axis of symmetry [206] and DNA locations 
represented by superhelical turns from the dyad, designated superhelical locations (SHL) -7 
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to SHL7. Two copies of each of the core canonical histone proteins (H2A, H2B, H3 and H4) 
make up the central histone octamer [207]. These core histones are positively charged and 
structurally constructed from three α helices, divided by two loops (α1-L1-α2-L2-α3). This 
histone fold motif is essential for heterodimerisation as each domain pairs with a 
complimentary histone fold (H2A pairs to H2B, and H3 pairs to H4) to form a handshake motif 
[201], [207], [208]. These heterodimers (two H2A/H2B and two H3/H4) come together to 
form a single structure, the four helix bundle. In histone H3, the α2 and α3 helices allow for 
two H3-H4 dimers to interact in a head on arrangement via a H3/H3 four helix bundle to form 
(H3/H4)2 tetramers. Using a similar four helix bundle, the H2A/H2B dimers bind to the  
(H3/H4)2 tetramer via the H4 and H2B histone folds to form the ordered histone octamer 
[209].  The architecture of the histone octamer also consists of several tail protrusions, 
including eight N-terminal tails, one from each of the histone proteins and two C -terminal 
tails protruding from histone H2A. These histones tails provide points of interaction 
with other nucleosomes and are the site of most PTMs [209]. The histone octamer forms a 
designated path for the nucleosomal DNA, with the octamer binding the central 121 bp of 
nucleosomal DNA. The histone-DNA interfaces are mediated by numerous protein, 
electrostatic interactions and direct and water-mediate hydrogen bonds to stabilise the 








Figure 1.12: Structural details of a nucleosome 
The structure of the nucleosome with detailed interactions of DNA and histones to near 
atomic level, with a view down the superhelical axis (left figure) and at a 90° angle (right 
figure). The ribbons in brown and green form the DNA backbone and the individual histones 
within the octamer are shown (H2A in orange, H2B in red, H3 in blue and H4 in green). The 
dyad axis shown as the dashed yellow line on the left, defined as the super helix site 0 is a 2-
fold axis of symmetry and associated vertically with the DNA at the top of each image. 
Indicated on the DNA backbone are the numbering of bases relative to the dyad from the 5′-
end (+) or the 3′-end (−), plus representative sites of DNA base damage facing inwards 
(yellow) and outwards (white) from the histone core. Image taken and adapted from [201]. 
 
1.5.1.3 Secondary structure 
Nucleosomes are joined together by ‘linker DNA’, which are short sections of DNA (15-20 bp) 
often associated with the linker histones (H1 and H5) to form nucleosomal arrays (10 nm 
beads-on-a-string like structures: Figure 1.11). Nucleosomal arrays are compacted to form 
the secondary structure of chromatin, a three-dimensional higher order structure, 30 nm 
chromatin fibres. The 30 nm fibre was first observed as early as 1980 [211], [212], however, 
the structure is still yet to be resolved with two possible models, the solenoid and zigzag. The 
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one start solenoid model consists of bent linker DNA joining neighbouring nucleosomes 
along a superhelical path [213]–[216]. The two start zig zag model involves two rows of 
nucleosomes connected by straight linker DNA in a radial or longitudinal arrangement [214], 
[217]–[219]. 
 
1.5.1.4 Tertiary structure 
The model for higher order chromatin structures is primarily based upon the visualisation of 
extracted metaphase chromosomes, which reveal a radial-loop protein scaffold model basis 
for the tertiary structure to chromatin [220]. However, this view of an ordered hierarchical 
coiling of the 30 nm fibre, which is increasingly compacted to higher order structures, is only 
one model [221]. It has been demonstrated that this radial-loop model cannot be 
extrapolated to interphase chromosomes [222] and other models based upon a less ordered 
structure have been proposed. Such suggestions include, a molten globule or polymer melt 
physical arrangement of compacted and irregularly folded nucleosome arrays [203], [223], 
[224]. This, however, does not account for the rod-like structures seen at metaphase and 
other chromatin organising and compacting proteins, such as heterochromatin protein 1 
(HP1)  and polycomb repressive complex 1 and 2 (PRC1/2), are likely to coordinate these final 
levels of organisation [221].  
 
1.5.2 Regulation of Chromatin structure 
Chromatin, the highly ordered structure our DNA is compacted into, poses potentially major 
issues for the cell when undergoing DNA dependent activities. Therefore, regulation of the 
chromatin structure is vital to keep it dynamic, allowing the DNA to be accessible to enable 
the cell to undergo activities, including transcription, DNA replication, repair and 
recombination. Remodelling of chromatin is generally thought to occur by two major events, 
which are not necessarily mutually exclusive. The first is co-ordinated by histone PTMs and 




1.5.2.1 Histone PTMs 
Histone PTMs are small chemical groups covalently added to the C or N-terminal tails of the 
histones, histone folds or globular domains (which mediate histone-histone or histone-DNA 
interactions) during or after protein synthesis [225]. There are over 100 histone PTMs 
reported, with the list growing each year, and the most up to date catalogue was published 
in 2015 [226]. However since then, histone acylations, hydroxylation, lipidation, 
monoaminylations and other nonenzymatic PTMs have been characterised [227]. The 
majority of histone PTMs occur on the N-terminal tails and the most well-known include, 
lysine acetylation, ubiquitylation and SUMOylation, lysine and arginine methylation, and 
serine, threonine and tyrosine phosphorylation [228]. These PTMs act as signals altering 
nucleosome stability and the local chromatin environment by changing chemical interactions 
either in or between nucleosomes [229]. PTMs therefore can enhance DNA damage 
accessibility in localised regions, and this process has been demonstrated to be particularly 
important in enhancing the efficiency of DNA DSB repair [230]. Histone PTMs can also act to 
stimulate the recruitment of ACRs. 
 
1.5.2.2 ATP-chromatin remodelling complexes 
ACRs utilise the energy of ATP hydrolysis to cause either the displacement or sliding of 
nucleosomes to expose DNA sequences, or even the ejection and subsequent replacement 
of histones. There are four families of ACRs (Figure 1.13). These are switching 
defective/sucrose non-fermenting (SW1/SNF), imitation switch (ISWI), chromodomain 
helicase DNA binding (CHD) and inositol requiring 80 (INO80). They all have a strong 
nucleosome affinity and share a conserved ATPase domain for remodelling and breaching 
histone DNA interfaces, histone PTM recognition domains, and domains to facilitate ATP 
hydrolysis to mediate histone-DNA contacts. Providing specificity for their respective 
families, the enzymes also possess flanking domains for family groupings [231]. SWI/SNF 
complexes are known to slide and evict nucleosomes from DNA and are classified by a C-
terminal bromo domain which binds to acetylated lysines within N-terminal histone tails, and 
an N-terminally located helicase-SANT (HSA) domain, which interacts with actin related 
proteins. Within the ISWI family, multiple members catalyse nucleosome spacing and 
chromatin formation, and the distinguishing C-terminal SANT and SLIDE domains recognise 
nucleosomes and bind DNA and unmodified H4 tails. The CHD family are characterised by 
two tandem chromo domains, which bind methylated lysines within N-terminal histone tails. 
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Finally, the INO80 family is defined by their specialised split ATPase domain and whose 
functions include nucleosome sliding and histone eviction [231]. 
 
Figure 1.13: ATP-dependent chromatin remodelling complex families 
ACRs share the catalytic ATPase subunit comprised of the DExx (blue) and HELICc (green) 
domains. The flanking domains, HAS, Bromo, Chromo, HAND, SANT and SLIDE define the 
individual families. Taken from [170].  
 
1.6 BER in chromatin 
In the literature, the evidence for the functionality of chromatin remodelling events and 
histone modifications in facilitating the DNA damage response is ever increasing, however, 
studies have focused primarily on DSB repair and NER [232], [233]. This data highlights the 
importance for these events in tightly packed regions of chromatin and similarly, it can be 
assumed that BER requires complete, unobstructed access to DNA damage to promote 
efficient repair. Furthermore, as progression through BER creates increasingly mutagenic 
lesions, a seamless transition between each stage in a timely manner is essential to avoid 
extended repair times and cytotoxicity. Therefore, time, space and access to DNA damage is 





1.6.1 BER in chromatin models in vitro 
 
1.6.1.1 Mononucleosome investigations  
The current main focus for investigating chromatin remodelling events occurring in BER in 
vitro are nucleosomal studies. These investigations have utilised reconstituted nucleosome 
core particles (NCPs), in general using a single nucleosome (mononucleosome) as a 
representation of the chromatin environment. Construction of mononucleosome substrates 
generally uses either recombinant histone proteins or histones purified from chicken 
erythrocytes in combination with DNA containing 601 or 5S positioning sequences. These 
substrates can then be used within assays, monitoring the activity of purified recombinant 
BER proteins, relevant to each stage of the pathway, and examining the impact on lesion 
positioning. Such studies have provided strong evidence for altered BER efficiency in 
chromatin although this is very much dependent on the site of the DNA lesion within the 
mononucleosome and particularly whether the DNA backbone containing the damage is 
facing inwards or outwards from the histone core. 
 
1.6.1.2 DNA base damage excision in chromatin 
The first stage of BER is initiated by specific DNA glycosylase base recognition, via a dual 
unspecific 3D searching and 1D tracking along the DNA backbone [234], [235]. In general, 
this step is deemed efficient when the sugar phosphate backbone is outwardly facing away 
from the histone octamer (DNA base facing inwards), as the DNA glycosylase enzymes utilise 
the “base-flipping” mechanism. In contrast base recognition in impeded where the sugar 
phosphate backbone is inwardly facing (DNA base facing outwards). To provide sufficient 
DNA glycosylase access, the requirement for DNA dissociation from the histones, which is 
stimulated through chromatin remodelling enzymes, has been suggested. 
Mononucleosome studies on the activities of the DNA glycosylases UNG2 and SMUG1 have 
reported a general impediment of enzyme activity associated with chicken erythrocyte 
histone octamer and L. variegatus 5S rRNA gene containing mononucleosomes. Here, a 3-
fold (UNG2) and 9-fold (SMUG1) decrease in enzymatic activity against mononucleosome 
substrates compared to free DNA was observed irrespective of the rotational lesion 
positioning (positions 19, 22 and 51) [236]. Additional investigations, using chicken 
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erythrocyte histone octamers and the X. borealis 5S RNA gene to generate a range of 
different 154 bp uracil-containing mononucleosome substrates, corroborate this, and found 
that cleavage of uracil at position 22 (relative to the dyad) where the backbone was facing 
outwards, was at a 6-fold slower rate than cleavage of 42 bp free DNA. Furthermore, in 
contrast to an inwardly facing substrate (position 28), UNG2 activity against the uracil site 
was up to 3000 times slower when compared to the free DNA substrate. This study also 
details the importance of lesion positioning relative to the dyad, demonstarting that the DNA 
glycosylase activity of UDG2 was slower the further distance away from the dyad [237]. 
Multiple studies further develop these findings and have examined the activity of both UDG 
and APE1 on guanine-uracil mismatches. Utilising mononucleosomes generated from 
chicken erythrocyte histones and DNA containing the TG nucleosome positioning sequence, 
experiments have shown that efficiencies of uracil excision within mononucleosomes were 
10-fold slower than of naked DNA. Furthermore, they also concluded that proficiency of 
uracil excision was dependent on rotational positioning, with an observed 2-3-fold increase 
in excision of the outwardly facing versus the inwardly facing mononucleosome substrate 
[238]. Supporting this are similar experiments using mononucleosomes containing the 601 
DNA sequence, that demonstrated a 3-19-fold lower rate of excision of uracil in the 
outwardly orientated mononucleosome versus the free DNA, but also a 3-5-fold more 
effective excision of this substrate in comparison to inwardly facing mononucleosome 
substrates. Positioning relative to the dyad also resulted in differences in uracil cleavage, 
where the most efficiently excised inwardly facing substrate was the furthest away from the 
dyad (position 49). However, this trend was not observed when examining outwardly facing 
substrates [239]. Yet, as these studies use a combined assessment of the action of both UDG 
and APE1 enzymes, any conclusions on the effect of rotational positioning on DNA 
glycosylase enzyme action alone cannot be clearly drawn. To this effect, whilst the same 
observations were described above, where UDG preferentially excises uracil lesions within 
mononuleosomes where the DNA backbone is facing outwards versus inwards, APE1 was 
only able to stimulate UDG activity on the outwardly facing substrate by ~1.5-fold [240]. 
OGG1 DNA glycosylase/lyase activity has also been demonstrated to be impeded by 
chromatin. Using 227 bp 601 nucleosome positioning DNA containing 8-oxoG at position 108 
(10 bp from the dyad) and recombinant X. laevis histone proteins, it was shown that cleavage 
of 8-oxoG within a mononucleosome subsrate was ~90-fold slower and 4-fold less efficient 
than cleavage of naked DNA [241]. Extension of this study examined 8-oxoG processing 
within dinucleosomes, and reavealed that lesion excision within linker DNA was of a similar 
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rate to that of free DNA, but that the presence of histone H1 reduced the efficiency of OGG1 
~10-fold [242]. Characterisation of NTH1-dependent lyase activity against 
mononucleosomes constructed using 171 bp L. variegatus 5S ribosomal DNA nucleosome 
positioning sequence DNA containing a thymine glycol (TG) site, found that the lesion within 
outwardly and inwardly facing TG mononucleosomes was processed at a ~1.6-fold or ~10-
fold reduced rate than free DNA. Furthermore, cleavage of the inwardly facing TG substrate 
was at a ~2-fold reduced rate in comparison to the outwardly facing TG substrate. 
Additionally, evidence of the negative impact of proximity of the lesion to the dyad axis on 
NTH1 activity was also presented, with the inward facing lesion at position 26 having an 
approximate 2-fold reduction in TG excision compared to the lesion at position 46. The effect 
of rotational positioning was still evident with proximity to the dyad, as the outwardly facing 
lesion at position 22 was excised with greater efficiency than the inwardly facing lesion. 
Again, this highlights the impact of lesion positioning on BER [243]. Corroborating this is 
further evidence in mononucleosomes generated with recombinant X. laevis histones 
reconstituted with 184 bp DNA containing TG sites and the L. variegatus 5S ribosomal DNA 
nucleosome positioning sequence. Here, a ~2-fold reduction in NTH1 activity against 
inwardly facing TG mononucleosomes was seen comparatively to substrates where the 
backbone is outwardly facing [244]. Utilising similar substrates, a comparative study of NTH1 
and NEIL1 activity in processing TG sites within mononucleosome substrates was performed. 
This was done under specific conditions, where the high non-specific binding activity of NEIL1 
versus NTH1 was compensated for via a 50-fold difference in enzyme concentrations. 
Nevertheless, it was observed that both enzymes displayed a similar cleavage efficiency on 
the mononucleosomes with the DNA backbone facing outwards, ~2-fold less than that of 
naked DNA. However, only 10 % of the inwardly facing TG sites from mononucleosomes were 
processed by NTH1 and NEIL1. Yet, with increasing NTH1 concentrations, enzyme efficiency 
against the substrate was significantly increased. Therefore, the study concluded that NTH1 
possessed functionality on both accessible and occluded TG lesions. NEIL1’s inability in 
processing TG sites within mononucleosomes was summarised to be due to its high non-
specific DNA binding capacity and postulates a requirement of other proteins to suppress 
this DNA binding or recruit the enzyme to specific sites of oxidative damage. Alternatively, 
the promotion of TG processing by NEIL1 in chromatin could be mediated by chromatin 
remodelling enzymes [245]. Also of note, is the differing cellular roles of the enzymes, which 
may indicate that NEIL1 does not function in chromatin. Previous evidence suggests NEIL1 
predominantly excises base damage from single stranded DNA generated during DNA 
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transcription and replication [246], in contrast to NTH1 that is a general DNA glycosylase for 
oxidative pyrimidines. Of interest though, these two enzymes are controlled by the same 
regulatory mechanism involving ubiquitylation-dependent degradation [247]. 
 
1.6.1.3 AP site incision in chromatin 
With a similar approach to the assessment of DNA glycosylase activity, AP site detection by 
APE1 has also been found to be dependent on damage orientation within 
mononucleosomes. Evidence in mononucleosomes reconstituted using 147 bp 601 DNA or 
150 bp TG motif containing DNA shows a 2-fold (TG sequence) and 3-fold (601 sequence) 
reduction in cleavage of a natural AP site or tetrahydrofluran (THF) by APE1 inwardly facing 
lesions, in comparison to outwardly facing sites. Furthermore, this reduced cleavage was 
investigated in gel shift mobility assays and demonstrated to be as a consequence of reduced 
APE1 binding to the inwardly facing substrate, rather than reduced activity [248].  
Interestingly, following on from this study, it was revealed that two naturally occurring 
variants of APE1, R237C and G241R, have reduced activity on both inwardly and outwardly 
facing AP site containing 147 bp 601 DNA within mononucleosome substrates, but not on 
naked DNA. Yet, there was no evidence of differences in mononucleosome binding observed 
[249]. Also of note, is the in vitro evidence linking reduced APE1 activity on AP sites within 
mononucleosomes (15-fold reduction) with the mutation of five lysine residues (to arginines) 
in the amino tail region of histone H4. This highlights the potential importance of epigenetics 
in this stage of BER and predicting the involvement of histone tails and PTMs in DNA strand 
cleavage [250]. 
 
1.6.1.4 DNA end processing in chromatin 
The impact of chromatin on the DNA synthesis stage of BER, co-ordinated by Pol β, seems to 
be dependent on a range of factors including the DNA substrate itself, translational 
positioning and rotational orientation of the single nucleotide gaps. Initial reports, from 
mononuclesomes constructed using 146 bp L. variegatus 5S rRNA gene containing DNA 
fragments and chicken erythrocyte histone octamers, demonstrated the ability of Pol β to 
extend a UDG and APE1 generated 3’-hydroxyl terminus (in position 22) by one nucleotide 
but at a lower efficiency when compared to free DNA. Additionally, the constraint of 
proximity to the dyad was observed, where at position 51 a greater reduction in the capacity 
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for extension was observed. Most probably, this is as a result of the increased energetic cost 
associated with introducing a 90 degree kink, a requirement for Pol β activity, into the DNA 
at these locations [236]. Following on from this, two studies concluded a complete inhibition 
of Pol β DNA synthesis activity as a result of histone octamer presence. These investigations 
observed no DNA synthesis in either outwardly or inwardly facing uracil mononucleosomes 
following cleavage by UDG and APE1 [238], and a strong inhibition of Pol β-dependent gap 
filling of a 227 bp 601 DNA sequence containing 8-oxoG mononucleosome, prepared via 
OGG1 and APE1 processing [241]. Thus, demonstrating irrespective of rotational setting, this 
stage of the pathway was a major restriction on BER in chromatin and indicating that 
nucleosome remodelling maybe an essential step for promoting Pol β activity.  
Alternatively, single nucleotide gap containing substrates have been used to directly 
measure the impact of the mononucleosome structure on Pol β activity. In 
mononucleosomes constructed with recombinant X. laevis histone octamers and 184 bp L. 
variegatus 5S rDNA nucleosome positioning sequence DNA, Pol β was found to be ~3-fold 
more active on a gap where the DNA backbone was outwardly facing versus inwardly facing 
[244]. This was thought to be a result of the natural bending of the outward substrate which 
facilitates the 90 degree kink required for Pol β activity. In contrast to this, studies with 147 
bp 601 DNA sequence containing mononucleosomes, found inwardly facing gap substrate 
(position 10) were 2-fold more amenable to Pol β extension than there outwardly facing 
(position 4) counterpart. However, as both substrates were 2.5-3-fold less efficient 
substrates for Pol β than free DNA, the reported observations between inwardly and 
outwardly facing substrates on Pol β extension may be more indicative of the position of the 
GAP sites relative to the dyad [239]. Further evidence on the importance of translational 
positioning on gap filling activity is provided in a comparative study between outward facing 
substrates at position 10 and 35, and an inwardly facing substrate at position 49 which 
exhibited a 3- (position 35) and 4-fold (position 49) increase, respectively in Pol β extension 
activity [239].  A study similarly using 147 bp 601 DNA sequence based mononucleosomes 
has investigated the impact of the histone proteins on the individual steps co-ordinated by 
Pol β in the form of gap filling and 5’-dRP lyase activity. Interestingly, it was discovered that 
5’-dRP residue removal by Pol β was strikingly enhanced by ~16-fold in mononucleosomes 
(position 60) in comparison to free DNA, whereas 5’-dRP removal at positions 35 (outward 
facing) and 49 (inward facing) were cleaved with the same efficiency as free DNA. Regarding 
Pol β DNA synthesis activity, very strong inhibition (~2600-fold) was observed when the gap 
was close to the dyad (position 10) in comparison to free DNA. Additionally, in comparison 
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to free DNA, at positions 49 and 35, the difference in kinetics was 277-fold and 4-fold. DNA 
synthesis proximal to the dyad (position 10) in outwardly facing GAP substrates, was again 
noticeably slower compared to the other sites (~6-fold and 360-fold versus positions 49 and 
35, respectively) [251]. Therefore, it appears evident that of the two enzymatic steps that 
Pol β catalyses, the DNA synthesis stage is most greatly impacted by the presence of histone 
proteins within the mononucleosome. 
 
1.6.1.5 DNA ligation in chromatin 
End processing within BER, namely the ligation of the nick by XRCC1-LigIIIα, unlike the other 
stages of the pathway has been found to be unaffected by lesion orientation (in respect to 
the histone core). This is evidenced by studies within a 184 bp L. variegatus 5S ribosomal 
DNA nucleosome positioning sequence mononucleosome, where although initial 
investigations only demonstrated ~40 % of the substrate appeared to be ligated, with a 10-
fold increase in XRCC1-LigIIIα concentration, increases in ligation efficiency of both inward 
and outward facing nicks in 5S DNA was observed. Therefore, the theory that XRCC1-LigIIIα 
drove nucleosome disruption during BER to promote transient unwrapping of DNA from the 
histone octamer was developed. However, in full reconstitution reactions with the relevant 
enzymes in 601-based TG containing DNA sequences, very little ligation was observed. 
Therefore, the previously suggested model of XRCC1-LigIIIα-dependent unwrapping is 
counteracted by the lack of nucleosome disruption observed in these full reconstituted 
reactions, thus, providing little evidence to suggest that this mechanism of BER occurs in 
chromatin [244]. More recently though, evidence suggests spontaneous partial unwrapping 
of DNA from the histone octamer facilitates ligation by XRCC1-LigIIIα, which acts by encircling 
the DNA substrate. Comparison of nick ligation within 5S ribosomal DNA mononucleosomes 
positioned inwards towards the histone core showed a ~3-fold reduction in ligation 
efficiency with the lesion 26 bp from the dyad axis compared to 46 bp away. This apparent 
reduced ligation efficiency of ligation was also confirmed in the more stable 601 DNA 
sequence by XRCC1-LigIIIα. Together, this suggests that ligation at sterically occluded sites 
within the mononucleosome only occurs when the nicked DNA is exposed by periodic, 




1.6.2 BER in cell culture models 
Evidence from in vitro studies strongly suggest chromatin remodelling events are required in 
vivo to promote BER, particularly where DNA damage sites are inaccessible to BER enzymes. 
To enhance DNA damage accessibility, two not necessarily mutually exclusive major events 
are thought to mediate remodelling of chromatin. The first is co-ordinated by histone PTMs, 
and the second by ACRs. There are a large variety of histone PTMs which include the addition 
of small chemical groups to the N-terminal tails of the histones through acetylation, 
methylation and phosphorylation, and/or the addition of proteins such as ubiquitin 
(ubiquitylation) and small ubiquitin like modifier (SUMO) (SUMOylation). These PTMs act as 
signals altering nucleosome stability and the local chromatin environment by changing 
chemical interactions either in or between nucleosomes [229]. Utilising the energy of ATP 
hydrolysis, ACRs can cause either the displacement or sliding of nucleosomes to expose DNA 
sequences, or even the ejection and subsequent replacement of histones. There are four 
families of ACRs; SW1/SNF, ISWI, CHD and INO80 [231]. 
 
1.6.2.1 Histone post-translational modifications  
Despite evidence of the large number of histone PTMs, the affect they can have on chromatin 
structure and evidence of substantial cross-talk between them, research into the epigenetic 
status of histone proteins within chromatin and its influence on BER is relatively limited. An 
initial study demonstrating the importance of histone ubiquitylation in chromatin 
remodelling in response to oxidative DNA damage, provided evidence of histone H2B lysine 
120 ubiquitylation catalysed by the E3 ubiquitin ligase mouse double minute 2 homolog 
(Mdm2). Using siRNA mediated depletion of USP7 (a known regulator of Mdm2) in HeLa cells, 
it was demonstrated in alkaline comet assays that DNA damage induced by H2O2 resulted in 
a 2-fold delay of repair up to one hour post treatment, as a consequence of reduced cellular 
levels of Mdm2 and therefore histone H2B ubiquitylation. Thus, the model for a stabilising 
Mdm2/USP7 complex allowing for ubiquitylation of histone H2B by Mdm2 when DNA 
damage is detected, promoting open chromatin and therefore efficient BER, was proposed 
[253]. More recently, a study has investigated the response of oxidative DNA base damage 
and SSBs generation in HeLa cells via H2O2, -irradiation and high-linear energy transfer (LET) 
IR treatment and demonstrated that only the latter, which included -particle irradiation 
and low energy protons, was there elevated levels of histone H2B lysine 120 
monoubiquitylation. Furthermore, histone H2B monoubiquitylation induction catalysed by 
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the E3 ubiquitin ligases ring finger protein 20/40 (RNF20/40) and male-specific lethal-2 
homolog 1 (MSL2) was shown to be induced several hours after high-LET irradiation, 
correlating with the slow kinetics of repair indicative of CDD in the comet assay. It is well 
characterised that high-LET radiation generates CDD, defined by multiple types of DNA 
damage in close proximity. In fact, these sites are largely comprised of SSBs and/or alkali-
labile sites and thus are likely dependent on the BER pathway for their repair. Therefore, this 
study provides supporting evidence for a key role for histone H2B lysine 120 ubiquitylation 
in enhancing efficiency of BER [80].  
Histone acetylation has also been reported to have an impact on BER. Although the 
ambiguous nature of these reports, given that most have been performed in vitro using 
mononucleosome substrates, leaves some major conclusions lacking. One such example, in 
mononucleosomes prepared with 145 bp 601 8-oxoG containing DNA complexed with X. 
laevis histones, a ~1.5-2-fold increase in OGG1 activity on substrates where histone H2B had 
been acetylated, in comparison to mononucleosomes comprised of unmodified histone H2B, 
was seen. The neutralisation of lysine residues in histone H2B was hypothesised to result in 
relaxation of the mononucleosome and thus DNA unwrapping. Although there was no 
specific evidence for this, or even of further investigations into the impact of acetylation of 
specific lysine residues on stimulating OGG1 activity [254]. Interestingly, a more recent study 
has reported that site-specific acetylation on histone H3 within mononucleosomes decreases 
Pol β activity on single nucleotide gaps, conflicting the previously reported role of histone 
acetylation in BER. Of note, investigations using GAP mononucleosomes generated from 
UDG and APE1 treated 147 bp uracil containing DNA and X. laevis histone H3 acetylated at 
lysine 14 or 56, demonstrated inhibition of Pol β extension activity. This was only observed 
when substrates were outwardly orientated near the dyad (position 10). Also of interest, 
histone acetylation had no impact on UDG or APE1 activity on the excision of uracil outwardly 
or inwardly facing, so this appears specific to modulating Pol β during BER  [255]. 
 
1.6.2.2 Chromatin remodelling factors  
Identification of ACRs involved in BER has been a cumulative effort of both in vitro and in vivo 
studies. Early in vitro work with 601 DNA and X. laevis histone octamer mononucleosomes 
identified yeast SWI/SNF as a factor promoting OGG1 and APE1 excision of 8-oxoG by ~8-
fold, improving efficiency to that of naked DNA. This study also discovered that OGG1 and 
APE1 generated GAP mononucleosomes were also processed at a ~7-fold improved rate by 
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Pol β in the presence of the SWI/SNF complex [241]. The authors also developed a 
dinucleosome model incorporating 8-oxoG into the linker DNA region, and discovered that 
the yeast ACR, remodels the structure of chromatin (RSC), a member of the SWI/SNF family, 
increased OGG1 activity against the 8-oxoG site by ~5-fold. Furthermore, they found that 
the histone chaperone nucleosome assembly protein 1 (NAP-1) enhanced 8-oxoG excision, 
mediating the removal of histone H1 from the linker DNA [242]. These studies are also 
supported by evidence from yeast, where RSC has been shown to promotes survival in 
response to MMS exposure, that generates DNA base alkylation and further endorsing 
efficient BER through making the chromatin more accessible [256], [257]. Additional 
evidence of RSC functioning within BER has been provided in studies using 
mononucleosomes comprised of 255 bp uracil containing 601 DNA with X. laevis histones. 
Here it was shown that the histone chaperone facilitates chromatin transcription (FACT), 
expressed and purified from HeLa cells, facilitates UDG1 excision of inwardly facing uracil 
sites via promotion of RSC’s remodelling activity. It was also demonstrated that FACT and 
RSC collectively enhanced accessibility to the uracil lesion via nucleosome sliding, providing 
valuable insight into the mechanisms of chromatin remodelling involved in the first stage of 
BER [258].  
Another study, utilising a less common but interesting approach, investigated the impact of 
the ACRs ISW1 and ISW2 on uracil oligonucleosome arrays, constructed with a sodium 
bisulfite treated tandem repeating DNA sequence of 12 copies of a 208 bp fragment of the 
L. variegates 5S ribosomal RNA gene, combined with histone octamers from chicken 
erythrocytes. GAP substrates were generated by treating the uracil lesions with UDG and 
APE1 and Pol β activity against these arrays was shown to be stimulated ~4-fold by yeast 
purified ISW1 and ~6-fold by ISW2. Although limited in scope, this study does suggest that 
at least the DNA polymerase step of BER is enhanced via these complexes [259]. Further 
suggestions of a role of ISWI complexes within BER is provided through more recent evidence 
that Special AT-rich Sequence-binding Protein 1 (SATB1), which has been previously 
demonstrated to direct ISWI to chromatin loop domains [260], has also been classified as an 
accessory factor in BER. SATB1 has been shown to directly interact with OGG1 to stimulate 
the activity of the enzyme on 8-oxoG containing DNA in vitro [261]. Although this does not 
provide direct evidence that SATB1 plays an important role in enhancing OGG1 activity on 
chromatin, it is suggestive of factors required to support chromatin remodelling during BER. 
Indeed, evidence that Amplified in Liver Cancer 1 (ALC1), a member of the SNF2 superfamily, 
is also a likely chromatin remodelling enzyme involved in SSB processing during BER. ALC1 
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was first reported to be recruited, in a poly(ADP-ribose)-dependent manner, to sites of laser-
induced DNA damage in U2OS cells, and that shRNA-mediated depletion of ALC1 resulted in 
increased sensitivity of the cells to oxidative stress via H2O2 treatment [262]. In 
mononucleosomes ALC1 has also been shown to promote nucleosome sliding, which was 
enhanced by activated PARP-1. However, a specific role of ALC1 in BER is lacking justification, 
as this nucleosome sliding wasn’t specifically shown to result in improved accessibility of the 
BER proteins to DNA base damage. Nevertheless, this study did provide supporting evidence 
that ALC1 promotes chromatin relaxation following laser micro-irradiation of U2OS cells 
[263]. Furthermore, ALC1 knockout in chicken DT40 cells resulting in an epistatic PARP-1 
deletion displayed sensitivity to both H2O2 and MMS, and a deficiency in SSB repair following 
H2O2 treatment through comet assay analysis. Also, of note, ALC1 knockout in human TK6 
cells displayed MMS sensitivity and slower repair kinetics of SSBs under MMS and H2O2 
induced conditions. However, siRNA mediated-depletion of ALC1 in U2OS cells had no impact 
on the recruitment of XRCC1 or Pol β to laser induced DNA damage, suggesting a specific role 
for ALC1 in chromatin remodelling which promotes BER in vivo [264].  
 
1.7 Ubiquitylation 
Ubiquitin (Ub) is a small 76 amino acid, 8 kDa highly conserved and stable protein (Figure 
1.14), which is generally covalently linked to lysine (K) residues of target proteins via 
ubiquitylation [265]. This occurs in a three step ATP-dependent process by an enzyme 
cascade involving an E1 activating enzyme, an E2 conjugating enzyme and an E3 ubiquitin 
ligase [266]. There are a range of Ub modifications with a myriad of outcomes. In its simplest 
form, ubiquitylation modifies proteins via the addition of single ubiquitin moieties, termed 
monoubiquitylation [267]. This can also occur at several K residues on the target protein, 
with the event being classed as mono or multi-ubiquitylation [268]. Furthermore, as Ub itself 
also contains K residues it can form ubiquitin chains, leading to polyubiquitylation at the 
residues K6, K11, K27, K29, K33, K48 or K63, with K48 and K63 chains being the most 
extensively characterised [269], [270]. Ubiquitylation and the ubiquitin proteasome pathway 
(UPP) has been demonstrated to mediate protein-protein interactions, play a regulatory role 
in protein localisation, conformation and activity as well as have an involvement in signalling 
networks and transcriptional regulation of a range of pathways including, DDR, the cell cycle 






Figure 1.14: The structure of ubiquitin 
Ub is a small 76 amino acid, 8 kDa protein which can be covalently linked through any of its 
lysine (K6, K11, K27, K29, K33, K48 and K63) residues or between the C-terminal glycine (G76) 
and N-terminal methionine (M1) residue of Ub moieties. Image taken from [271]. 
 
1.7.1 Ubiquitin Proteosome Pathway (UPP) 
The UPP is an ATP-dependent three-step enzyme cascade (Figure 1.15). It is initiated via an 
E1 activating enzyme that mediates Ub activation in an ATP-dependent reaction, whereby 
the E1’s cysteine active site and the C-terminus of Ub (glycine 76) bond form a high energy 
thiol ester E1-Ub intermediate. Next, the activated Ub is transferred from the E1 to a thiol 
group on the active site cysteine of an E2-conjugating enzyme. In the third step, the E3 ligase 
interacts with both the substrate protein and the Ub bound E2. This binding, facilitates the 
formation of an isopeptide bond between the C-terminus of the Ub moiety and the e-amino 
group of a K residue on the substrate protein [272]. The human genome encodes for 10 E1s, 




Figure 1.15: The Ubiquitin Proteosome Pathway 
In an ATP-dependent reaction, Ub is activated and bound to an E1-activating enzyme (E1). 
Next, the ubiquitin is transferred from the E1 and conjugated to an E2-conjugating enzyme 
(E2). Finally, E3 ubiquitin ligases facilitate the transfer of ubiquitin from the E2 to lysine 
residues on the substrate protein (P). RING-type E3s (R-E3) mediate transfer of Ub to the 
protein. HECT-type E3s (H-E3) use a E3-Ub intermediate before transferring Ub moiety to the 
protein. Ub modifications include the addition of a single (monoubiquitylation) or multiple 
(polyubiquitylation) Ub moieties. Adapted from [271]. 
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The E3 ligases, given that they consist of over 600 enzymes, provide the greatest variability 
and specificity to the UPP. The E3s can be divided into three subtypes, the really interesting 
new gene (RING)-type, which are the largest family comprising of 600 enzymes [271], the 
homologous to E6-AP carboxy terminus (HECT)-type of which there are 28 enzymes [274], 
and the RING between RING (RBR)-type family with 14 members [275]. RING-type E3s 
function through a mediation of the Ub transfer directly from the Ub bound E2 to the 
substrate protein. RING-type E3s are characterised by a zinc finger domain or a U-box 
domain, which is similar in structure but in lieu of zinc ion coordination, utilises charge and 
polar amino acid residues to provide a scaffold for E2 binding [276]. Therefore, the RING or 
U-box domains function as a scaffold to orientate the Ub bound E2 to mediate transfer of Ub 
to the target substrate protein. Another common feature of RING-types is dimerization, 
functioning as monomers or homo/heterodimers [271]. Additionally, some RING-type E3s 
have multiple subunits such as cullin-RING ligases (CRLs) and anaphase-promoting 
complex/cyclosome (APC/C) [277], [278]. HECT-type E3 ligases were the first family to be 
discovered through the identification of the E6AP protein [279], [280]. Within the HECT-type 
E3 family there are 28 members, the majority of which fall into two main subfamilies based 
upon similarities in the N-terminal domain. The NEDD4 subfamily, consisting of nine 
members which share WW and C2 domains and HERC E3 ligases, consisting of six proteins, 
which contain at least one regulator of chromatin condensation 1(RCC)-like domains (RLD). 
The remaining 13 HECT-type E3s are characterised as ‘other’ HECT E3’s [274]. The HECT 
domain, positioned at the C-terminus of all HECT-type E3s, is a 40 kDa domain and provides 
the catalytic activity to these E3s and differentiates the HECT-type E3s from the RING-types. 
This catalytic mechanism involves the formation of an E3-Ub intermediate, where the Ub is 
firstly transferred to the cysteine active site of the HECT-type E3 via a transthiolation 
reaction, before the Ub moiety is conjugated to the target substrate protein [279], [281]. The 
RBR-type, like HECT-type E3s, contain an active site cysteine and conjugate Ub to the 
substrate via a E3-Ub thioester intermediate. However, they also possess a RING domain, 
resulting in their classification as RING-HECT hybrids [275]. Of the 14 RBR-type E3s identified, 
the most highly studied is Parkin, due to mutations in the PARK2 gene being associated with 
autosomal recessive juvenile Parkinson's disease [282], [283]. RBR-type E3s are complex 
multi-domain enzymes, however, they are defined based upon their RBE module which 
consists of an in-between-RING (IBR) domain sandwiched between two RING domains 
(RING1-IBR-RING2) [284], [285].   
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Further complexity is added to the UPP by the diverse types of Ub modifications (Figure 
1.16). Monoubiquitylation typically is involved within signalling pathways and regulates the 
target protein in several ways including activity, localisation and interactions [267], [268]. 
Additionally, Ub itself contains several internal K residues (K6, K11, K27, K29, K33, K48 and 
K63) allowing for the formation of Ub polymer chains, termed polyubiquitylation. These 
chains can exist in a myriad of topologies, including homotypic chains (one linkage type), 
heterotypic chains (mixed linkage types) or branched chains (one ubiquitin is linked at 
multiple K residues) with K48 and K63 chains being most extensively characterised (Figure 
1.16) [269], [270], [286], [287]. The outcomes of polyubiquitylation are numerous, however 
the most well-known outcome is the targeting of proteins for proteasomal degradation 
(Figure 1.15) [266]. This process is crucial for the cell to modulate steady-state and regulated 
protein levels, as well as to rapidly remove and degrade damaged proteins [288]. This is 
principally achieved through the addition of a four or more K48-linked homotypic 
polyubiquitin chains to target proteins for degradation via the 26S proteasome [289], 
although K11, K27 and K29-linked homotypic chains can also target proteins for degradation 
[290]. Furthermore, to note is the range of complexity which can be afforded by the differing 
types of Ub modifications, an example of which can be seen in the ubiquitylation of PCNA. 
This factor recruits DNA polymerases dependent on its ubiquitylation state, where 
monoubiquitylated PCNA on K164 triggers error-prone DNA repair, recruiting TLS 
polymerases [291]. In contrast, K63-linked polyubiquitylation of PCNA at the same site 








Figure 1.16: Schematic representation of ubiquitin modifications 
In its simplest form, ubiquitylation modifies proteins via the addition of single ubiquitin 
moieties (monoubiquitylation) or at several K residues on the target protein (multi-
monoubiquitylation). Additionally, Ub can be linked to itself via any of its seven internal K 
residues (K6, K11, K27, K29, K33, K48 and K63) allowing for the formation of Ub polymer 
chains, termed polyubiquitylation. These chains can exist in a myriad of topologies including, 
homotypic chains (one linkage type, K48 and K63 shown above), heterotypic chains (mixed 
linkage types) or branched chains (one ubiquitin is linked at multiple K residues). Adapted 
from [287].  
 
1.8 Identifying the ACR promoting AP site repair 
Within the Parson’s laboratory, a previous PhD student utilised reconstituted 
mononucleosomes containing a site-specific synthetic abasic site (THF) (section 4.2-4.4), and 
demonstrated that the DNA damage is less efficiently incised by recombinant AP 
endonuclease 1 (APE1) when the DNA backbone is facing the histone core (THF-IN) compared 
to that orientated away (THF-OUT). However, when utilising HeLa whole cell extracts, the 
difference in incision of THF-IN versus THF-OUT was less pronounced suggesting the 
presence of chromatin remodelling factors that stimulate THF accessibility to APE1 (Figure 
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1.17). Of note, the previous PhD student also discovered, when examining individual PTMs, 
that the incision of the THF-IN mononucleosome substrate by WCE was significantly 
dependent on the presence of factors promoting ubiquitylation (Figure 1.18). Therefore, this 
led to the development of the hypothesis that incision of an AP site within a 
mononucleosome substrate that is inaccessible to recombinant APE1, is more efficiently 
incised by APE1 in WCE due to the presence of histone modifiers and/or chromatin 




Figure 1.17: HeLa whole cell extract more efficiently incises a THF-IN mononucleosome 
substrate than recombinant APE1 
Incision of THF-OUT and THF-IN mononucleosome substrates (50 fmol) by increasing 
amounts of A-C: recombinant APE1 and D-F: HeLa whole cell extract. Shown is the mean 
percent substrate incision ± S.D. from at least three independent experiments, and 






Figure 1.18: Dependence of ubiquitylation on the effective incision of a THF-IN 
mononucleosome substrate by HeLa whole cell extract 
Incision of A-C: THF-IN and D-F: THF-IN mononucleosome substrates (50 fmol) with 1.3 μg 
and 0.04 μg HeLa WCE respectively, plus and minus 0.6nmol ubiquitin. Reactions were 
stopped after 10, 20, 30 and 60 minutes. Shown is the mean percent substrate incision ± S.D.  
from at least three independent experiments, and representative images from the respective 
gels. Adapted from [293], [294].  
To identify this factor, an unbiased purification scheme involving the separation of proteins 
in HeLa cell extracts by different ion-exchange and size exclusion chromatography columns, 
purified a chromatin remodelling activity from HeLa cell extracts. Mass spectrometry analysis 
identified potential candidates, and further assessment of proteins specifically involved in 
ubiquitylation resulted in the identification of the E3 ubiquitin ligase, HECTD1 as a promising 





HECTD1 is a 289 kDa member of the HECT E3 ubiquitin ligases. The HECT domain of HECTD1 
is located at amino acid 2151-2610, with the active site at amino acid position 2579. In 
addition to its catalytic domain, HECTD1 possesses two armadillo repeat-containing (ARM) 
domains and an ankyrin (ANK) domain consisting of four repeats, both of which have been 
implicated in mediating protein-protein interactions [295]. The MIB/HERC2 (MIB) domain is 
thought to be a major interaction domain, also mediating protein interactions [296]. HECTD1 
also consists of a SUN (SAD1/UNC) domain, thought to be involved in nuclear localisation 
[297], and a helicase bundle (H) (Figure 1.19) [298]. In regards to cellular localisation, HECTD1 
is known to translocate between the nucleus and cytoplasm, possessing eight nuclear 
localization sequences (NLS) and four nuclear export signals (NES) [299]. In addition, HECTD1 
has been observed to co-immunoprecipitate and pull-down with Importin α3/7, suggesting 
nuclear import by classical nuclear protein transport mechanisms [300].  
 
 
Figure 1.19: Human HECTD1 domain architecture 
Human HECTD1 is 2610 aa in length consisting of two armadillo repeat-containing (ARM) 
domains, an ankyrin-repeat (ANK) domain, a SAD1/UNC (SUN) domain, a MIB/HERC2 (MIB) 
domain, a helical bungle (H) and a homologous to E6-AP carboxy terminus (HECT) domain. 
Adapted from [298]. 
 
1.8.1.1 Cellular role of HECTD1 
Hectd1-homozygous mutant mouse embryos exhibit early lethality with several defects 
during their development, furthermore HECTD1 has been shown to target a range of distinct 
signalling pathways, implicating HECTD1 in several biological processes [301], [302]. HECTD1 
was first characterised to target heat shock protein 90 (HSP90) for ubiquitylation and control 
the cellular localisation and secretion of the protein necessary for regulation of the 
behaviour of cranial mesenchyme cells [301], [303]. HECTD1 is also involved in cell migration, 
regulating focal adhesion formation via the ubiquitylation mediated degradation of 
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phosphatidylinositol 4-phosphate 5-kinase type I γ (PIPKIγ90), where HECTD1 ubiquitylation 
of PIPKIγ90 at K97 mediated cell migration [304]–[306]. In addition, observations in mouse 
embryonic fibroblasts isolated from Hecdt1-mutant mice demonstrated accelerated cell 
migration, which was associated with a HECTD1-mediated regulation of IQGAP1 protein 
levels effecting focal adhesion and focal complex dynamics [307]. Furthermore, HECTD1 
functions as a negative regulator of Wnt/β-catenin signalling, by polyubiquitylating 
adenomatous polyposis coli (APC) with K-63 linked chains enhancing the interaction between 
APC and Axin, promoting β-catenin degradation [308]. Interestingly, HECTD1 was identified 
as a tankyrase druggable target, of interest as a potential cancer treatment [309], [310]. As 
an antagonist of the Wnt/β-catenin signaling pathway, a tankyrase-mediated degradation of 
HECTD1 can lead to the degradation of Axin, stabilising β-catenin and promoting growth 
[311]. HECTD1 has also been well characterised to have a role within epithelial-mesenchymal 
transition (EMT) and endothelial-mesenchymal transition (EndMT), implicated in the 
mediation of a range of target proteins. Through a ubiquitylation triggered degradation of 
the EMT transcription factor SNAIL, HECTD1 has been implicated in EMT. Furthermore, the 
observation of poor patient survival associated with low HECTD1 expression levels in cervical 
cancer specimens indicate that the protein is key for regulating cell migration. Investigations 
of hypoxia-triggered degradation of HECTD1 by microRNA and EGF mediated nuclear export 
of HECTD1 suggest that HECTD1 may regulate EMT through these signalling pathways in 
cervical cancer [299]. Also to note, HECTD1 has been shown to promote ubiquitylation-
dependent degradation of ACF7, and HECTD1 depletion in T47D breast cancer cells via 
increased ACF7 protein levels enhanced EMT, promoting tumour growth, survival and 
metastasis [312]. Together these findings suggest HECTD1 may play a general role within 
EMT through targeting multiple mechanisms.  
 
1.8.1.2 Implications of HECTD1 in human health  
Of interest is the recent attention on circular RNA HECTD1 (circHECT1), in particular the 
circHECTD1/HECTD1 pathway. CircHECTD1 is thought to be transcriptional regulator of 
HECTD1, regulating the levels via competition with its pre-mRNA. Most extensively this 
pathway has been implicated in silicosis, an occupational lung disease caused by the 
inhalation of crystalline silica dust, where HECTD1 was shown to be upregulated in 
macrophages from silicosis patients [313].  It has been suggested that upon exposure to 
silicon dioxide, the pre-mRNA competition mechanism of circHECTD1 is disrupted and 
decreased circHECTD1 levels resulting in increased HECTD1 protein levels triggers excessive 
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cell proliferation and migrations via EMT and EndMT. Ultimately resulting in the hallmark of 
the disease, silicosis pulmonary fibrosis which is currently untreatable, these new discoveries 
have provided a potential novel target, circRNAs, in the treatment of silicosis [313], [314].  
Additional implications of an important role for HECTD1 in human health, include its mapping 
to chromosome 14q12, the region associated with severe mental retard and Rett-like 
syndrome when duplicated or deleted [315]. Furthermore, via regulation of its known target 
proteins, HECTD1 has been implicated in cancer development. In fact, it has been 
demonstrated that the apidocyte-derived cytokine leptin upregulates HECTD1 expression 
[306], exacerbating the HECTD1-mediated ubiquitylation of PIPKIγ90 which is essential for 
ER-α-negative breast cancer cell invasion [304]. Interestingly, studies in MCF-7 breast cancer 
cells have implicated HECTD1 in the dysregulation of interphase loading of condensins, 
proteins which play an important role in the organisation of higher-order chromatin 
architecture. The architectural regulators condensin I and condensin II modulate estrogen-
regulated enhancer activation, in part by the recruitment of HECTD1 which in turn via a 
control of enhancer-associated coactivators/corepressors (p300 and RIP140) binding, results 
in gene transcription. However, it has been suggested that aberrant gene expression, 
triggered by elevation in HECTD1 expression, possibly underlies human cancer development 
[316]. HECTD1 expression was also shown to be upregulated in cancer associated fibroblasts 
obtained from the bone marrow of breast cancer patients, in comparison to the primary 
sites, again implicating HECTD1 in fibroblast migration/proliferation [317]. A HECTD1 
overexpression has been reported in LN-229 and LN-428 glioblastoma cells, associated with 
a USP15 stabilisation of HECTD1 causing a downregulation of Wnt pathway activity [318]. 
However, as previously stated, low HECTD1 expression levels has been associated with 
shorter disease-free survival in cervical cancer patients [299], and disease progression, 
including metastasis in breast cancer patients [312]. Reports have additionally demonstrated 
using multiple gene expression datasets a correlation of low HECTD1 protein expression and 
shorter disease-free survival in breast cancer patients and low mRNA levels of hectd1 with 
reduced survival in multiple cancer types, including breast, lung and brain [312], [319]–[321]. 
This may be reflective of the apparent broad functionality of HECTD1, but also suggests 





Chapter 2: Aims 
 
The major enzymes and mechanisms co-ordinating BER are well known and established, 
however, the process of BER in chromatin where DNA is compacted with histones, remains 
unclear. There is ever increasing evidence for changes to chromatin via remodelling events 
and histone PTMs which are necessary to facilitate the DDR, particularly in DSB repair and 
NER, where a number of chromatin remodelling events and histone modifications have been 
reported. This has, in particular, highlighted the importance of chromatin remodelling events 
within tightly packed regions of chromatin and similarly BER requires complete, 
unobstructed access to DNA base damage to promote efficient repair. Furthermore, 
progression through the BER pathway creates increasingly cytotoxic and mutagenic lesions, 
therefore, a seamless transition between each stage is essential, and repair must be 
completed in timely manner once BER in initiated. Thus time, space and access to DNA base 
damage is essential for the effective and efficient completion of BER in chromatin. Currently, 
the field is dominated by mononucleosome studies, which conclude that DNA lesion 
orientation and translational positioning impact the efficiency of BER enzyme activity. 
However, studies identifying chromatin remodelling enzymes or specific PTMs which are 
required to promote BER are limited.  
Therefore, the study presented in this thesis aimed to characterise HECTD1 as an enzyme 
functioning as a BER chromatin remodeller, identify the mechanism via which HECTD1 is 
acting, and determine the requirement for HECTD1 in a cellular context. In order to achieve 
this, the research project presented had three aims: 
I. Establishment of in vitro BER assays using mononucleosomal DNA containing 
occluded DNA damage sites to assess the ability of HECTD1 to promote multiple 
stages of BER 
II. Establishment of ubiquitylation assays to identify HECTD1 substrates for 
ubiquitylation 










3.1.1  601 nucleosome positioning sequence 
The Widom 601 strong nucleosome positioning sequence was used for mononuclesome 
experiments [322]. The positioning of the THF and TG site was previously determined from 
the crystal structure and sequence [239]. The pGEM-3Z-601 ampicillin resistant plasmid was 
kindly provided by Prof Peter O’Neil (CRUK/MRC Oxford Institute for Radiation Oncology, 
University of Oxford, UK).  
             5’-GCTCGGAATTCTATCCGACTGGCACCGGCAAGGTCGCTGTTCAATACATG   
3’-CGAGCCTTAAGATAGGCTGACCGTGGCCGTTCCAGCGACAAGTTATGTAC  
   
       CACAGGATGGTATATATCTGACACGTGCCTGGAGACTAGGGAGTAATCCC    
         GTGTCCTACCATATATAGACTGTGCACGGACCTCTGATCCCTCATTAGGG  
   
         CTTGGCGGTTAAAACGCGGGGGACCACGCGTTGGTG1GTTTAAGCCGTG    
         GAACCGCCAATTTTGCGCCCCCTGGTGCGCAACCAC2CAAATTCGGCAC  
   
         CTGGCGCTTGCTACGACCAATTGAGCGGCCTCGGCACCGGGATTCTCCAG    
         GACCGCGAACGATGCTGGTTAACTCGCCGGAGCCGTGGCCCTAAGAGGTC  
   
         GGCGGCCGCGTATAGGGTCCATCACATAAGGGATGAACTCGGTCTTAAGA 
         CCGCCGGCGCATATCCCAGGTAGTGTATTCCCTACTTGAGCCAGAATTCT  
 
         ATCATGC-3’ 
         TAGTACG-5’ 
 
Figure 3.1: Double stranded 256bp 601 nucleosome positioning DNA sequence  
Nucleotide sequence for the Widom 601 nucleosome positioning sequence. Nucleotides 
highlighted in yellow are a restriction digest site for Van91I and in green BgII. The 
nucleosome dyad is indicated to in black bold. The red 1 indicates a C base for THF 256bp 
DNA and an A base for TG 256bp DNA. The position of the THF or TG site is indicated by a red 
2. DNA damage sites on the lower strand produced inwards facing THF or TG sites when 




3.1.2 Oligonucleotides  
 
 
3.1.2.1 Oligonucleotides for the preparation of damage containing oligos 
Fluorescently tagged primers (Table 3.1) were used to amplify the 601 nucleosome 
positioning sequence from the pGEM3Z-601 cloning vector. Unlabelled primers (Table 3.1) 
were also used to amplify the 601 nucleosome positioning sequence for use in nucleosome 
reconstitutions as a carrier DNA to largely inhibit exonuclease activity of extracts in the BER 
in vitro assay. Short (17 bp) oligonucleotide sequences (Table 3.2) were annealed together 
and used to introduce a THF or TG (labelled 1) to the 601 nucleosome DNA sequence. 
Fluorescently tagged primers and THF/TG oligonucleotides were obtained from Integrated 
DNA Technologies (Leuvan, Belgium). Unlabelled primers obtained from Eurogentec 
(Seraing, Belgium).  
Table 3.1: Primers for DNA damage site DNA preparation  
Primers for producing 601 nucleosome positioning sequence. Shown is the forward and 
reverse primer sequence.   
 Primer sequence  
Inwards nucleosome 



















Table 3.2: Oligonucleotide sequence containing an inwardly facing THF (1) or TG (2) site 
following nucleosome reconstitution   
Primer sequences to generate a 17bp oligonucleotide with a 3’ 3 base overhang, with a THF 
(1) or TG (2) site positioned on the lower strand. Shown is the forward and reverse primer 
sequence.   
 Oligonucleotide sequence  






3.1.2.2 Oligonucleotides for ligation independent cloning 
LIC primers (Table 3.3) were utilised in order to clone the C-terminal cDNA sequence of 
murine hectd1 (amino acids 1762-2612) containing the active E3 ligase HECT domain from 
the pCMV-HA-HECTD1 mammalian expression vector into the pET28a bacterial expression 
vector. All custom oligonucleotide LIC primers were obtained from Eurogentec 
(Southampton, UK). 
Table 3.3: Custom oligonucleotide LIC primers 
Primer sequences used to reclone murine HECTD1 in the pET28a bacterial expression vector. 
Shown is the forward and reverse primer sequence and target DNA template amplified using 
PCR by the LIC primers.   














3.1.2.3 Oligonucleotides for site-directed mutagenesis 
Site-directed mutagenesis primers (Table 3.4) were utilised in order to generate a single 
cysteine (C) to glycine (G) point mutation in the active site of the truncated form of HECTD1 
(ΔN-HECTD1) using the pET28a-HECTD1-1761 plasmid. All custom oligonucleotide SDM 
primers were obtained from Eurogentec (Southampton, UK). 
Table 3.4: Custom oligonucleotide SDM primers 
Primer sequences used for the SDM of ΔN-HECTD1. Shown is the forward and reverse 
primer sequence for the C to G single mutant. Mutated C to G codons are highlighted in 
red.  
Mutant Oligonucleotide sequence  
C2579G Forward 
5’- TCGGTCAACACCGGTGTCCACTATCTTAAG -3’ 
Reverse 




The pGEM-3Z-601 plasmid was kindly provided by Prof Peter O’Neil (CRUK/MRC Oxford 
Institute for Radiation Oncology, University of Oxford, UK). Xenopus laevis histone (H2A, H2B, 
H3 and H4) bacterial expression plasmids by Prof Karolin Luger (University of Colorado 
Boulder, Boulder, USA). The bacterial expression pET14b APE1 plasmid by Prof Dianov 
(CRUK/MRC Oxford Institute for Radiation Oncology University of Oxford, UK) and the 
mammalian expression plasmid for full length murine HECTD1 (pCMV-HA-HECTD1) was 
kindly provided by Prof Irene Zohn (Center for Neuroscience Research, Children's Research 
Institute, Washington, DC, USA). The C-terminal cDNA sequence of murine hectd1 (amino 
acids 1762-2612) containing the active E3 ligase HECT domain was recloned into pET28a 
(pET28a-HECTD1-1761) by ligation-independent cloning (LIC). An E3 inactive mutant version 
of pET28a-HECTD1-1761 (pET28a-mutHECTD1-1761) was generated using a site-directed 
mutagenesis (SDM) technique. The bacterial expression plasmids for the E1 (UBE1) and 9x 
E2 (UbE2H, Cdc34a, UbE2D1, UbE2D2, UbE2D3, UbE1E1, UbE2L3, UbE2L6, and UbE2C) 




3.1.4 siRNA sequences 
Small interfering RNA (siRNA) sequences were used to interfere and knockdown the 
expression of specific genes as listed in Table 3.5. For knockdown of HECTD1 expression a 
pool of 4 siRNA sequences was used to increase knockdown efficiency. 
Table 3.5: siRNA pool sequences for knockdowns.  
HECTD1 siRNA pool obtained from Dharmacon (Lafayette, Colorado USA) and Qiagen AllStars 
non-targeting control from Qiagen (Southampton, UK). siRNA pool contains 4 individual 
oligonucleotides. Sequences were obtained as 5 nmol lyophilised pellets and were diluted to 
10 μM with RNase-free water in a Tissue culture hood with laminar flow, mixed on an orbital 
shaker for 30 minutes at room temperature and aliquoted. 
siRNA Target sequence 









Antibodies were used to probe for specific proteins of interest during immunoblot analysis. 
Antibodies were diluted in Odyssey blocking buffer (LI-COR Biosciences, Cambridge, UK) and 
1x phosphate buffered saline (PBS, Fisher scientific UK, Loughborough, UK) 1:1 with 1 % 
tween-20 (Sigma Aldrich, St. Louis, Missouri, USA) and applied to Immobilon-FL 
polyvinylidene diflouride (PVDF) membranes (Sigma Aldrich, St. Louis, Missouri, USA). The 










Table 3.6: Primary Antibodies 
Reactivity, concentration, dilution, molecular weight, source and code shown where 
applicable for each antibody. Antibodies were obtained from Abcam, (Cambridge, UK), 
Bethyl Labs, (Montgomery, Texas, USA), Cell Signalling (Danvers, Massachusetts, USA), Prof 
Dianov (CRUK/MRC Oxford Institute for Radiation Oncology University of Oxford, UK), 
Novagen (Pledran, France), Sigma-Aldrich (St. Louis, Missouri, USA). 































































Table 3.7: Secondary Antibodies 
Host organism, dilution, source and code shown for each antibody. Fluorescently tagged 
secondary antibodies were selected so secondary antibody could bind to primary antibody. 
Secondary antibodies were obtained from Invitrogen (Waltham, Massachusetts, USA) or Li-
cor biosciences (Lincoln, Nebraska, USA). 
Antibody Host organism Dilution Source Code 
Alexa Fluor 680 
anti-mouse IgG 
Goat 1:10000 Invitrogen A21057 
Alexa Fluor 680 
anti-rabbit IgG 
Goat 1:10000 Invitrogen A21076 
IR Dye 800 anti-
rabbit IgG 
Goat 1:10000 Li-Cor 926-32211 
IR Dye 800 anti-
mouse IgG 
Goat 1:10000 Li-Cor 926032210 
 
 
3.1.6 General laboratory reagents 
General laboratory reagents were obtained from Sigma-Aldrich (St Louis, USA), Bio-Rad 
(Hemel, Hempstead, UK), or Fisher Scientific (Loughborough, UK). Chromatography columns 
were from GE Healthcare (Little Chalfont, UK). Ubiquitin was from Boston Biochemicals 
(Cambridge, MA, USA). Overexpression of recombinant proteins was performed using 
Rosetta2 (DE3) pLysS bacterial cells (Merck-Millipore, Watford, United Kingdom) and purified 
via HisTrap HP affinity chromatography column (GE Healthcare, Little Chalfont, UK). 
 
3.1.7 Tissue culture reagents 
AG06173, AG16409 and WI-38 lung fibroblasts were obtained from Prof Dianov, (CRUK/MRC 
Oxford Institute for Radiation Oncology, University of Oxford, UK). All tissue culture reagents 
were obtained from Sigma Aldrich (St. Louis, Missouri, USA) including; Dulbecco’s 
phosphate-buffered saline (PBS), trypsin-EDTA solution 0.25 % (2.5 g porcine trypsin and 0.2 
g EDTA. 4 Na/L of Hank balanced salt solution with phenol red) and Dulbecco’s Modified 
Eagle’s Medium (DMEM) with hydroxyethyl piperazineethanesulfonic acid (HEPES) 
modification, 4500 mg/l, 25 mM HEPES and sodium bicarbonate, sterile filtered was 
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supplemented with 10 % fetal bovine serum (FBS, non-USA origin, sterile filtered) 2 mM L-
glutamine, 100 U penicillin, 0.1 mg streptomycin and 1 % MEM Non-essential amino acid 
solution.  
 
3.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was utilised in order to separate the proteins based on their molecular weight. 
Gels were prepared by initially making the separating gel (377 mM Tris-HCl pH 8.8, 0.1 % SDS, 
2 mM EDTA and the appropriate concentration of acrylamide/bis solution 30:0.8 (Bio-Rad, 
Hemel, Hempstead, UK)), 1 % ammonium persulphate (APS) and 0.1 % 
tetramethylethylenediamine (TEMED) were added to initiate polymerisation and the gel 
poured into a 1.5 mm empty gel cassette until three quarters full and the gel allowed to set 
following overlay with 100 % ethanol. The percentage gel used was dependent on the size of 
protein being analysed. Once set the 5 % stacking gel (125 mM Tris-HCl pH 6.8, 0.1 % SDS, 2 
mM EDTA, 5 % acrylamide/bis solution (30:0.8; Bio-Rad, Hemel, Hempstead, UK), 1 % APS, 
and 0.1 % TEMED) was then added to the remaining quarter of the gel cassette, following 
removal of the ethanol, and either a 10-well or 15-well 1.5 mm comb added and the gel 
allowed to set. Protein extracts (typically 40 µg), in vitro ubiquitylation reaction samples or 
chromatography protein fraction samples were prepared in SDS-PAGE sample buffer (25 mM 
Tris-HCl pH 6.8, 2.5 % mercaptoethanol, 1 % SDS, 10 % glycerol, 0.05 mg/ml bromophenol 
blue, and 1 mM EDTA) and heated for 5 min at 95°C prior to loading on the polyacrylamide 
gel. Electrophoresis was performed in 1x Tris-glycine SDS (TGS) running buffer, (25 mM Tris-
HCl, 0.192 M glycine and 0.1 % SDS, pH 8.5 (Fisher Scientific UK, Loughborough, UK) for 110 
minutes at 125 V in a SDS-PAGE Mini Gel Tank (Fisher Scientific, Loughborough, UK). The 
Precision Plus Protein All Blue Prestained Protein Standards (10-250 kDa; Bio-Rad, Hemel, 
Hempstead, UK) were used as standard protein markers.  Protein levels following 
electrophoretic separation via SDS-PAGE were analysed by either gel protein staining 
(section 3.3) or immunoblotting (section 3.4). 
 
3.3 SDS-PAGE gel protein staining 
The SDS-PAGE gel following electrophoresis (section 3.2) was then rinsed in dH2O before 
incubation in InstantBlue protein stain (Expedeon, San Diego, California, USA) for 1 hour at 
room temperature on a rotating platform. The gel was then washed in 1x PBS for 1 hour at 
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room temperature on a rotating platform. The gel was imaged using the Li-Cor Odyssey 
Infrared Imaging Analysis System (LI-COR Biosciences, Cambridge,UK). 
 
3.4 Immunoblotting 
Following separation of proteins by SDS-PAGE (section 3.2), proteins were transferred onto 
an Immobilon-FL polyvinylidene difluoride (PVDF) membrane (Millipore, Watford, UK) by 
electrophoresis at 20 V for 1 hour in transfer buffer (1x Tris-glycine (TG; 25 mM Tris-HCl pH 
8.3, 192 mM glycine; Fisher Scientific, Loughborough, UK), 20 % methanol) using the Mini 
Blot Module (Fisher Scientific, Loughborough, UK). The PVDF membrane was blocked in 
Odyssey blocking buffer, diluted 1:1 in 1x PBS for 1 hour at room temperature on a rotating 
platform. The blocking buffer was then removed, and the membrane probed with the 
appropriate primary antibody diluted to the relevant concentration (Table 3.6) in Odyssey 
blocking buffer and 1x PBS (1:1), 0.1 % tween-20 and incubated overnight at 4°C on a rotating 
platform. The membrane was then washed three times for 5 minutes with 1x PBS containing 
0.1 % tween-20 and the relevant secondary added diluted to the suggested ratio (Table 3.7) 
in Odyssey blocking buffer and 1x PBS (1:1) with 0.1 % tween-20 for 1 hour at room 
temperature. The membrane was washed as before and an additional final wash was 
performed with 1x PBS prior to imaging using the Li-Cor Odyssey Infrared Imaging Analysis 
System. 
 
3.5 WCE preparation 
Following the harvesting of cells (section 3.23.4), the cell pellet was frozen at -80°C for 1 
hour. The pellet was thawed on ice and resuspended in once packed cell volume (PCV) of 
buffer I (10 mM Tris-HCl pH 7.8, 200 mM KCl, 1 µg/ml of each protease inhibitor; aprototin, 
chymostatin, leupeptin and pepstatin, 100 μM Phenylmethylsulfonyl fluoride (PMSF) and 1 
mM DTT). Following resuspension two PCV of buffer II (10 mM Tris-HCl pH 7.8, 600 mM KCl, 
40 % glycerol, 2 mM EDTA, 0.2 % NP-40, 1 μg/ml of each protease inhibitor; aprototin, 
chymostatin, leupeptin and pepstatin and 1 mM DTT) was added and the suspension 
thoroughly mixed before being mixed via rotation at 4°C for 30 minutes. The cell lysate 
suspension was centrifuged at 40,000 x g for 20 minutes at 4oC, the supernatant collected 
and stored at -80°C. 
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3.5.1 Protein concentration  
Protein concentration was measured using the Bradford protein assay using the protein 
assay dye reagent (Biorad Laboratories Ltd, Hercules, California, USA) to measure 
absorbance at an optical density (OD) of 595 nm (A595) using a UV spectrophotometer, 
following zeroing of the spectrophotometer with a blank sample.  A 0.2 mg/ml BSA protein 
standard was used as a reference to convert the A595 into mg/ml using the calculation: 
Sample concentration (mg/ml): = (0.2/A595BSA) x 40 x A595SAMPLE 
 
3.6 Acid extraction of histones 
Following the harvesting of cells (section 3.23.4), the cell pellet was frozen at -80°C for 1 
hour. The pellet was thawed on ice, resuspended in 100 µl hypotonic buffer (10 mM Tris-HCl 
(pH 8.0), 1 mM KCl, 1.5 mM MgCl2, 1 µg/ml of each protease inhibitor: aprototin, 
chymostatin, leupeptin and pepstatin, and 100 μM PMSF) and the suspension thoroughly 
mixed before being mixed via rotation at 4°C for 30 minutes. The intact nuclei were then 
pelleted by centrifugation at 10,000 × g for 10 minutes at 4°C and following removal of the 
supernatant (cytoplasmic fraction), the nuclei resuspended in 80 µl 0.4 M sulfuric acid and 
incubated overnight at 4°C with rotation. Samples were then centrifuged at 16,000 × g for 
10 minutes at 4°C, the supernatant containing histones removed into fresh eppendorf’s and 
40 µl trichloroacetic acid added dropwise with mixing. The histones were then pelleted by 
centrifugation at 16,000 × g for 10 minutes at 4°C, the supernatant removed, and the pellet 
washed with 100 µl ice cold acetone, centrifuged at 16,000 × g for 10 minute at 4°C, twice. 
The histone pellet was then air-dried for 5-10 minutes at room temperature, before being 
dissolved in 50 µl ddH2O and the protein concentration measured by the Nanodrop ND-1000 
spectrometer. 
 
3.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA molecules based on their size in 
kilobases (kb). Agarose gels (1.5 %, 1 %  or 0.7 %) were prepared by dissolving agarose (broad 
separation range) in 1x or 0.2x Tris-acetate-EDTA (TAE) buffer (Fisher Scientific, 
Loughborough, UK) and heated until the agarose had dissolved, 5 nM SYBR Safe DNA gel stain 
(Fisher Scientific, Loughborough, UK) was added to the solution (except when DNA was 
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fluorescently labelled) and poured into the gel tray of a Mini-Sub Cell GT electrophoresis tank 
(Bio-Rad, Hemel, Hempstead, UK) and left to set for 30 minutes. Once set DNA samples, 
prepared in 1x DNA loading dye (Fisher Scientific, Loughborough, UK) were loaded onto the 
submerged gel. The GeneRuler 1 kb DNA ladder (Fisher Scientific, Loughborough, UK) was 
used as a reference for DNA size. Electrophoresis was performed at 100 V for 1 hour in 1x 
TAE or at 75 V for 1.5 hours in 0.2x TAE and the gel was imaged using the Li-Cor Odyssey 
Infrared Imaging Analysis System.  
 
3.8 Polyacrylamide gel electrophoresis (PAGE) 
PAGE was utilised for the analysis of native DNA samples. Polyacrylamide gels (8 %) were 
prepared using acrylamide/bis-acrylamide solution 19:1 40 % (w/v) (National Diagnostics, 
Nottingham, UK) diluted in 0.5x TBE (44.5 mM Tris, 44.5 mM boric acid and 1 mM EDTA 
(Sigma Aldrich, St. Louis, Missouri, USA)) with 1.25 % APS and 0.25 % TEMED to initiate 
polymerisation. DNA samples were prepared in 5x EMSA loading buffer (30 % glycerol, 0.25 
% xylene cyanol and 0.25 % bromophenol blue (Fisher Scientific UK, Loughborough, UK)) and 
electrophoresed for 3 hours at 175 V, 20 W using the HoeferTM SE400 vertical electrophoresis 
unit (Fisher Scientific UK, Loughborough, UK) with the unit covered for light protection of the 
florescent tags. The gel was imaged using the Li-Cor Odyssey Infrared Imaging Analysis 
System.  
 
3.9 Denaturing PAGE 
Denaturing PAGE was utilised for the analysis of denatured DNA samples. Polyacrylamide 
denaturing (7 M urea) gels (8 %) were prepared using acrylamide/bis-acrylamide solution 
19:1 40 % (w/v) diluted in 1x TBE (90 mM Tris, 90 mM Boric acid, 2 mM EDTA) and the 
solution sterile filtered (0.45 μm and 0.2 μm syringe filters) prior to polymerisation initiation 
with 1.25 % APS and 0.25 % TEMED. Once polymerised, the gel was pre-run to warm the gel 
to around 40°C by electrophoresis for 30 minutes at 300 V prior to sample loading.  Samples 
were mixed 1:1 with formamide loading dye (formamide 0.025 % (w/v) (9.5 % (w/v) Sigma 
Aldrich St. Louis, Missouri, USA) 0.25 % bromophenol blue), heated at 95°C for 5 minutes 
prior to loading onto the 8 % polyacrylamide denaturing gel and being electrophoresed for 
1.75 hours at 300 V, 20 W in 0.5 TBE. The gel was imaged using the Li-Cor Odyssey Infrared 
Imaging Analysis System. 
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3.10 Transformation of competent cells 
Library efficient DH5α competent bacterial cells (Invitrogen, Fisher Scientific, Loughborough, 
UK) were used for the cloning and amplification of plasmid constructs for subsequent 
plasmid DNA purification (section 3.11). On ice, 50 μl DH5α cells were thawed and mixed 
with 1-10 ng of plasmid DNA (or the full 2 μl LIC reaction, or 1 μl Dpn1-treated SDM reaction) 
via gentle mixing. This mix was then incubated on ice for 30 minutes, before being 
transformed via heat shock at 42°C for 45 seconds and placed on ice for a further 2 minutes. 
To the DH5α cells, 950-1950 μl of pre-warmed (37°C) 5 ml lysogeny broth (LB; 2.5 % w/v LB 
granules (10 g/L Tryptone, 5 g/L yeast extract and 10 g/L sodium chloride; Fisher Scientific, 
Loughborough, UK), 0.5 % NaOH, pH 7.2) was added and the DH5α cells incubated at 37°C 
for 1 hour with shaking at 225 rpm. LB agar plates (2.5 % w/v LB granules, 1.5 % w/v agarose, 
0.5 % NaOH, pH 7.2) were prepared with appropriate selective antibiotic (30 μg/ml of 
kanamycin or 50 μg/ml of ampicillin) and 50-2000 μl of transformed DH5α cells plated. Plates 
were left overnight to incubate at 37°C. Single colonies were selected and inoculated into 5 
ml LB containing relevant selective antibiotic using a sterile inoculation loop and incubated 
at 37°C overnight with 225 rpm shaking. 
Rosetta2(DE3)pLysS and Rosetta2(DE3) bacterial cells (Merck-Millipore, Watford, United 
Kingdom) were used for the overexpression of recombinant His-tagged proteins. On ice, 20 
μl Rosetta2 cells were thawed and mixed with 5 ng of plasmid DNA via gentle mixing. This 
mix was then incubated on ice for 30 minutes, before being transformed via heat shock at 
42°C for 30 seconds and placed on ice for a further 2 minutes. To the Rosetta2 cells, 500 μl 
of pre-warmed (37°C) 5 ml LB was added and the Rosetta2 cells incubated at 37°C for 1 hour 
with shaking at 225 rpm. LB agar plates were prepared with selective antibiotics and 50-200 
μl of transformed Rosetta2 cells plated. Plates were left overnight to incubate at 37°C. Single 
colonies were selected and inoculated into 5 ml LB containing 30 μg/ml kanamycin and 34 
μg/ml chloramphenicol selective antibiotics using a sterile inoculation loop and incubated at 
37°C overnight with 225 rpm shaking. 
 
3.11 Plasmid DNA purification from bacterial cultures  
Following the amplification of plasmid DNA in 5 ml overnight cultures grown following the 
transformation of competent bacterial cells (section 3.10), the plasmid DNA was purified 
from bacterial contaminants using the QIAprep Spin Miniprep Kit (Qiagen, Southampton, 
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UK). The 5 ml overnight culture was centrifuged at 5000 rpm for 5 minutes to pellet the 
bacteria. The supernatant was removed, and the plasmid DNA purified from the bacterial 
pellet as per the QIAprep Spin Miniprep Kit manufacturer’s instructions. DNA concentration 
was measured using Nanodrop ND-1000 spectrometer at a wavelength of OD 260nm. 
Confirmation of DNA sequence was achieved by DNA sequencing from the Sanger 
Sequencing Service (provided by Source Bioscience Sequencing, Nottingham, UK). 
 
3.12 Ligation independent cloning 
In order to generate the bacterial recombinant protein expression vector pET28a-HECTD1-
1761 expressing truncated HECTD1 protein (ΔN-HECTD1), a LIC cloning strategy was 
employed [323]. The empty pET28a vector (Merck, Darmstadt, Germany) was amplified by 
PCR using custom oligonucleotide primers flanked by LIC sequences (Table 3.3).  Similarly, 
gene inserts for a mammalian vector of murine HECTD1 were amplified by PCR using custom 
oligonucleotide primers flanked by LIC sequences (Table 3.3). PCR reactions consisted of 5 
ng of the relevant DNA component with 1x HF Phusion buffer (containing 1.5 mM MgCl2 
(Fisher Scientific, Loughborough, UK)) or 1x GC Phusion buffer (containing 1.5 mM MgCl2 
(Fisher Scientific, Loughborough, UK)), 200 μM of each dNTP (dATP, dGTP, dTTP and dCTP), 
0.02 U/μl Phusion High-Fidelity DNA Polymerase (Fisher Scientific, Loughborough, UK) and 
0.3 μM of relevant forward and reverse custom LIC primers (Eurogentec, Southampton, UK 
(Table 3.3)). PCR was performed in the Techne Prime Thermal Cycler PCR machine (Techne, 
Staffordshire, UK) where they were incubated for 2 minutes at 98°C, followed by 30 cycles 
of 98°C (30 seconds per kb), 57°C (30 seconds per kb), and 72°C (30 seconds per kb). Final 
extension was performed at 72°C for 5 minutes and reaction mixtures were stored at 4°C. 
PCR products were analysed via agarose gel electrophoresis (section 3.7) on a 1 % agarose 
gel in 1x TAE running buffer at 100 V for 1 hour. Gels were analysed using the LI-COR Odyssey 
Infrared Imaging System. Reactions were incubated with 0.02 U/μl DpnI for 90 minutes at 
37°C in a Techne Prime Thermal Cycler PCR machine to digest methylated DNA. PCR DNA 
products were purified using the QIAquick PCR Purification Kit (Qiagen, Southampton, UK) as 
per the manufacturer’s instructions. DNA concentration was measured using Nanodrop ND-
1000 spectrometer at a wavelength of OD 260nm. Following this, complimentary LIC 
overhangs were generated. 10 μl reaction mixtures were prepared consisting of 5 μl purified 
PCR DNA product, 1x T4 DNA Polymerase buffer (165 mM Tris acetate pH 7.9, 330 mM 
sodium acetate, 50 mM magnesium acetate, and 5 mM DTT (Fisher Scientific, Loughborough, 
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UK)), 2.5 mM dCTP (for insert DNA) or dGTP (for vector DNA), 5 mM DTT, 0.5 mg/ml bovine 
serum albumin (BSA), and 0.5 U/μl T4 DNA polymerase (Fisher Scientific, Loughborough, 
UK)). Reactions were incubated at 22°C for 30 minutes followed by 80°C for 30 minutes in a 
Techne Prime Thermal Cycler PCR machine. LIC (vector:insert) reactions were incubated at 
ratios of 1:0.5, 1:1 and 1:3 at 22°C for 10 minutes to anneal insert into the bacterial 
expression vector. LIC reactions were transformed into library efficient DH5α competent 
bacterial cells (Invitrogen, Fisher Scientific, Loughborough, UK) via heat shock and the 
plasmids amplified and purified via the previously described methods (sections 3.10 and 
3.11).  
 
3.13 Site-directed mutagenesis 
Site-directed mutagenesis was used to generate an E3 ligase inactive mutant of ΔN-HECTD1 
(pET28a-mutHECTD1-1761) via a single cysteine (C) to glycine (G) point mutation in the active 
site. PCR reactions consisted of 250 pg/μl of the plasmid of interest (pET28a-HECTD1-1761), 
0.3 μM of relevant forward and reverse custom SDM primers (Eurogentec, Southampton, UK 
(Table 3.4)), 1x HF Phusion buffer (containing 1.5 mM MgCl2 (Fisher Scientific, Loughborough, 
UK)), 200 μM of each dNTP (dATP, dGTP, dTTP and dCTP) and 0.02 U/μl Phusion High-Fidelity 
DNA Polymerase (Fisher Scientific, Loughborough, UK). Samples were incubated in the 
Techne Prime Thermal Cycler PCR machine (Techne, Staffordshire, UK) for 2 minutes at 98°C, 
followed by 18 cycles of 98°C for 30 seconds, 55°C for 1 minute per kb and 72°C for 8 minutes. 
Final extension was performed at 72°C for 20 minutes before storage at 4°C. PCR products 
were analysed via agarose gel electrophoresis (section 3.7) on a 1 % agarose gel in 1x TAE 
running buffer at 90 V for 1 hour. Gels were analysed using the LI-COR Odyssey Infrared 
Imaging System (LI-COR Biosciences, Cambridge, UK). Reactions were incubated with 0.02 
U/μl DpnI for 90 minutes at 37°C in a Techne Prime Thermal Cycler PCR machine to digest 
methylated DNA. SDM reactions were transformed into library efficient DH5α competent 
bacterial cells (Invitrogen, Fisher Scientific, Loughborough, UK) via heat shock and the 







3.14 Preparation of His-tagged proteins 
 
 
3.14.1 Overexpression of recombinant His-tagged proteins 
His-tagged pET28a-HECTD1-1761 or pET28a-mutHECTD1-1761 plasmid was transformed via 
heat shock into Rosetta2(DE3)pLysS bacterial cells and the plasmid DNA amplified in 5 ml 
overnight cultures (section 3.10). Following this, 400 µl of the 5 ml overnight Rosetta2 
bacterial culture was used to feed three 40 ml LB cultures (containing 30 mg/ml kanamycin 
and 0.1 % glucose) and grown until an OD600nm of 0.6-0.8 at 37°C with 225 rpm shaking. The 
entire 40 ml cultures were expanded to 400 ml LB cultures (containing 30 mg/ml kanamycin 
and 0.1 % glucose) and grown until an OD600nm of 0.6-0.8 at 37°C with 225 rpm shaking. 
Protein expression was induced via the addition of 1 mM IPTG and incubated at 30°C with 
225 rpm shaking for 3 hours. The cultures were centrifuged at 8000 rpm for 20 minutes, the 
supernatant aspirated and pellets stored at -80°C.  
 
 
3.14.2 Bacterial cell lysis 
The bacterial cell pellet previously acquired (section 3.14.1) was thawed and resuspended in 
bacterial lysis buffer (25 mM Tris-HCl, pH8, 0.5 M NaCl, 5 % glycerol, 5 mM imidazole, 100 
mM PMSF and 1 µg/ml of each protease inhibitor; leupeptin, chemostatin, pepstatin and 
aprototin). 0.1 mg/ml lysozyme was added and the cells were incubated on ice for 15 
minutes. Cells were lysed by sonication for 3x15 second bursts with 30 seconds intervals on 
ice. Cell lysates were transferred to Oakridge tubes and centrifuged at 25000 rpm for 20 
minutes at 4°C. The supernatant was collected and filtered through a 1 μM syringe prefilters 
followed by a 0.45 μM syringe filter. 
 
3.14.3 His-trap chromatography purification of recombinant His-tagged proteins 
The bacterially overexpressed His-tagged recombinant proteins were purified from the 
bacterial cell lysate via 1 ml HisTrap HP affinity chromatography columns (GE Healthcare, 
Little Chalfont, UK) attached to the AKTA-prime FPLC. The column was equilibrated at 4°C 
using 2-3 column volumes of HisTrap buffer A (25 mM Tris-HCl pH 8.0, 0.5 M NaCl, 5 % 
glycerol, 5 mM imidazole, and 100 μM PMSF). The lysate was loaded onto the column which 
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was washed with HisTrap buffer A, eluting unbound proteins until UV signal stabilisation. 
Bound proteins were collected via a linear gradient of 5-250 mM imidazole with 20 ml 
HisTrap buffer A and HisTrap buffer B (25 mM Tris-HCl pH 8.0, 0.5 M NaCl, 5 % glycerol, 250 
mM imidazole, and 100 μM PMSF) collecting 0.5 ml fractions. Fractions were analysed by 
SDS-PAGE (section 3.2), gel protein staining (section 3.3) and immunoblotting (section 3.4) 
using anti-His antibodies to select fractions.  Fractions containing the purified recombinant 
protein of interest were pooled, concentrated and buffer exchanged into JPDB buffer (50 
mM Tris-HCl pH 8, 50 mm KCl, 1 mM EDTA, 5 % glycerol) using 15 ml, 10 MWCO Amicon Ultra 
centrifugal filters (Millipore, Watford, UK) to 500 μl at 5000 rpm and 4°C before storage at    
-80°C.  
 
3.15 Preparation of site specific DNA damage containing DNA 
 
 
3.15.1 Amplification of 601 nucleosome positioning sequence 
The 601 nucleosome positioning sequence was amplified from the pGEM3Z-601 plasmid 
using fluorescently tagged primers (Table 3.1). PCR reactions consisted of 200 μM dNTPS 
(Sigma Aldrich, St. Louis, Missouri, USA), 1x Phusion HF buffer, 2 mM MgCl2, 0.02 U/µl 
Phusion Hot Start II DNA polymerase (Fisher Scientific UK, Loughborough, UK), 0.3 μM of 
each forward and reverse primers and 25 pg/μl P-GEM3Z-601 plasmid.  PCR was performed 
in the Techne Prime Thermal Cycler PCR machine (Techne, Staffordshire, UK) where the 15 
reactions were incubated for 1 minute at 98°C, followed by 40 cycles of 98°C for 20 seconds, 
57°C for 45 seconds, and 72°C for 45 seconds. Final extension was performed at 72°C for 10 
minutes and reaction mixtures were stored at 4°C. The 256 bp nucleosome positioning 
sequence was analysed via agarose gel electrophoresis (section 3.7) on a 1.5 % agarose gel 
in 1x TAE running buffer at 100 V for 1 hour. Gels were analysed using the LI-COR Odyssey 
Infrared Imaging System. The PCR reactions were pooled and purified using the QlAquick PCR 
purification kit as per the manufacturer’s instructions, split across three columns and eluted 
in EB buffer. DNA concentration was measured using Nanodrop ND-1000 spectrometer at a 




3.15.2 Restriction digests of the 601 nucleosome positioning sequence 
The central 17 bp region with 3 base overhang of the 256 bp nucleosome positioning 
sequence was removed via restriction digest using 20 U Bgll and 50 U Van91I restriction 
enzymes with 1 x Buffer R (Fisher Scientific UK, Loughborough, UK) and incubated overnight 
at 37°C at 800 rpm. To check the efficiency of the restriction digests the 127 bp and 106 bp 
digest products was analysed via agarose gel electrophoresis (section 3.7) on a 1.5 % agarose 
gel in 1x TAE running buffer at 100 V for 1 hour. Gels were analysed using the LI-COR Odyssey 
Infrared Imaging System.  After efficient restriction digest, the entire sample was loaded onto 
an 8 % PAGE gel and the digest products separated in 0.5x TBE at 175 V, 20 W for 3 hours. 
The gel was imaged using the LI-COR Odyssey Infrared Imaging System. The digested 
products (127 bp and 106 bp) were excised from the gel and sliced into small pieces and 
placed into separate 1.5 ml amber tube and stored at -80°C for a minimum of 20 minutes in 
accordance with the freeze/squeeze method of DNA extraction [324].  
 
3.15.3 DNA purification from gel pieces 
DNA (127 bp and 106 bp) in gel pieces following freezing were incubated in TE buffer (10 mM 
Tris, pH 8 and 1 mM EDTA) at 37°C for 3 hours at 800 rpm. Following incubation, the TE buffer 
was removed and filtered through Spin-X columns by centrifugation at 13,000 x g for 1 
minute. The flow through was collected and transferred to amber 1.5 ml tubes. Gel pieces 
were re-incubated in fresh TE buffer for 1 hour at 37°C and 800 rpm and the TE buffer filtered 
as before. The gel pieces were then added to the Spin-X columns and centrifuged at 13,000 
x g for 5 minutes to remove any residual TE buffer. The filtrates were then concentrated 
using Amicon Ultra 0.5 ml devices (10 kDa MWCO (EMD Millipore, Darmstadt, Germany)) to 
approximately 50 μl. DNA concentration was measured using Nanodrop ND-1000 
spectrometer at a wavelength of OD 260nm. The purification of the two digest products was 
checked and analysed using PAGE (section 3.8) on an 8 % polyacrylamide gel.  
 
3.15.4 Preparation of duplex oligonucleotide 
The duplex oligonucleotide was prepared for ligation by creating a reaction mix containing 
either the two 20 bp single strand DNA sequences for THF-IN or TG-IN (Table 3.2) at 10 pmol 
with 200 mM NaCl in TE buffer. The oligonucleotides were then heated at 95°C for 5 minutes 
in a metal heat block which was then removed from the heater to allow the samples to slow 
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cool to room temperature for approximately 2 hours, allowing strand annealing. After 
annealing they formed a 17 bp oligonucleotide with a 3’- 3-base overhang (17 bp duplex 
oligonucleotide).  
 
3.15.5 Sequential ligation of restriction digest products 
The DNA digest product with the highest DNA concentration was ligated to the 17bp duplex 
oligonucleotide, which was in 3 times excess of the DNA (127 bp or 106 bp) with 5 U T4 DNA 
ligase and 1x T4 DNA ligase buffer (Thermo Scientific, Massachusetts, USA) and incubated 
overnight at 4°C. Ligation efficiency was checked to ensure >90 % efficiency by analysis 
against an unligated DNA control using 8 % PAGE (section 3.8) and the 147 or 126 bp IR700 
or AF680 tagged ligated DNA visualised. If ligation was unsuccessful, more duplex 
oligonucleotide DNA and T4 ligase was added and overnight ligation repeated. Once 
successful ligation was obtained the samples were heated at 65°C for 10 minutes to 
inactivate T4 DNA ligase and denature any duplex oligonucleotide DNA. The DNA was then 
purified by using the MinElute reaction clean-up kit following the manufacturer’s instructions 
(Qiagen, Hilden, Germany). DNA was eluted by two sequential 10 µl elutions with buffer EB 
into a 1.5 ml amber tube.  
Following this a second ligation of the ligated DNA and the remaining 106 bp or 126 bp DNA 
fragment was prepared together with 5 U T4 DNA ligase and 1x T4 DNA ligase buffer and 
incubated overnight at 4°C. Ligation efficiency was checked to ensure >90 % efficiency by 
analysis against the first ligation as a control using 8 % PAGE (section 3.8) and the fully ligated 
256 bp DNA gel purified, extracted from gel pieces, concentrated and the purity checked as 
stated previously (section 3.15.3). The concentration of the final 256 bp DNA containing a 
THF or TG site was measured using Nanodrop ND-1000 spectrometer at a wavelength of OD 
260nm and stored at -20°C until required. 
 
3.16 Preparation of unlabelled 601 DNA 
Unlabelled 601 nucleosomal DNA sequence, as carrier DNA, was prepared in the same 
manner as THF and TG containing DNA (section 3.15.1), amplified using the same PCR 




3.17 Expression and purification of recombinant histones 
The protocol, which is detailed below, was followed from Luger et al [325] and the Xenopus 
Laevis histones (H2A, H2B, H3 and H4) expression vectors were obtained from Professor 
Karolin Luger (University of Colorado Boulder, Boulder, USA). 
 
3.17.1 Recombinant histone expression 
Rossetta2(DE3)pLysS cells were transformed with 2.5 ng pET-expression vector for H2A, H2B 
and H3, whereas the pET-expression vector for H4 was transformed into Rosetta2(DE3) cells 
(Merck-Millipore, Watford, UK) (section 3.10). For recombinant histone expression, 200 µl 
2x TY media (1 % (w/v) bacto tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl, pH 7 (Sigma 
Aldrich, St.Louis, Missouri, USA)) was added to the cell/plasmid mix and incubated at 37°C 
for 1 hour with shaking at 225 rpm. TYE agar plates (1 % bacto tryptone, 0.5 % yeast extract, 
0.8 % NaCl, 1.5 % (w/v) agar, (Fisher Scientific UK, Loughborough, UK)) were prepared with 
50 μg/ml ampicillin and 34 μg/ml chloramphenicol selective antibiotics and 75 μl of 
transformed Rosetta2 cells plated. Plates were left overnight to incubate at 37°C. Single 
colonies were selected and inoculated in four separate universal tubes 2 ml 2xTY media 
containing 50 μg/ml ampicillin, 34 μg/ml chloramphenicol and 0.1 % glucose incubated at 
37°C with shaking until an OD600nm of 0.4. 0.5 ml was removed from each culture and added 
to 10 ml 2xTY containing 50 μg/ml ampicillin, 34 μg/ml chloramphenicol and 0.1 % glucose 
and incubated at 37°C with shaking until an OD600nm of 0.4. 8 ml of each culture was then 
added to 500 ml 2xTY containing 50 μg/ml ampicillin, 34 μg/ml chloramphenicol and 0.1 % 
glucose and incubated at 37°C with shaking until an OD600nm of 0.4. Histone expression was 
induced by adding 0.2 mM IPTG (Fisher Scientific UK, Loughborough, UK) to each culture and 
incubated at 30°C with shaking for 2 hours. Cells were harvested and centrifuged at 5000 
rpm for 10 minutes at room temperature and the supernatant removed. Each cell pellet was 
re-suspended in 10 ml wash buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 5 mM β-
mercaptoethanol, 0.3 mM PMSF (Sigma Aldrich, St. Louis, Missouri, USA) and stored at -80°C. 
 
3.17.2 Inclusion body preparation 
The histone proteins are expressed in an insoluble form, thus must be isolated from inclusion 
bodies following cell lysis. Therefore, the bacterial cells in wash buffer were thawed at 37°C, 
1 mg/ml lysozyme added and incubated on ice for 30 minutes. Cells were lysed by sonication 
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for 2x30 second bursts with 30 seconds intervals on ice. Cell lysates were transferred to 
Oakridge tubes and centrifuged at 25,000 rpm for 20 minutes at 4°C. The supernatant was 
removed and 10 ml wash buffer added (as used previously with added 1% Triton X-100, 
(Fisher Scientific UK, Loughborough, UK)). Lysates were further sonicated and centrifuged an 
additional three times as described before, on the final resuspension 10 ml wash buffer was 
added without Triton. In exception, H4 was only sonicated, centrifuged and re-suspended in 
wash buffer the once as it is prone to lysis. After this final wash step, all histones were 
centrifuged for a final time, the supernatant poured off and the histone pellets stored at -
20°C.  
 
3.17.3 Recombinant histone purification by gel filtration chromatography 
Histone purification involved a two-step purification procedure and each histone protein was 
purified separately. The first step involved gel filtration using an AKTA fast protein liquid 
chromatography (FPLC, GE Healthcare, Little Chalfont, UK) under denaturing conditions. A 
320ml Sephacryl S-200 gel filtration column, (GE Healthcare, Little Chalfont, UK) was 
attached to an AKTA FPLC purifier and equilibrated with gel filtration buffer (20 mM sodium 
acetate pH 5.2, 1 M NaCl, 7 M urea, 1 mM EDTA and 5 mM β-mercaptoethanol) for 1.5 
column volumes at 1.5 ml/min. The histone pellets were individually incubated in 200 μl 
Dimethyl sulfoxide (DMSO (Sigma Aldrich, St. Louis, Missouri, USA)) for 30 minutes at room 
temperature then minced in 10 ml 1x unfolding buffer (7 M guanidinium HCl (Fisher scientific 
UK, Loughborough, UK), 20 mM Tris pH 7.5, 10 mM DTT) which was added dropwise. The 
pellets were stirred for 1 hour at room temperature. This was then centrifuged at 23,000 x g 
for 20 min at 20°C, the supernatant removed and filtered through 1 µm syringe filters. Using 
a 10 ml superloop (GE healthcare, Little Chalfont, UK) the sample was loaded onto the S-200 
column at 1.5 ml/min. After approximately 85 ml, the protein started to elute and 4 ml 
fractions were collected until the UV signal reduced and stabilised so no more protein was 
being eluted. The peak fractions were analysed by 16 % SDS-PAGE (section 3.2) and gel 
staining (section 3.3) to identify peaks containing the relevant histones. 
 
3.17.4 Recombinant histone purification by FPLC ion-exchange chromatography 
Fractions from gel filtration chromatography (section 3.17.3) containing histones were 
dialysed in snakeskin dialysis tubing (35 mm Dry ID, 7 kDa MWCO (Thermo Fisher Scientific, 
Massachusetts, USA)) in 2 L of distilled water containing 2 mM β-mercaptoethanol at 4°C for 
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2 hours. The histone fractions were then dialysed in fresh distilled water containing 2 mM β-
mercaptoethanol at 4°C overnight. The dialysed fractions were concentrated in Amicon Ultra 
centrifugal concentrators (3 kDa MWCO (Merck-Millipore, Watford, UK)) to approximately 
1-2 ml. A 1 ml HiLoad 16/10 sepharose high performance MonoS column (GE Healthcare, 
Little Chalfont, UK), was attached to the AKTA FPLC and the column equilibrated with cold 
low salt buffer (20 mM NaAc pH 5.2, 0.1 M NaCl, 7 M urea, 1 mM EDTA, 5 mM β-
mercaptoethanol) for 3 column volumes at 1 ml/min. The dialysed histone sample was then 
loaded onto the column which was washed until no more protein eluted. Histone proteins 
were gradient eluted with 20 ml low salt buffer to high salt buffer (20 mM NaAc pH 5.2, 1 M 
NaCl, 7 M urea, 1 mM EDTA, 5 mM β-mercaptoethanol) at 1 ml/min collecting 0.5 ml 
fractions. The peak fractions were analysed by 16 % SDS-PAGE and gel staining as above 
(section 3.17.3). Fractions containing histones were pooled and dialysed in snakeskin dialysis 
tubing (35 mm Dry ID, 7 kDa MWCO) in 2 L water with 5 mM β-mercaptoethanol at 4°C 
overnight. This was dialysed for a further 4 hours at 4°C with fresh water and 5 mM β-
mercaptoethanol. The dialysed fractions were concentrated in Amicon Ultra centrifugal 
concentrators (3 kDa MWCO) to 0.5 ml. The concentration of the histones was measured 
Nanodrop ND-1000 spectrometer at a wavelength of OD 280 nm using molecular weights 
and extinction coefficients (ɛ) (Table 3.8). Histones were aliquoted in the following equimolar 
amounts in preparation for octamer refolding (2mg H2A, 2mg H2B, 2.25mg H3 and 1.17mg 
H4) and stored at -80°C. 
Table 3.8: Histone molecular weights and extinction coefficients (ɛ) 
Molecular weight and ɛ used to calculate the concentration of the histone proteins using the 
Nanodrop ND-1000 spectrometer at a wavelength of OD 280 nm 
Histone Molecular weight (KDa) ɛ (cm/M) x 103 
H2A 13.96 4.05 
H2B 13.77 6.07 
H3 15.27 4.04 





3.17.5 Refolding of the histone octamer 
The histone aliquots were individually dissolved to a concentration of 2 mg/ml using 1.25x 
unfolding buffer (25 mM Tris-HCL pH 7.5, 8.75 M guanidinium HCL, 12.5 mM DTT) and 
incubated on ice for 2 hours to allow the proteins to unfold. All the histones were then mixed 
with an equal volume of 1x unfolding buffer to create a 1 mg/ml histone solution. Histones 
were then dialysed in snakeskin dialysis tubing (35 mm Dry ID, 7 kDa MWCO) in 600 ml 
refolding buffer (10 mM Tris-HCl pH7.5, 2 M NaCl, 1 mM EDTA, 5 mM β-mercaptoethanol) 
for 6 hours at 4°C and further dialysed overnight in fresh refolding buffer at 4°C. The histones 
were then dialysed for a final 4 hours in fresh refolding buffer at 4°C. The dialysed histone 
octamer was centrifuged at 14,000 rpm for 20 minutes at 4°C, the supernatant collected and 
concentrated using Amicon Ultra centrifugal concentrators (10 kDa MWCO) to 400 μl. This 
was then loaded in two 200 µl samples onto a 24 ml Superdex 200 10/300GL gel filtration 
column (GE Healthcare, Little Chalfont, UK), attached to a FPLC (equilibrated with refolding 
buffer for 1.5 hours at 0.5 ml/min) and 0.5 ml fractions collected until the UV signal reduced 
and stabilised. The peak fractions were analysed by 16 % SDS-PAGE and gel staining as above 
(section 3.17.3). Fractions containing the histone octamer in the correct equimolar ratios 
were pooled and concentrated to 0.5 ml using Amicon Ultra centrifugal concentrators (10 
kDa MWCO). The concentration of the histones was measured Nanodrop ND-1000 
spectrometer at a wavelength of OD 280nm and 40 % glycerol and 5 M NaCl was added to 
produce a 5 mg/ml histone octamer stock which was stored at -20°C.  
 
3.18 Nucleosome Reconstitution 
The nucleosome reconstitution mix was prepared by mixing 5 pmol fluorescently labelled 
256 bp THF or TG DNA, 75 pmol unlabelled 601 nucleosomal DNA, 50 μg BSA molecular 
biology grade (New England Biolabs Ltd, Luton, UK), 0.01 % NP-40, 2 M NaCl, 80 pmol Histone 
Octamer in a final volume of 280 μl distilled water. This was incubated for 10 minutes at 
room temperature before being transferred to pre-washed (with distilled water and 0.1 
mg/ml BSA) 6.4 mm diameter dialysis tubing 8 kDa MWCO (Fisher Scientific UK, 
Loughborough, UK).  The mix was dialysed in 500 ml of decreasing concentrations of NaCl 
(1.6 M, 1.2 M, 0.8 M, 0.6 M, 0.2 M and 0.075 M NaCl, with 10 mM Tris HCl pH 7.4, 1 mM 
EDTA and 5 mM β-mercaptoethanol) for 1.5 hours each at 4°C and the final dialysis left 
overnight (0.075 M NaCl). The efficiency of the nucleosome reconstitution was analysed 
using a 0.7 % agarose gel in 0.2x TAE buffer (section 3.7). 50 fmol of the nucleosome 
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reconstitution and unlabelled 601 nucleosomal free DNA in 5x loading buffer with a 100 bp 
DNA ladder were loaded onto the agarose gel and electrophoresed at 75 V for 1.5 hours. The 
gel was imaged using the Li-Cor Odyssey Infrared Imaging Analysis System (LI-COR 
Biosciences, Cambridge,UK). Comparison to the free DNA was used to quantify successful 
nucleosome reconstitution whereby a shift to a high molecular weight species 
(approximately 700 bp) was observed when the nucleosome was formed. If >90 % successful, 
the mononucleosome substrate was stored at 4°C. 
 
3.19 In vitro BER assay and DNA extraction 
Reactions, prepared on ice, contained 50 fmol DNA containing the site-specific THF or TG 
site, 0.7 pmol GST-E1 activating enzyme, 2.5 pmol E2 conjugating enzyme (combination of 9 
different E2s (UbE2H, Cdc34, UbE2D1, UbE2D2, UbE2D3, UbE2E1, UbE2L3, UbE2L6 and 
UbE2C)), 0.6 nmol ubiquitin (Boston Biochemicals, Cambridge, USA) and 1 µg acetylated BSA 
in buffer (25 mM Tris-HCl (pH 8.0), 50 mM KCl, 2 mM ATP, 8.5 mM MgCl2, 0.5 mM EDTA, 8.5 
% glycerol and 1 mM DTT), 50 fmol APE1 or 1.45 pmol NTH1 and ΔN-HECTD1 or ΔN-
mutHECTD1 (0-15 pmol titration). Reactions were incubated in 1.5 ml amber eppendorfs for 
1 hour at 30°C with 800 rpm. Reactions were stopped by the addition of 20 mM EDTA and 
0.4 % SDS. DNA was extracted using phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma 
Aldrich St. Louis, Missouri, USA)  and then once with chloroform:isoamyl alcohol (24:1) 
(Sigma Aldrich St. Louis, Missouri, USA) where at each step the sample was vortexed and 
centrifuged at 15,000 x g for 1 minute and the upper aqueous (DNA containing) layer 
removed. Following this, reactions were cleaned up in Bio-Spin P-30 Gel Columns (Bio-Rad, 
Watford, UK), prepared with 3x washes in TE buffer centrifuged at 15,000 x g for 1 minute 
and 1 final wash at 15,000 x g for 2 minutes. Samples were added to the columns and 
centrifuged at 15,000 x g for 4 minutes before being analysed by 8 % denaturing PAGE 
(section 3.9). 
 
3.20 In vitro ubiquitylation assay 
To assess the in vitro ubiquitylation of APE1 and the core histone proteins (H2A, H2B, H3 and 
H4), reaction mixtures were prepared in LoBind reaction tubes (Eppendorf, Stevenage, UK). 
Reaction mixtures consisted of 5.88 pmol APE1 or 1.85 pmol histone octamer, 1x ubiquitin 
buffer (25 mM Tris-HCl pH 8.0, 5 mM MgCl2, 200 μM CaCl2, 1 mM DTT, and 10 μM MG-132), 
102 
 
40 mM ATP, 0.7 pmol glutathione S-transferase (GST)-E1 activating enzyme, 2.5 pmol E2-
conjugating enzyme (a combination of nine different E2s, unless otherwise stated), and 0.6 
pmol ubiquitin. The source of E3 ligase activity was provided by the addition of ΔN-HECTD1 
(APE1 reactions; 2.76 pmol, 5.52 pmol and 13.8 pmol, histone octamer reactions; 5.1 pmol, 
10.2 pmol and 20.41 pmol). Reactions were incubated at 30°C for 1 hour with 800 rpm 
shaking. The reactions were stopped by the addition of 3x SDS-PAGE sample buffer (25 mM 
Tris-HCl pH 6.8, 2.5 % -mercaptoethanol, 1 % SDS, 10 % glycerol, 1 mM EDTA, 0.05 mg/ml 
bromophenol blue), heated at 95°C for 5 minutes, and analysed via 10 % SDS-PAGE (section 
3.2) and immunoblotting (section 3.4). 
 
3.21 In vivo ubiquitylation assay 
To assess the in vivo ubiquitylation of the histone H2B and H3 proteins, WI-38 cells were 
seeded into 10 cm dishes, grown until 30-50 % confluent before being transfected with 
HECTD1 siRNA or non-targeting siRNA for 48 hours (section 3.24). Following this, cells were 
incubated on ice for 5 minutes to supress DNA repair activity and, except for in control 
conditions, irradiated with 10 Gy IR. Following induction of DNA damage (section 3.25), the 
media was aspirated, cells were washed in 5 ml PBS, media replaced, and cells incubated at 
37°C and 5 % CO2 in a humidified cell culture incubator for a set period (15 minutes, 30 
minutes or 1 hour). Cells were then harvested (section 3.23.4), histone extracts prepared 
(section 3.6) before samples were analysed via 16 % SDS-PAGE (section 3.2) and 
immunoblotting (section 3.4).   
 
3.22 DNase footprinting  
 
3.22.1 DNase footprinting free DNA dose titration 
Reactions, prepared on ice, contained 50 fmol DNA containing the site-specific THF site, 
DNase I (0-0.5 units) and 1x DNase I reaction buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM 
CaCl2, pH 7.6) (New England Biolabs Ltd, Luton, UK). Reactions were incubated in 1.5 ml 
amber eppendorfs for 2 minutes at room temperature. Reactions were stopped by mixing 
1:1 with formamide loading dye (formamide 0.025 % (w/v) (9.5 % (w/v) Sigma Aldrich St. 
Louis, Missouri, USA) 0.25 % bromophenol blue), heated at 95°C for 5 minutes prior to 
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electrophoresis analysis by 8 % denaturing PAGE (section 3.9) sequencing gel, 
electrophoresed for 80 minutes at 1800 V, 42 W in 0.5x TBE using the Thermo ScientificTM 
OwlTM Aluminium-Backed Sequencers (Fisher Scientific UK, Loughborough, UK) with the  unit 
covered for light protection of the fluorescently-labelled DNA. The gel was imaged using the 
Li-Cor Odyssey Infrared Imaging Analysis System. 
  
3.22.2 DNase footprinting mononucleosome dose titration 
  
3.22.2.1 Phenol:chloroform:isoamyl alcohol DNA extraction 
Reactions, prepared on ice, contained 100 fmol THF-IN mononucleosome substrate, DNase I 
(0-2 units) and 1x DNase I reaction buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM CaCl2, pH 
7.6) (New England Biolabs Ltd, Luton, UK). Reactions were incubated in 1.5 ml amber 
eppendorfs for 2 minutes at room temperature. Reactions were stopped by the addition of 
20 mM EDTA and 0.4 % SDS. DNA was extracted using phenol:chloroform:isoamyl alcohol 
(25:24:1) (Sigma Aldrich St. Louis, Missouri, USA) and then once with chloroform:isoamyl 
alcohol (24:1) (Sigma Aldrich St. Louis, Missouri, USA) where at each step the sample was 
vortexed and centrifuged at 15,000 x g for 1 minute and the upper aqueous (DNA containing) 
layer removed. Following this, reactions were cleaned up in Bio-Spin P-30 Gel Columns (Bio-
Rad, Watford, UK), prepared with 3x washes in TE buffer centrifuged at 15,000 x g for 1 
minute and 1 final wash at 15,000 x g for 2 minutes. Samples were added to the columns and 
centrifuged at 15,000 x g for 4 minutes before being mixed 1:1 with formamide loading dye 
(formamide 0.025 % (w/v) (9.5 % (w/v) Sigma Aldrich St. Louis, Missouri, USA) 0.25 % 
bromophenol blue), heated at 95oC for 5 minutes prior to electrophoresis analysis by 8 % 
denaturing PAGE (section 3.9) sequencing gel, electrophoresed for 80 minutes at 1800 V, 42 
W  in 0.5x TBE using the Thermo ScientificTM OwlTM Aluminium-Backed Sequencers (Fisher 
Scientific UK, Loughborough, UK) with the unit covered for light protection of the 
fluorescently-labelled DNA. The gel was imaged using the Li-Cor Odyssey Infrared Imaging 




3.22.2.2 Ethanol precipitation DNA extraction  
Reactions, prepared on ice, contained 100 fmol THF-IN mononucleosome substrate, DNase I 
(0-2 units) and 1x DNase I reaction buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM CaCl2, pH 
7.6) (New England Biolabs Ltd, Luton, UK). Reactions were incubated in 1.5 ml amber 
eppendorfs for 2 minutes at room temperature. Reactions were stopped by the addition of 
20 mM EDTA and 0.4 % SDS. DNA was extracted using phenol:chloroform:isoamyl alcohol 
(25:24:1) (Sigma Aldrich St. Louis, Missouri, USA)  and then once with chloroform:isoamyl 
alcohol (24:1) (Sigma Aldrich St. Louis, Missouri, USA) where at each step the sample was 
vortexed and centrifuged at 15,000 x g for 1 minute and the upper aqueous (DNA containing) 
layer removed. Following this, the aqueous layer was mixed with 10 μg glycogen, 1/10 
volume of 3 M NaAc pH 5.2 and 2.5 volumes of cold 100 % ethanol. Samples were mixed 3-
5 times by inversion and incubated at -80°C for >1 hour. Samples were centrifuged at 16,000 
x g for 30 minutes and the supernatant aspirated, 3 volumes of cold 70 % ethanol added and 
centrifuged for a further 10 minutes and the supernatant aspirated. Pellets were left to air 
dry for 5 minutes and 10 μl TE buffer added and pellets thoroughly resuspended. Samples 
were mixed 1:1 with formamide loading dye (formamide 0.025 % (w/v) (9.5 % (w/v) Sigma 
Aldrich St. Louis, Missouri, USA) 0.25 % bromophenol blue), heated at 95oC for 5 minutes 
prior to electrophoresis analysis by 8 % denaturing PAGE (section 3.9) sequencing gel, 
electrophoresed for 80 minutes at 1800 V, 42 W in 0.5x TBE using the Thermo ScientificTM 
OwlTM Aluminium-Backed Sequencers (Fisher Scientific UK, Loughborough, UK) with the unit 
covered for light protection of the fluorescently-labelled DNA. The gel was imaged using the 
Li-Cor Odyssey Infrared Imaging Analysis System.  
 
3.22.3 DNase footprinting with the in vitro BER assay 
Reactions, prepared on ice, contained 100 fmol THF-IN mononucleosome substrate, either 0 
pmol or 10 pmol ΔN-HECTD1, 0.7 pmol GST-E1 activating enzyme, 2.5 pmol E2 conjugating 
enzyme (combination of 9 different E2s), 0.6 nmol ubiquitin (Boston Biochemicals, 
Cambridge, USA), 1 µg acetylated BSA in buffer (25 mM Tris-HCl (pH 8.0), 50 mM KCl, 2 mM 
ATP, 8.5 mM MgCl2, 0.5 mM EDTA, 8.5 % glycerol and 1 mM DTT) and 50 fmol APE1. Reactions 
were incubated in 1.5 ml amber eppendorfs for 1 hour at 30°C with 800 rpm. Reactions were 
stopped by the addition of 20 mM EDTA and 0.4 % SDS. DNA was extracted using 
phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma Aldrich St. Louis, Missouri, USA)  and 
then once with chloroform:isoamyl alcohol (24:1) (Sigma Aldrich St. Louis, Missouri, USA) 
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where at each step the sample was vortexed and centrifuged at 15,000 x g for 1 minute and 
the upper aqueous (DNA containing) layer removed. Following this, the aqueous layer was 
mixed with 10 μg glycogen, 1/10 volume of 3 M NaAc pH 5.2 and 2.5 volumes of cold 100 % 
ethanol. Samples were mixed 3-5 times by inversion and incubated at -80°C for >1 hour. 
Samples were centrifuged at 16,000 x g for 30 minutes and the supernatant aspirated, 3 
volumes of cold 70 % ethanol added and centrifuged for a further 10 minutes and the 
supernatant aspirated. Pellets were left to air dry for 5 minutes and 10 μl TE buffer added 
and pellets thoroughly resuspended. The samples were then incubated with 1 unit DNase I 
in 1x DNase I reaction buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.5 mM CaCl2, pH 7.6) (New 
England Biolabs Ltd, Luton, UK). Reactions were incubated in 1.5 ml amber eppendorfs for 2 
minutes at room temperature. Reactions were stopped by mixing 1:1 with formamide 
loading dye (formamide 0.025 % (w/v) (9.5 % (w/v) Sigma Aldrich St. Louis, Missouri, USA) 
0.25 % bromophenol blue), heated at 95°C for 5 minutes prior to electrophoresis analysis by 
8 % denaturing PAGE (section 3.9) sequencing gel, electrophoresed for 80 minutes at 1800 
V, 42 W in 0.5x TBE using the Thermo ScientificTM OwlTM Aluminium-Backed Sequencers 
(Fisher Scientific UK, Loughborough, UK) with the unit covered for light protection of the 
fluorescently-labelled DNA. The gel was imaged using the Li-Cor Odyssey Infrared Imaging 
Analysis System.   
 
3.23 Tissue culture 
Tissue culture work was carried out using an aseptic technique and performed in a class II 
hood with laminar flow (Esco Global, Barnsley, UK) that was cleaned with 70 % ethanol 
thoroughly before and after use. Trypsin, PBS and complete DMEM media (containing 10 % 
FBS, 2 mM glutamine and 1 % pen-strep) were warmed in a water bath at 37°C prior to use. 
All plastics were tissue culture grade and cells were grown in a humidified cell culture 
incubator in 5 % CO2 at 37°C. 
  
3.23.1  Thawing cells 
Cryovials containing cells frozen in DMEM and 10 % DMSO were removed from liquid 
nitrogen storage and rapidly defrosted for 1 minute in a 37°C water bath. 1 ml complete 
DMEM was added to the cells and gently mixed via pipetting. The cell suspension was 
centrifuged at 1500 rpm for 3 minutes and the DMSO containing supernatant removed. The 
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cell pellet was resuspended and diluted in complete DMEM media to 12 ml and transferred 
to a T75 flask and incubated at 37°C and 5 % CO2 in a humidified cell culture incubator. Once 
cells were approximately 80-90 % confluent the cells were sub-cultured. 
 
3.23.2 Sub culturing 
Once cells were approximately 80-90 % confluent, cells were sub-cultured by aspirating 
DMEM media from the T75 flask and washing the monolayer of cells with 10 ml PBS. The PBS 
was aspirated, and the cells were incubated with 1 ml 0.25 % trypsin-EDTA for 1-5 minutes 
at 37°C and 5 % CO2 in a humidified cell culture incubator. Once the adherent cells had 
detached the trypsin was neutralised using 9 ml media and the cells mixed to create a single-
cell suspension. WI-38 cells were split 1:8 and AG06173 and AG16409 cells split 1:4 into a 
new T75 flask. Cells were stored incubated at 37°C and 5 % CO2 in a humidified cell culture 
incubator. 
 
3.23.3 Long-term storage of cells 
Cells were collected (section 3.23.2) in order to bring them into a single-celled suspension. 
The cell suspension was centrifuged at 1500 rpm for 3 minutes. The resulting cell pellet was 
resuspended in 1 ml freezing medium (FBS with 10 % DMSO) and transferred to a cryovial. 
The cryovials were placed in a Corning™ CoolCell™ LX Cell Freezing Vial Container (Fisher 
Scientific, Loughborough, UK) and placed into a -80°C freezer for 24 hours before being 
transferred to long-term storage in liquid nitrogen. 
 
3.23.4 Harvesting cells 
Tissue culture dishes containing cells that were approximately 80-90 % confluent were 
removed from the tissue culture incubator, the media aspirated and the dishes washed with 
cold PBS before being aspirated. A second volume of cold PBS was added, adhered cells were 
carefully collected using a cell scraper and transferred to a pre-cooled 15 ml tube, this 
process was repeated a second time. The 15 ml tube was centrifuged at 1500 rpm for 5 
minutes at 4°C, the supernatant removed, and the pellet resuspended in 1 ml of cold PBS 
before being transferred to a pre-cooled 1.5 ml eppendorf. The 1.5 ml microcentrifuge tube 
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was then centrifuged at 1500 rpm for 5 minutes at 4°C, the supernatant removed and the 
pellet frozen at -80°C. 
 
3.23.5 Seeding cells 
Cells were seeded prior to various experiments and assays and were collected (section 
3.23.2) in order to bring them into a single-cell suspension. Cells were counted using a 
haemocytometer. In general, 5x106 cells were seeded in 5 ml complete DMEM for a 10 cm 
dish and 1x105 cells in 1 ml complete DMEM for a 3.5 cm dish. 
 
 
3.24 RNA interference  
Depletion of endogenous protein levels was achieved via siRNA-mediated mRNA depletion. 
Cells were seeded into either 3 cm or 10 cm dishes and grown until 30-50 % confluent in 
complete DMEM at 37°C and 5 % CO2 in a humidified cell culture incubator. Per 10 cm dish, 
10 μl Lipofectamine RNAiMax (Life Technologies, Paisley, UK) was added to 500 μl 
supplement-free DMEM and separately, 40 nM of siRNA (Table 3.5) added to 500 μl 
supplement-free DMEM. The supplement free DMEM/Lipofectamine RNAiMax mix was 
added to the supplement free DMEM/siRNA mix, mixed thoroughly and incubated for 10 
minutes at room temperature. This 1 ml solution was then added dropwise to the 10 cm cell 
culture dish containing cells containing 5 ml complete media, and evenly distributed by 
gentle agitation of the dishes. Cells were incubated for 48 hours at 37°C and 5 % CO2 in a 
humidified cell culture incubator. For 3 cm dishes, 2.5 μl Lipofectamine RNAiMAX and 40 nM 
siRNA was added to cells in 250 μl supplement free DMEM using the same method.  
 
3.25 Induction of DNA damage 
AG06173, AG16409 or WI-38 cells were seeded into tissue culture dishes, grown until 30-50 
% confluent before being transfected with HECTD1 siRNA or non-targeting siRNA for 48 hours 
(section 3.24). DNA damage was induced through treatment with ionising radiation (IR) using 
the CellRad X-Ray irradiator (Faxitron, Tuscan, USA) at 3 Gy/minute, hydrogen peroxide 




3.26 Clonogenic assay  
AG06173, AG16409 or WI-38 cells were seeded into 3.5 cm dishes, grown until 30-50 % 
confluent before being transfected with HECTD1 siRNA or non-targeting siRNA for 48 hours 
(section 3.24). Following this, cells were either incubated on ice for 5 minutes to supress DNA 
repair activity and irradiated with increasing doses of IR (0-4 Gy) or incubated with increasing 
does of H2O2 (0-300 µM) or MMS (0-1.5 mM) at 37°C and 5 % CO2 in a humidified cell culture 
incubator. Following induction of DNA damage, the media was aspirated, cells were washed 
in 1 ml PBS, 200 μl 0.25 % trypsin-EDTA added to the cells which were incubated at 37°C and 
5 % CO2 in a humidified cell culture incubator until cells lifted off the tissue culture dishes. 
Trypsin was neutralised in 800 μl media and cells counted using a haemocytometer. A 
defined number of cells were seeded in 2 ml complete DMEM media at two different cell 
densities in triplet for each treatment in 6-well plates (Table 3.9). The plates were incubated 
at 37°C and 5 % CO2 in a humidified cell culture incubator for 7-10 days until colonies were 
clearly visible (>50 cells/colony). Cells were fixed and stained by removing media, washing 
the cells in PBS, and adding 0.5 % crystal violet in 6 % glutaraldehyde (Fisher Scientific UK, 
Loughborough, UK) for 1 hour, washed and left to air dry. Colonies were counted using the 
GelCount colony counter (Oxford Optronix, Oxford, UK). Relative colony forming units 
(surviving fraction) were expressed as colonies per treatment relative to colonies observed 
in the untreated control for each treatment, calculated using the calculation shown below. 
Average surviving fractions were calculated, and values plotted on a log scale against 
treatment doses. Statistical analysis was performed by the CFAssay for R package [326].  
Plating efficiency =                               Number of colonies for untreated control/ 
                                                                       seeding density of untreated control 
Surviving fraction =                            Number of colonies for selected condition/ 










Table 3.9: Clonogenic assay seeding densities relative to treatment 
Numbers shown are the two seeding densities used in triplicate per 6-well plate for HECTD1 
and non-targeting siRNA treatments at each dose of IR, H2O2 or MMS.  
 Seeding density 
IR (Gy) dose  
0 Gy 250/500 
1 Gy 500/1000 
2 Gy 1000/2000 
4 Gy 2000/4000 
H2O2 (µM) dose  
0 µM 250/500 
50 µM 500/1000 
100 µM 1000/2000 
200 µM 2000/4000 
300 µM 4000/8000 
MMS (mM) dose  
0 mM 250/500 
0.25 mM 500/1000 
0.5 mM 500/1000 
0.75 mM 1000/2000 
1 mM 1000/2000 
1.25 mM 2000/4000 
1.5 mM 2000/4000 
 
 
3.27 COMET assay  
The comet assay was used to study repair kinetics following induction of DNA damage [327]. 
WI-38, AG06173 or AG16409 lung fibroblasts were transfected with siRNA targeting either 
HECTD1 or the Qiagen AllStars non-targeting control sequence (section 3.24). To induce DNA 
damage, cells in suspension were treated with 1.5 Gy IR using the CellRad X-ray irradiator at 
3 Gy/min or with 10 µM H2O2 for 5 minutes on ice in the alkaline comet assay and 4 Gy IR or 
30 µM H2O2 in the same manner for the neutral comet assay. DNA damage was also induced 
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for the alkaline comet assay to cells in a monolayer via 0.5 mM MMS treatment in complete 
DMEM at 37°C and 5 % CO2 in a humidified cell culture incubator for 1 hour.   
 
3.27.1 Alkaline COMET assay 
WI-38, AG06173 or AG16409 that had been transfected with siRNA for either HECTD1 or the 
Qiagen AllStars non-targeting control were trypsinised, diluted to 1x105 cells/ml and 250 μl 
cell suspension placed into a 24 well plate prior to DNA damage induction for IR and H2O2 
treatment or following DNA damage induction via MMS. Following this, on ice, cells were 
mixed with 800 µl 1 % low melting point agarose (LMPA (Fisher Scientific UK, Loughborough, 
UK)) in PBS loaded onto to a pre-coated microscope slides (1 ml 1 % normal melting point 
agarose (NMPA (Fisher Scientific UK, Loughborough, UK)) in distilled water). Once the 
agarose had set, slides were placed in a 37°C humidified incubator for a selected length of 
time to allow for DNA repair. Following incubation, slides were lysed in coplin jars containing 
cold lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris base, pH 10.5, 10 % DMSO and 1 % 
tween-20) for >1 hour at 4°C. Slides were placed in a comet assay tank (Appleton Woods Ltc, 
Birmingham, UK) and DNA was allowed to unwind for 30 minutes in cold electrophoresis 
buffer (300 mM NaOH, 1 mM EDTA, 1 % DMSO, pH>13), before electrophoresis was 
performed 25 V, 300 mA for 25 minutes. The slides were then washed 3 times with 1 ml cold 
neutralisation buffer (500 mM Tris-HCl pH 8) for 5 minutes and air dried overnight. Slides 
were rehydrated with distilled water (pH 8.0) for 30 minutes and the DNA stained with 1 ml 
SYBR Gold (1:20,000 in distilled water, pH8.0 (Fisher Scientific UK, Loughborough, UK) for 30 
minutes and air dried again overnight (light protected). Slides were imaged using the BX61 
Olympus microscope and 10x magnification (Olympus, Shinjuku, Japan), taking 10 images per 
slide, containing at least 5 cells per image, with 2 slides per time point. Images were analysed 
using Komet 6.0 software (Andor Technology, Belfast) in order to calculate % tail DNA values. 
 
3.27.2 Neutral COMET assay 
WI-38, AG06173 or AG16409 that had been transfected with siRNA for either HECTD1 or the 
Qiagen AllStars non-targeting control were trypsinised, diluted to 1x105 cells/ml and 250 μl 
cell suspension placed into a 24 well plate prior to DNA damage induction for IR and H2O2 
treatment. Following this, on ice, cells were mixed with 800 µl 1 % low melting point agarose 
(LMPA (Fisher Scientific UK, Loughborough, UK)) in PBS loaded onto to a pre-coated 
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microscope slides (1 ml 1 % normal melting point agarose (NMPA (Fisher Scientific UK, 
Loughborough, UK)) in distilled water). Once the agarose had set, slides were placed in a 
37°C humidified incubator for a selected length of time to allow for DNA repair. Following 
incubation, slides were lysed in coplin jars containing cold lysis buffer (2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris base, 1 % N-lauroylsarcosine, pH 9.5, 10 % DMSO and 1 % tween-20), for 
>1 hour at 4°C. Following lysis, slides were washed 3x with 1 ml cold electrophoresis buffer 
(1x TBE (18 mM Tris-borate, 0.4 mM EDTA, pH 8.3) for 5 minutes, before slides were placed 
and DNA was allowed to unwind in a comet assay tanks, for 30 minutes in cold 
electrophoresis buffer. Electrophoresis was performed 25 V, 20 mA for 25 minutes. The slides 
were then washed 3 times with 1 ml cold PBS for 5 minutes and air dried overnight. Slides 
were then stained, imaged and analysed in the same manner as outlined above in the 



















CHAPTER 4: RESULTS I 
 
In vitro investigation of HECTD1 as a chromatin remodelling enzyme 
enhancing APE1 activity 
 
4.1  Introduction 
The compaction of genetic material into chromatin is essential for the organisation of DNA 
within the nucleus and involves co-ordinated levels of folding amongst histones and non-
histone chromosomal proteins. Via multiple mechanisms, DNA within compacted regions is 
then made accessible to the complex machinery of essential biological processes including 
gene transcription, DNA replication and DNA repair. Therefore, an increasing research focus 
has been the changes to chromatin via remodelling events and histone PTMs which are 
necessary to facilitate the DNA damage response. In particular, evidence has been reported 
during DSB repair and NER [232], [233]. This is specifically important for tightly packed 
regions of chromatin and similarly, it can assumed, that BER requires complete, unobstructed 
access to DNA base damage to promote efficient repair. Furthermore, as the pathway 
creates increasingly cytotoxic and mutagenic lesions as it progresses, it is essential that there 
is a seamless transition between each stage, and that repair is completed in a timely manner 
once BER in initiated. Therefore time, space and access to DNA base damage is essential for 
the effective and efficient completion of BER in chromatin.    
Despite this, the molecular mechanisms through which this is co-ordinated and the specific 
enzymes that promote chromatin remodelling required for BER remain elusive. Recently, and 
as summarised in section 1.6, we have summarised the multitude of in vitro studies utilising 
mononucleosome substrates containing site specific DNA base damage that demonstrate the 
requirement for chromatin remodelling to facilitate BER, particularly in occluded regions. We 
also highlighted preliminary evidence to date for the identity of ACRs, their mechanisms and 
the role of histone PTMs in modulating the cellular capacity for BER [170].  
A previous PhD student in our group, developed two mononucleosome substrates with site-
specific THF sites in two orientations, rotationally positioned so the DNA backbone was 
facing outwards (THF-OUT) so accessible to APE1, or facing inwards (THF-IN) towards the 
histone octamer and therefore sterically occluded to APE1. Here it was discovered that the 
incision of a THF site within a mononucleosome substrate that is inaccessible to recombinant 
APE1 (THF-IN), is more efficiently incised by APE1 in WCE due to the presence of histone 
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modifiers and/or chromatin remodelling factors. This stimulatory activity within the WCE 
was isolated by adopting a sequential chromatography approach and mass spectrometry 
analysis identified the E3 ubiquitin ligase HECTD1 as a strong candidate required to facilitate 
BER through histone ubiquitylation and/or chromatin remodelling. 
My aim was to establish a role for HECTD1 in enhancing the repair of DNA base damage 
within occluded sites within chromatin. In this chapter, I will describe use of previously 
established techniques within Dr Parsons’ laboratory to generate THF-IN mononucleosome 
substrates. Additionally, I will describe LIC cloning as a technique used to clone the murine 
HECTD1 gene truncated at amino acid 1761 from the mammalian expression vector and into 
the pET28a bacterial expression vector, to allow the protein to be expressed and purified 
from E coli cells. Using these substrates, I aimed to establish conditions to examine the 
processing of these inaccessible THF-IN sites by APE1 via in vitro BER assays and investigate 
whether HECTD1 can enhance in vitro the activity of APE1 on THF-IN mononucleosome 
substrates.  
 
4.2 Preparation of THF-IN site containing DNA 
In order to analyse the ability of HECTD1 to stimulate APE1 incision of sterically occluded THF 
sites, it was important in the first instance to produce a THF-IN containing DNA segment with 
nucleosome interacting properties, positioned 10 bp from the dyad (Figure 4.1). This DNA 
substrate was generated containing a site specific THF site on the lower strand in the central 
area of the DNA sequence, with proximal restriction sites (section 3.1.1, Figure 3.1). The 
Widom 601 nucleosome positioning sequence was amplified from the pGEM-3Z-601 plasmid 
using PCR and the central 17 bp removed using Van91I and BglI restriction enzymes to 
produce, once purified, two DNA sequence fragments. These were sequentially ligated to a 
pre-prepared 17 bp duplex oligonucleotide containing a THF site on the lower strand, 
resulting in the production of a site specific THF-IN DNA substrate, which when complexed 
with a histone octamer, generated a mononucleosome substrate where the DNA backbone 
of the THF site faced inwards towards the histone octamer and was therefore occluded from 




Figure 4.1: Structure of the nucleosome core particle composed of the 601 DNA sequence 
Image was acquired from Protein Data Bank structure 3LZ0 (orientation 1) and indicated are 
the positions of the dyad and 10 bp from the dyad the THF-IN site, with the DNA backbone 





Figure 4.2: Schematic diagram of the formation of the THF-IN containing DNA and 
nucleosome 
1. The 256 bp Widom 601 nucleosome positioning sequence was amplified from the pGEM-
3Z-601 plasmid using PCR with fluorescently tagged primers (shown as red and green circles). 
2.The central 17 bp was then removed using a Van91l and BgII double restriction digest to 
generate a green labelled (green circle) 127 bp digest product and red labelled (red circle) 
106 bp digest product. 3. A 17 bp duplex oligonucleotide (shown in blue) containing a THF-
IN (blue rectangle) was then sequentially ligated to the 127 bp (green) and 106 bp (red) DNA 
fragments, producing the final 256 bp DNA which was then 4. reconstituted with the histone 




4.2.1 Amplification of the 601 nucleosome positioning sequence 
The Widom 601 wild-type strong nucleosome positioning sequence was amplified from the 
pGEM-3Z-601 plasmid using PCR with 5’-fluroescent labelled primers (Figure 4.2, stage 1). 
For production of THF-IN DNA the forward primer was tagged with IRDye800 (green label) 
and the reverse with IRDye700 (red label), due to the increased signal intensity of the 
IRDye700 tag so THF incision could be more strongly visualised using the Odyssey Image 
Analysis system. As the DNA marker was not visible due to the use of fluorescently tagged 
primers negating the use of a SYTO60 dye, successful generation of the 256 bp 601 
nucleosome positioning sequence PCR product was visualised as yellow, as the product 
contained both IRDye700 and IRDye800 5’ labelled ends and the fluorescent primers were 
also clearly visible underneath each of the PCR products (Figure 4.3). The verified 256 bp 
DNA was subsequently purified using a PCR purification kit and the yield was found to be 
approximately ~135 μg for 15 pooled PCR reactions.  
 
Figure 4.3: Amplification of the 256 bp 601 nucleosome positioning sequence 
PCR product of the 601 wild-type strong nucleosome positioning sequence containing both 
the IRDye800 and IRDye700 florescent tags and the IRDye800 forward primer IRDye700 
reverse primer separated by electrophoresis on a 1.5 % agarose gel at 100 V for 1 hour, 
imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. 
 
4.2.2 Double restriction digest of the 601 nucleosome positioning sequence 
Following purification of the 256 bp 601 nucleosome positioning sequence, the central 17 bp 
region was removed using Van91l and BgII restriction enzymes (region shown in section 
3.1.1, Figure 3.1). These enzymes produced a IRDye800 tagged 127 bp DNA fragment and a 
IRDye700 tagged 106 bp DNA fragment, both with sticky ends to facilitate subsequent 
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ligation (Figure 4.2, stage 2). Completion of the restriction digest was confirmed by 
comparison to the original purified 256 bp PCR product (Figure 4.4A, lane 1), where the 
Van91l and BgII digestion product (Figure 4.4A, lane 2) is absent of the 256 bp PCR product 
and only the 127bp and 106 bp DNA fragments are present. The 127bp and 106 bp DNA 
fragments were then purified from each other using PAGE separation and gel extraction. To 
assure 100 % efficiency in the production and purification of these digest products, the 127 
bp (Figure 4.4B, lane 2) and 106 bp (Figure 4.4B, lane 3) DNA products were compared to the 
original PCR product (Figure 4.4B, lane 1). Again, as the DNA is fluorescently labelled use of 
a DNA marker was not applicable here. 
 
Figure 4.4: 127bp and 106 bp Van91I/Bg11 restriction digest products 
A. Original 256 bp PCR product (lane 1) against the Van91l and BgII digestion product (lane 
2) following separation by electrophoresis on a 1.5 % agarose gel at 100 V for 1 hour. B. 
Original 256 bp PCR product (lane 1) against the IRDye800 tagged 127 bp DNA digest product 
(lane 2) and IRDye700 tagged 106 bp DNA digest product (lane 3) following PAGE separation 
on an 8 % polyacrylamide gel in 0.5x TBE run at 175 V, 20 W for 3 hours, gel extraction and 
DNA purification. Gels were imaged using the Li-Cor Odyssey Infrared Imaging Analysis 
System. 
 
4.2.3 Sequential ligations to incorporate the THF-IN site 
To maximise ligation efficiency, the 127 bp and 106 bp DNA digest products were ligated 
sequentially to a 17 bp THF-IN containing duplex oligonucleotide with complimentary sticky 
ends (section 3.1.2.1, Table 3.2) (Figure 4.2, stage 3). In the first instance, the 127 bp segment 
was ligated to the THF-IN containing duplex oligonucleotide. This was successfully observed 
as a ligated 147 bp DNA ligation product (Figure 4.5A, lane 3) in comparison to the original 
5’-IRDye800 labelled 127 bp DNA (Figure 4.5A, lane 2). This was gel purified using the 
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MinElute reaction clean up kit and then ligated to the 106 bp DNA digest product. Successful 
ligation was evidenced by the formation of the full 256 bp substrate DNA (Figure 4.4B, lane 
3), in comparison to the unligated second ligation mix (Figure 4.5B, lane 2). This was purified 
using PAGE separation and gel extraction, and the successful purification of the final 256 bp 
substrate containing a site specific THF-IN site (Figure 4.5C, lane 2) was confirmed via 
comparison to the original purified PCR product (Figure 4.5C, lane 1). As before, the use of a 
DNA marker was not applicable here, due to the DNA being fluorescently labelled. This 256 
bp substrate containing a site specific THF-IN site now could be used in the nucleosome 
reconstitution with the prepared histone octamer. This demonstrates that I had successfully 
developed a technique to generate a DNA substrate containing a site specific THF-IN site, 
which I could use to examine the effect of HECTD1 on APE1 incision activity rates at occluded 
THF sites in mononucleosomes. For ease of quantification, the DNA substrates were labelled 
so the IRDye700, the most intense signal when imaging with the Li-Cor Odyssey Infrared 
Imaging Analysis System, was on the DNA lesion-containing strand, which would be incised 










Figure 4.5: Sequential Ligations to generate a 256 bp DNA substrate containing a THF-IN 
site 
A. Ligation Reaction 1. Original 256 bp PCR product (lane 1), before (lane 2) and after ligation 
(lane 3) of the IRDye800 tagged 127 bp DNA with the 17 bp duplex oligonucleotide. B. 
Ligation Reaction 2. Original 256 bp PCR product (lane 1), before (lane 2) and after the second 
ligation (lane 3) using the IRDye800 tagged 147 bp and IRDye700 tagged 106 bp DNA, 
producing a 256 bp product containing a THF-IN site. C. Original 256 bp PCR product (lane 1), 
final 256 bp substrate containing a site specific THF-IN site following purification by PAGE 
separation and gel extraction (lane 2).  All PAGE gels contained 8 % polyacrylamide and 0.5x 
TBE, and were run at 175 V, 20 W for 3 hours, gels were imaged using the Li-Cor Odyssey 
Infrared Imaging Analysis System. 
 
4.3 Histone octamer preparation 
E.coli were individually transformed with pET-expression vectors for Xenopus Laevis histones 
(H2A, H2B, H3 and H4) and the recombinant histone overexpressed via IPTG induction. The 
bacteria were harvested, cells lysed and the proteins purified from inclusion bodies by gel 
filtration and ion-exchange chromatography under denaturing conditions (7 M urea), using 
an FPLC. The histones were then unfolded, combined in equimolar ratios and refolded to 
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form the octamer. The histone octamer was subsequently purified in high salt containing 















Figure 4.6: Strategy for the histone purification process  
E.coli were individually transformed with each histone expression plasmid (for H2A, H2B, H3 
and H4), and following IPTG induction to overexpress the proteins, the bacteria cells were 
harvested and lysed. Each histone was then individually purified from inclusion bodies. 
Firstly, using a Sephacryl S200 column (size exclusion chromatography) eluting at 
approximately 14 kDa followed by a Mono-S column (ion exchange chromatography) eluting 
at approximately 300 mM NaCl. Both chromatography steps used an AKTA FPLC and were 
under denaturing conditions (7 M urea). The presence of histones in fractions was analysed 
by SDS-PAGE and Instant Blue protein staining. Once identified, the histones were unfolded, 
combined in equimolar ratios and allowed to refold to form the histone octamer. The 
octamer was purified using a Superdex 200 column (size exclusion chromatography) and 
AKTA FPLC with a high salt buffer (2 M NaCl), with proteins eluting at approximately 108 kDa. 
Purity and stoichiometry of the histone octamer was analysed by SDS-PAGE and Instant Blue 




4.3.1 Recombinant histone purification: gel filtration chromatography 
Following lysis and purification of individual histones from inclusion bodies of E.coli 
overexpressing recombinant histones, the proteins were initially purified by size exclusion 
chromatography using a Sephacryl S200 column and a AKTA FPLC under denaturing 
conditions (7 M urea). The UV trace and fraction numbers collected when protein started to 
elute from AKTA FPLC correlates to the amount of protein being eluted and is shown for each 
of the four histones; H2A (Figure 4.7A), H2B (Figure 4.8A) H3 (Figure 4.9A) and H4 (Figure 
4.10A). These traces show two major peaks, the first relating to bacterial DNA contaminants 
and the second, latter peak to the histone of interest. The proteins within these fractions 
were separated by SDS-PAGE and Instant Blue protein stained (H2A (Figure 4.7B), H2B (Figure 
4.8B) H3 (Figure 4.9B) and H4 (Figure 4.10B)). Full length histone H2A (13.96 kDa) was shown 
to elute in fractions 10-15 (Figure 4.7), H2B (13.77 kDa) was shown to elute in fractions 10-
14 (Figure 4.8), H3 (15.27 kDa) was shown to elute in fractions 9-18 (Figure 4.9) and H4 (11.24 
kDa) was shown to elute in fractions 14-19 (Figure 4.10). Of note, the upper band correspond 
to the full-length histones and the lower band are slightly degraded histones. Fractions 





Figure 4.7: Purification of recombinant histones H2A gel filtration chromatography 
Following protein overexpression in E-coli, histone H2A was initially purified by size exclusion 
chromatography using a gel filtration, Sephacryl S200 column and an AKTA FPLC under 
denaturing conditions (7 M urea). A. H2A UV trace (blue) from the FPLC are shown with the 
fraction number below in red. B. Shown below the chromatogram is the corresponding 16 % 
SDS-PAGE gel stained with Instant blue protein stain, fraction number indicated and with 
protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 minutes and imaged 




Figure 4.8: Purification of recombinant histones H2B gel filtration chromatography 
Following protein overexpression in E-coli, histone H2B was initially purified by size exclusion 
chromatography using a gel filtration, Sephacryl S200 column and an AKTA FPLC under 
denaturing conditions (7 M urea). A. H2B UV trace (blue) from the FPLC are shown with the 
fraction number below in red. B. Shown below the chromatogram is the corresponding 16 % 
SDS-PAGE gel stained with Instant blue protein stain, fraction number indicated and with 
protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 minutes and imaged 





Figure 4.9: Purification of recombinant histones H3 gel filtration chromatography 
Following protein overexpression in E-coli, histone H3 was initially purified by size exclusion 
chromatography using a gel filtration, Sephacryl S200 column and an AKTA FPLC under 
denaturing conditions (7 M urea). A. H3 UV trace (blue) from the FPLC are shown with the 
fraction number below in red. B. Shown below the chromatogram is the corresponding 16 % 
SDS-PAGE gel stained with Instant blue protein stain, fraction number indicated and with 
protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 minutes and imaged 






Figure 4.10: Purification of recombinant histones H4 gel filtration chromatography 
Following protein overexpression in E-coli, histone H4 was initially purified by size exclusion 
chromatography using a gel filtration, Sephacryl S200 column and an AKTA FPLC under 
denaturing conditions (7 M urea). A. H4 UV trace (blue) from the FPLC are shown with the 
fraction number below in red. B. Shown below the chromatogram is the corresponding 16 % 
SDS-PAGE gel stained with Instant blue protein stain, fraction number indicated and with 
protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 minutes and imaged 
using the Li-Cor Odyssey Infrared Imaging Analysis System.  
 
 
4.3.2 Recombinant histone purification: ion exchange chromatography 
Pooled fractions from the initial size exclusion chromatography step were dialysed in distilled 
water containing 2 mM β-mercaptoethanol, before purification by ion exchange 
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chromatography using a Mono-S column and a AKTA FPLC under denaturing conditions (7 M 
urea). Fractions were collected following a salt gradient elution and the UV trace with 
fraction numbers is shown for each of the four histones; H2A (Figure 4.11A), H2B (Figure 
4.12A) H3 (Figure 4.13A) and H4 (Figure 4.14A). The proteins within these fractions were 
separated by SDS-PAGE and Instant Blue protein stained. Full length histone H2A (Figure 
4.11B) was shown to elute in fractions 13-19, H2B in fractions 12-18 (Figure 4.12B), H3 in 
fractions 12-20 (Figure 4.13B) and H4 in fractions 14-22 (Figure 4.14B).  Of note, the upper 
band correspond to the full-length histones and the lower band, in the preceding fractions 
are slightly degraded histones. Fractions containing the individual histones were pooled, 
dialysed in distilled water containing 2 mM β-mercaptoethanol and concentrated using 3 kDa 
MWCO Amicon Ultra centrifugal concentrators to 15-30 mg/ml. The protein concentration 
of the histones were measured using a Nanodrop ND-1000 spectrometer at a wavelength of 
OD 280 nm with molecular weights and extinction coefficients (ɛ) and per 2 L bacterial culture 




Figure 4.11: Purification of recombinant histone H2A by ion exchange chromatography 
Pooled histone H2A containing fractions from the initial size exclusion chromatography step 
were further purified using a Mono-S column and a AKTA FPLC under denaturing conditions 
(7 M urea) and eluted under a salt gradient. A. H2A UV trace (blue) from the FPLC are shown 
with the fraction number below in red. B. Shown below the chromatogram is the 
corresponding 16 % SDS-PAGE gel stained with Instant Blue protein stain, fraction number 
indicated and with protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 





Figure 4.12: Purification of recombinant histone H2B by ion exchange chromatography 
Pooled histone H2B containing fractions from the initial size exclusion chromatography step 
were further purified using a Mono-S column and a AKTA FPLC under denaturing conditions 
(7 M urea) and eluted under a salt gradient. A. H2B UV trace (blue) from the FPLC are shown 
with the fraction number below in red. B. Shown below the chromatogram is the 
corresponding 16 % SDS-PAGE gel stained with Instant Blue protein stain, fraction number 
indicated and with protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 





Figure 4.13: Purification of recombinant histone H3 by ion exchange chromatography 
Pooled histone H3 containing fractions from the initial size exclusion chromatography step 
were further purified using a Mono-S column and a AKTA FPLC under denaturing conditions 
(7 M urea) and eluted under a salt gradient. A. H3 UV trace (blue) from the FPLC are shown 
with the fraction number below in red. B. Shown below the chromatogram is the 
corresponding 16 % SDS-PAGE gel stained with Instant Blue protein stain, fraction number 
indicated and with protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 





Figure 4.14: Purification of recombinant histone H4 by ion exchange chromatography 
Pooled histone H4 containing fractions from the initial size exclusion chromatography step 
were further purified using a Mono-S column and a AKTA FPLC under denaturing conditions 
(7 M urea) and eluted under a salt gradient. A. H4 UV trace (blue) from the FPLC are shown 
with the fraction number below in red. B. Shown below the chromatogram is the 
corresponding 16 % SDS-PAGE gel stained with Instant Blue protein stain, fraction number 
indicated and with protein marker for 10-50 kDa. Gel was electrophoresed at 175 V for 110 




4.3.3 Refolding of the histone octamer 
The histone octamer, formed by combining purified histones in equimolar ratios and dialysis 
in refolding buffer, was purified by gel filtration chromatography using a Superdex 200 
column and an AKTA FPLC. Collected fractions and the UV trace obtained from the FPLC are 
shown (Figure 4.15A) in addition to the separation of proteins by SDS-PAGE and analysis by 
Instant Blue protein staining (Figure 4.15B). Fractions 25-27, indicated by the red asterisk, 
show histone octamer formation at the expected molecular weight (108 kDa; between 66-
150 kDa), determined from calibration of the Superdex 200 column with protein molecular 
weight standards, as shown above the representative gel image. Note, fractions 28-34 
contain H2A/H2B dimers which have failed to fully form the octamer with H3 and H4. 
Fractions containing the histone octamer were pooled, concentrated and stored in glycerol 
(for protein stabilization). This preparation acted as a histone octamer source for use in the 
nucleosome reconstitution with the site specific THF-IN DNA to generate the 




Figure 4.15: Purification of the histone octamer by gel filtration chromatography 
The histone octamer, generated by combining purified histones in equimolar ratios and 
dialysis in refolding buffer, was purified by size exclusion chromatography using a Superdex 
200 column and an AKTA FPLC. A. The UV trace (blue) from the FPLC with the red asterisk 
indicating the histone octamer peak is shown with the fraction number shown below in red. 
B. Below the chromatogram is the corresponding 16 % SDS-PAGE gel stained with Instant 
Blue protein stain, fraction number indicated, and calibrated with protein marker weight 
standards at 10-50 kDa. The gel was electrophoresed at 175 V for 110 minutes and imaged 




4.4 Generation of the site specific THF-IN mononucleosome substrate  
Mononucleosomes were reconstituted by incubation of the purified histone octamer with 
the site specific THF-IN DNA substrate, in an optimised ratio in a high salt (2 M NaCl) 
containing buffer. The reconstitution was then dialysed using a salt gradient to promote 
mononucleosome formation (Figure 4.2, stage 4). This was confirmed by agarose gel 
electrophoresis, where a shift from the lower molecular weight of 256 bp free DNA to a 
higher molecular weight of approximately 750 kDa was observed, indicating successful 
nucleosome formation. A reconstitution efficiency of 95 % was deemed acceptable for use 
of the mononucleosome substrate in in vitro BER repair assays to measure APE1 activity.  
 
4.4.1 Optimisation of nucleosome reconstitution 
In the first instance, the optimal THF-IN substrate DNA:histone octamer ratio was 
investigated. A total of four ratios, 1:0.25, 1:0.5, 1:1 and 1:5 (THF-IN substrate DNA:histone 
octamer) were examined to determine which provided the most complete nucleosome 
reconstitution, whilst minimising any substantial aggregate formation. In all reconstitutions 
the THF-IN substrate DNA, histone octamer mix was incubated in a high salt (2 M NaCl) 
containing buffer and then dialysed using a salt gradient to promote mononucleosome 
formation. The DNA was then separated using agarose gel electrophoresis, where a shift 
from the lower molecular weight of 256 bp free DNA to a higher molecular weight of 
approximately 750 kDa was used to determine successful nucleosome formation. At ratios 
of 1:0.25 (Figure 4.16A, lane 3) and 1:0.5 (Figure 4.16A, lane 4) some nucleosome 
reconstitution was observed, although this was nowhere near the acceptable reconstitution 
efficiency of 95 %, therefore these ratios were not deemed appropriate for generating the 
mononucleosome substrate for use in the in vitro BER repair assay. Next, the ratios 1:5 
(Figure 4.16B, lane 3) and 1:1 (Figure 4.16B, lane 4) were investigated for optimal 
nucleosome reconstitution. Observation of both the 1:5 (Figure 4.16B, lane 3) and 1:1 (Figure 
4.16B, lane 4) ratios demonstrated near full nucleosome reconstitutions, reaching the 
acceptable 95 % nucleosome efficiency. However, at the 1:5 (Figure 4.16B, lane 3) ratio, a 
degree of smearing was seen, indicative of aggregate formation. As a 1:1 THF-IN substrate 
DNA:histone octamer ratio generated efficient nucleosome reconstitution, to avoid wastage 
of the histone octamer, the optimal THF-IN substrate DNA:histone octamer ratio was 




Figure 4.16: Optimisation of THF-IN mononucleosome reconstitution 
Nucleosome reconstitution was compared using four ratio’s A 1:0.25 (lane 3) and 1:0.5 (lane 
4) THF-IN substrate DNA:histone octamer and B 1:5 (lane 3) and 1:1 (lane 4) THF-IN substrate 
DNA:histone octamer. All reconstitution were compare to free DNA (lane 2), whereby a shift 
from the 256 bp free DNA control, to a high molecular weight species (lane 3), approximately 
700 bp, was observed if the THF-IN mononucleosome was successfully formed. DNA was 
separated using a 0.7 % agarose gel and electrophoresed in 0.2x TAE at 75 V for 1.5 hours. A 
100 bp GeneRuler DNA ladder (lane 1) was utilised to identify the size of the DNA.  
 
4.4.2 Generation of the THF-IN mononucleosome substrate 
Mononucleosomes were reconstituted by incubation of the purified histone octamer with 
the site specific THF-IN DNA substrate, in a 1:1 ratio in a high salt (2 M NaCl) containing 
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buffer. The reconstitution was then dialysed using a salt gradient to promote 
mononucleosome formation (Figure 4.2, stage 4). This was confirmed by agarose gel 
electrophoresis, where a shift from the lower molecular weight of 256 bp free DNA to a 
higher molecular weight of approximately 750 kDa was observed (Figure 4.17), indicating 
successful nucleosome formation. Near full nucleosome reconstitution was observed (Figure 
4.17, lane 3), with a reconstitution efficiency of 95 % which was deemed acceptable for use 
of the mononucleosome substrate in in vitro BER repair assays to measure APE1 activity.  
 
Figure 4.17: Generation of a THF-IN Mononucleosome  
Nucleosome reconstitution was compared to free DNA (lane 2), whereby a shift from the 256 
bp free DNA control, to a high molecular weight species (lane 3), approximately 700 bp, was 
observed when the THF-IN nucleosome was successfully formed. A 1:1 DNA: histone octamer 
ratio was used. DNA was separated using a 0.7 % agarose gel and electrophoresed in 0.2x 
TAE at 75 V for 1.5 hours. A 100 bp GeneRuler DNA ladder (lane 1) was utilised to identify 
the size of the DNA.  
 
4.5 Cloning and purification of recombinant HECTD1 
 
4.5.1 Ligation independent cloning (LIC) of HECTD1 
LIC cloning was employed to clone the murine HECTD1 gene truncated at amino acid 1761 
from the mammalian expression vector and into the pET28a bacterial expression vector 
(Figure 4.18). The protein was truncated, as full length murine HECTD1 consists of 2612 
amino acids and is 289 kDa in size, making it extremely difficult to express and purify from 
bacterial overexpression systems. Therefore, I cloned a truncated version containing the 
active E3 ubiquitin ligase (HECT) domain (amino acids 2156-2612), which is required for 
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ubiquitylation of the target protein, plus an additional 389 amino acids immediately N-
terminal to this domain (Figure 4.21). This would allow the protein of 96 kDa to be expressed 
and purified from E coli cells. Also, of note, murine HECTD1 protein displays very high 
homology (98.2 % homology by amino acid sequence) to the human protein. 
 
Figure 4.18: Schematic diagram of the LIC strategy used to generate the pET28a-HECTD1-
1761 plasmid 
1. Vector was linearised and along with the insert amplified by PCR. 2. Insert and vector DNA 
treated with DpnI and T4 DNA Polymerase to remove methylated DNA bases and create 
complimentary base overhangs between the vector and insert. 3. LIC (vector:insert) 
reactions were incubated at ratios of 1:0.5, 1:1 and 1:3 before 4. bacterial transformation of 
the insert containing plasmid into library efficient DH5α competent bacterial cells via heat 
shock.  
Empty pET28a bacterial expression vector (Figure 4.19) and murine HECTD1 from the 
mammalian expression vector (kindly provided by Prof I. Zohn at the Childrens National 
Medical Center, USA) was first amplified by touchdown PCR using custom oligonucleotide 
primers flanked by LIC sequences (Table 3.3). The size of the pET28a DNA product (5369 bp) 
(Figure 4.22A) and ΔN-HECTD1 gene (2550 bp) (Figure 4.22B) was analysed and confirmed 
via agarose gel electrophoresis. Following PCR amplification, DpnI treatment for DNA 
methylation and purification of DNA products purified using the QIAquick PCR Purification 
Kit. The individual DNA products were treated with T4 DNA polymerase to generate the 
complementary LIC overhangs and the ΔN-HECTD1 insert incubated with the empty pET28a 
vector at vector:insert ratios of 1:0.5, 1:1 and 1:3 to anneal the insert into the bacterial 
expression vector. E. coli cells were transformed with pET28a: ΔN-HECTD1 LIC reactions and 
grown on selective media containing kanamycin. Successful colonies were inoculated into 5 
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ml of LB media with kanamycin and grown overnight at 37°C to amplify the pET28a-HECTD1-
1761 plasmid DNA (Figure 4.20), which was then purified from bacterial contaminants using 
the QIAprep Spin Miniprep Kit (QIAGEN). Confirmation of successful cloning of the gene 
insert for ΔN-HECTD1 was achieved by DNA sequencing from the Sanger Sequencing Service 
(provided by Source Bioscience Sequencing, Nottingham, UK). This plasmid could now be 
used to overexpress and purify C-terminally His-tagged ΔN-HECTD1 from bacterial cells.  
 
Figure 4.19: Vector map for the empty pET28a bacterial expression plasmid 
Target genes were cloned into the empty pET28a vector and used for recombinant protein 
expression in bacteria. The target gene is transcribed by T7 bacteriophage RNA polymerase 
under control of the T7 promotor. The pETa28a vector carries kanamycin antibiotic 
resistance and the option for a 6x N-terminal or C-terminal poly-histidine tag. Adapted from 




Figure 4.20: Vector map for the empty pET28a-HECTD1-1761 bacterial expression plasmid 
The gene for murine HECTD1 truncated at aa 1761 was cloned from the mammalian 
expression plasmid for full length murine HECTD1 (pCMV-HA-HECTD1) into empty pET28a 
vector for expression of ΔN-HECTD1 in a bacterial system. The pETa28a vector carries 
kanamycin antibiotic resistance and adds a C-terminal poly-histidine tag.  
 
 
Figure 4.21: Representative diagram of murine HECTD1  
Diagrammatic representation of the full length murine HECTD1 protein, including location of 
functional domains. Ankyrin domains (amino acids 396-613), Mindbomb domain (amino 
acids 1271-1343) and HECT domain (amino acids 2156-2612). The ΔN-HECTD1 truncated 




Figure 4.22: PCR amplification of a pET28a vector and gene inserts for ΔN-HECTD1 
A PCR product of amplification of the empty pET28a vector using complementary 
oligonucleotide primers flanked by relevant LIC sequences B PCR product of amplification of 
the insert for ΔN-HECTD1 from pCMV-HA-HECTD1, separated by electrophoresis on a 1 % 
agarose gel at 100 V for 1 hour, imaged using the Li-Cor Odyssey Infrared Imaging Analysis 
System. A 1 kb GeneRuler DNA ladder was utilised to identify the size of the PCR product.  
 
4.5.2 Affinity chromatography purification of HECTD1 
Rosetta2(DE3)pLysS bacterial cells, transformed via heat shock with His-tagged pET28a-
HECTD1-1761, were grown until an OD600nm of 0.6 in a 400 ml culture. Protein expression 
of C-terminally His-tagged ΔN-HECTD1 was induced via IPTG (1 mM) addition for 3-16 hours 
to determine test expression of the protein. SDS-PAGE protein separation, followed by 
Instant Blue protein staining and immunoblotting using anti-His-tag antibodies, revealed that 
the 96 kDa ΔN-HECTD1 was expressed and stable with a 3 hour IPTG induction (Figure 4.23A-
B, lane 2), but not with overnight induction (Figure 4.23A-B, lane 3). From this test 
expression, protein inductions were routinely performed for 3 hours with IPTG and the 
bacterial cell lysate from a scaled up 1.2 L culture was purified using a 1 ml HisTrap HP affinity 
chromatography column and AKTA FPLC. Fractions were collected following a linear 
imidazole elution (0-250 mM) and the UV trace obtained from the FPLC with fraction number 
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(Figure 4.24A) is shown in addition to the separation of proteins by SDS-PAGE and analysis 
by Instant Blue protein staining to detect total protein (Figure 4.24B), and by immunoblotting 
with anti-His-tag antibodies to detect His-tagged ΔN-HECTD1 (Figure 4.24C). The first protein 
peak correlated with fractions 5-10 on the UV trace (Figure 4.24A) was associated with 
contaminating bacterial proteins. However, the shoulder on the UV trace from fraction 10 
onwards, contained isolated and purified recombinant ΔN-HECTD1. Confirmation by SDS-
PAGE protein staining (Figure 4.24B) and immunoblotting (Figure 4.24C), revealed the 
presence of ΔN-HECTD1 in fractions 10-32, but the full length protein (96 kDa) was found to 
undergo degradation to that of a slightly smaller molecular weight (85 kDa). Attempts were 
made to further isolate the intact ΔN-HECTD1 via ion exchange and size exclusion 
chromatography. In the first instance, the pooled ΔN-HECTD1 containing fractions from the 
initial HisTrap HP affinity column chromatography step were further purified by ion exchange 
chromatography using a Mono-Q column and a FPLC. Fractions were collected following a 
salt gradient elution (50-1000 mM KCl) and the UV trace obtained from the FPLC with fraction 
number (Figure 4.25A) is shown in addition to the separation of proteins by SDS-PAGE and 
analysis by Instant Blue protein staining to detect total protein (Figure 4.25B), and by 
immunoblotting with anti-His-tag antibodies to detect His-tagged ΔN-HECTD1 (Figure 4.25C). 
Although two peaks can be visualised on the UV trace between fractions 4 and 22 (Figure 
4.25A), when the fractions were analysed by Instant Blue protein staining (Figure 4.25B) and 
immunoblotting with anti-His-tag antibodies (Figure 4.25C), His-tagged ΔN-HECTD1 was not 
detected, indicating that the protein was heavily degraded or lost. Following this, the second 
chromatography to further isolate the intact ΔN-HECTD1 was modified and the pooled ΔN-
HECTD1 containing fractions from the initial HisTrap HP affinity column chromatography step 
were further purified by size exclusion chromatography using a Superdex 200 column and a 
FPLC using a 150 mM KCl gradient elution. The UV trace obtained from the FPLC with fraction 
number (Figure 4.26A) is shown in addition to the separation of proteins by SDS-PAGE and 
analysis by Instant Blue protein staining to detect total protein (Figure 4.26B), and by 
immunoblotting with anti-His-tag antibodies to detect His-tagged ΔN-HECTD1 (Figure 4.26C). 
The UV trace does not indicate any significant protein elution (Figure 4.26A) and when the 
fractions were analysed by Instant Blue protein staining (Figure 4.26B) and immunoblotting 
with anti-His-tag antibodies (Figure 4.26C), His-tagged ΔN-HECTD1 was not detected, 
indicating that the protein was heavily degraded or lost. Therefore, a single chromatography 
approach, using HisTrap HP affinity chromatography was adopted, as crucially this protein 
cross-reacts with the His-tagged antibodies, suggesting that the protein is being degraded 
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from the N terminus (as the protein is C-terminally tagged) and includes the fully intact E3 
ligase HECT domain required for its enzymatic activity. Therefore, these fractions were 
pooled, buffer exchanged (50 mM Tris-HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) to 
remove imidazole, the protein concentrated, and the concentration measured using a 
Nanodrop ND-1000 spectrometer at a wavelength of OD 280 nm with molecular weights and 
extinction coefficients (ɛ), before aliquoting and storage at -80°C. 
 
Figure 4.23: Test expression via IPTG induction of recombinant His-tagged ΔN-HECTD1 
Following protein overexpression in E-coli of ΔN-HECTD1, cell lysate samples were taken pre 
IPTG (lane 2), 3 hours (lane 3) and 16 hours (lane 4) post IPTG induction. Bacterial cell lysates 
separated by 10 % SDS-PAGE and analysed by A Instant Blue protein stain and B 
immunoblotting using His-tag specific antibodies. Recombinant His-tagged ΔN-HECTD1 
indicated, with protein marker (10-250 kDa). All gels were electrophoresed at 175 V for 110 




Figure 4.24: HisTrap HP affinity column chromatography purification of recombinant His-
tagged ΔN-HECTD1 
Following protein overexpression in E-coli, ΔN-HECTD1 was purified from the bacterial cell 
lysate by a HisTrap HP affinity chromatography column and AKTA FPLC using a linear 0-250 
mM imidazole gradient elution. A UV trace (blue) from the FPLC is shown with the fraction 
number below in red. Corresponding analysis of the fractions by B 10 % SDS-PAGE gel stained 
with Instant Blue protein stain and C immunoblotting using His-tag specific antibodies. 
Fraction number and recombinant His-tagged ΔN-HECTD1 indicated, with protein marker 
(10-250 kDa). All gels were electrophoresed at 175 V for 110 minutes and imaged using the 




Figure 4.25: Ion exchange chromatography purification of recombinant His-tagged ΔN-
HECTD1 
Pooled ΔN-HECTD1 containing fractions from the initial HisTrap HP affinity column 
chromatography step were further purified using a Mono-Q column and a FPLC using a linear 
50-1000 mM KCl gradient elution. A UV trace (blue) from the FPLC is shown with the fraction 
number below in red. Corresponding analysis of the fractions by B 10 % SDS-PAGE gel stained 
with Instant Blue protein stain and C immunoblotting using His-tag specific antibodies. 
Fraction number indicated, with protein marker (10-250 kDa). All gels were electrophoresed 
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Figure 4.26: Size exclusion chromatography purification of recombinant His-tagged ΔN-
HECTD1 
Pooled ΔN-HECTD1 containing fractions from the initial HisTrap HP affinity column 
chromatography step were further purified by size exclusion chromatography using a 
Superdex 200 column and a FPLC using a 150 mM KCl gradient elution. A UV trace (blue) from 
the FPLC is shown with the fraction number below in red. Corresponding analysis of the 
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fractions by B 10 % SDS-PAGE gel stained with Instant Blue protein stain and C 
immunoblotting using His-tag specific antibodies. Fraction number indicated, with protein 
marker (10-250 kDa). All gels were electrophoresed at 175 V for 110 minutes and imaged 
using the Li-Cor Odyssey Infrared Imaging Analysis System. 
 
4.6 In vitro BER activity of APE1 on THF-IN mononucleosome substrate  
In the first instance, THF-IN site incision within a mononucleosome substrate (prepared as 
described in section 4.4.) by recombinant APE1 was examined. The percentage incision from 
two independent BER assays using a titration of APE1 was performed for the THF-IN 
mononucleosome substrate. As expected, this confirmed previous work within the group, 
that the THF-IN mononucleosome substrate (50 fmol) is poorly processed by recombinant 
APE1, with cleavage reaching a maximum of 35-40 % with 200 fmol (a four fold-excess) of 
APE1 (Figure 4.27). This is unsurprising due to the inability of APE1 to access the THF site 
when the DNA backbone is facing inwards towards the histone octamer. This APE1 titration 
was then used to establish reaction conditions for a ΔN-HECTD1 titration, where it was 
decided that 50 fmol APE1 (generating ~20 % incision) was sufficient for future in vitro 







Figure 4.27: APE1 In vitro BER assay titration on THF-IN mononucleosome substrates  
A Purified recombinant APE1 concentration titration (0-200 fmol) using THF-IN (blue) 
mononucleosome substrate (50 fmol) and B representative gel with full length 256 bp DNA 
(S) and cleaved 116 bp THF-IN DNA (P) indicated. PAGE gels contained 8 % polyacrylamide, 7 
M Urea and 1x TBE and were run at 300 V, 20 W for 1.75 hours, gels were imaged and 
percentage incision quantified using the Li-Cor Odyssey Infrared Imaging Analysis System. 
Shown is the mean percent substrate incision ± S.E. from two independent experiments. 
  
4.7 In vitro BER activity of APE1 and HECTD1 on THF-IN mononucleosome 
substrate  
The ability of ΔN-HECTD1 to stimulate APE1 activity on THF-IN mononucleosome substrates 
was examined, from three independent BER assays using a titration of recombinant ΔN-
HECTD1. I determined that ΔN-HECTD1 (0-15 pmol) was able to significantly stimulate the 
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activity of recombinant APE1 against the THF-IN mononucleosome substrate from 20 to 57 
% THF-incision (Figure 4.28B, lanes 3-6 and Figure 4.28A (blue)), as determined by the 
proportion of cleaved 116 bp THF-IN DNA (P) relative to full length 256 bp DNA (S) (Figure 
4.28B). When examining the effect of HECTD1 on THF site excision by APE1 within the 
mononucleosome substrate an initial titration of 2 pmol ΔN-HECTD1 resulted in a moderate 
increase in percentage THF-incision, from the observed control levels (20 %) to 26 % THF-
incision. A further increase in the concentration of ΔN-HECTD1 in the reaction to 5 pmol 
resulted in a similar degree of increase in percentage THF-incision from 28 % THF-incision 
achieved with 2 pmol ΔN-HECTD1 to 34 % THF-incision. The following incubation with 10 
pmol ΔN-HECTD1 resulted in a significant shift in APE1 incision of the THF-IN 
mononucleosome, reaching 50 % THF-incision, with the final titration step, an incubation of 
15 pmol ΔN-HECTD1 reaching the observed maximum of 57 % THF-incision of the THF-IN 
mononucleosome by APE1.  
It was also important to verify that ΔN-HECTD1 alone had no impact on the incision of the 
THF-IN mononucleosome. Therefore, except for the absence of APE1, in the same reaction 
conditions the THF-IN substrate was incubated with a titration of recombinant ΔN-HECTD1 
(0-15 pmol) alone in the in vitro BER assay. In the absence of APE1 I observed no significant 
incision of the THF site, with percentage THF-incision, as determined by the proportion of 
cleaved 116 bp THF-IN DNA (P) relative to full length 256 bp DNA (S) (Figure 4.28B), remaining 
at control levels at all ΔN-HECTD1 titration points (Figure 4.28A (orange)). Therefore, I can 
conclude that there was no impact of ΔN-HECTD1 alone on incision of the THF-IN substrate 
(Figure 4.28B, lanes 7-10 and Figure 4.28A (orange)). This data confirmed HECTD1 as a 




Figure 4.28: HECTD1 promotes incision of THF-IN mononucleosome substrate by 
recombinant APE1 in vitro 
Stimulation of APE1-dependent incision of the THF-IN mononucleosome substrate by ΔN-
HECTD1. A Purified recombinant ΔN-HECTD1 concentration titration (0-15 pmol) using THF-
IN mononucleosome substrate in the presence (blue) and absence (orange) of APE1 (50 fmol) 
and B representative gel with full length 256 bp DNA (S) and cleaved 116 bp THF-IN DNA (P) 
indicated. PAGE gels contained 8 % polyacrylamide, 7 M Urea and 1x TBE and were run at 
300 V, 20 W for 1.75 hours, gels were imaged and percentage incision quantified using the 
Li-Cor Odyssey Infrared Imaging Analysis System. Shown is the mean percent substrate 
incision ± S.E. from three independent experiments. 
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4.8 Analysis of the E3 ubiquitin ligase dependency of HECTD1 
In order to determine if the E3 ubiquitin ligase activity of HECTD1 is key for it to function as 
a chromatin remodelling enzyme, as we presume, a site directed mutagenesis (SDM) 
approach was chosen to mutate the active site cysteine (C) residue to a glycine (G) residue 
(Figure 4.29). This substitution was selected as both amino acids have similar biochemical 
properties, minimising the impact on the overall structure and folding of ΔN-HECTD1.  
D  D  D  Y  V  L  K  R  Q  F  S  A  L  V  P  A  F  D  P  R  P  G  R  
T  N  V  Q  Q  T  T  D  L  E  I  P  P  P  G  T  P  H  S  E  L  L  E  
E  V  E  C  T  P  S  P  R  L  A  L  T  L  K  V  T  G  L  G  T  T  R  
E  V  E  L  P  L  T  N  F  R  S  T  I  F  Y  Y  V  Q  K  L  L  Q  L  
S  C  N  G  N  V  K  S  D  K  L  R  R  I  W  E  P  T  Y  T  I  M  Y  
R  E  M  K  D  S  D  K  E  K  E  N  G  K  M  G  C  W  S  I  E  H  V  
E  Q  Y  L  G  T  D  E  L  P  K  N  D  L  I  T  Y  L  Q  K  N  A  D  
A  A  F  L  R  H  W  K  L  T  G  T  N  K  S  I  R  K  N  R  N  C  S  
Q  L  I  A  A  Y  K  D  F  C  E  H  G  T  K  S  G  L  N  Q  G  A  I  
S  S  L  Q  S  S  D  I  L  N  L  T  K  E  Q  P  Q  A  K  A  G  N  G  
Q  S  P  C  G  V  E  D  V  L  Q  L  L  R  I  L  Y  I  V  A  S  D  P  
Y  S  R  I  S  Q  E  D  G  D  E  Q  P  Q  F  T  F  P  P  D  E  F  T  
S  K  K  I  T  T  K  I  L  Q  Q  I  E  E  P  L  A  L  A  S  G  A  L  
P  D  W  C  E  Q  L  T  S  K  C  P  F  L  I  P  F  E  T  R  Q  L  Y  
F  T  C  T  A  F  G  A  S  R  A  I  V  W  L  Q  N  R  R  E  A  T  V  
E  R  T  R  T  T  S  S  V  R  R  D  D  P  G  E  F  R  V  G  R  L  K  
H  E  R  V  K  V  P  R  G  E  S  L  M  E  W  A  E  N  V  M  Q  I  H  
A  D  R  K  S  V  L  E  V  E  F  L  G  E  E  G  T  G  L  G  P  T  L  
E  F  Y  A  L  V  A  A  E  F  Q  R  T  D  L  G  T  W  L  C  D  D  N  
F  P  D  D  E  S  R  H  V  D  L  G  G  G  L  K  P  P  G  Y  Y  V  Q  
R  S  C  G  L  F  T  A  P  F  P  Q  D  S  D  E  L  E  R  I  T  K  L  
F  H  F  L  G  I  F  L  A  K  C  I  Q  D  N  R  L  V  D  L  P  I  S  
K  P  F  F  K  L  M  C  M  G  D  I  K  S  N  M  S  K  L  I  Y  E  S  
R  G  D  R  D  L  H  C  T  E  S  Q  S  E  A  S  T  E  E  G  H  D  S  
L  S  V  G  S  F  E  E  D  S  K  S  E  F  I  L  D  P  P  K  P  K  P  
P  A  W  F  N  G  I  L  T  W  E  D  F  E  L  V  N  P  H  R  A  R  F  
L  K  E  I  K  D  L  A  I  K  R  R  Q  I  L  G  N  K  S  L  S  E  D  
E  K  N  T  K  L  Q  E  L  V  L  R  N  P  S  G  S  G  P  P  L  S  I  
E  D  L  G  L  N  F  Q  F  C  P  S  S  R  I  Y  G  F  T  A  V  D  L  
K  P  S  G  E  D  E  M  I  T  M  D  N  A  E  E  Y  V  D  L  M  F  D  
F  C  M  H  T  G  I  Q  K  Q  M  E  A  F  R  D  G  F  N  K  V  F  P  
M  E  K  L  S  S  F  S  H  E  E  V  Q  M  I  L  C  G  N  Q  S  P  S  
W  A  A  E  D  I  I  N  Y  T  E  P  K  L  G  Y  T  R  D  S  P  G  F  
L  R  F  V  R  V  L  C  G  M  S  S  D  E  R  K  A  F  L  Q  F  T  T  
G  C  S  T  L  P  P  G  G  L  A  N  L  H  P  R  L  T  V  V  R  K  V  
D  A  T  D  A  S  Y  P  S  V  N  T  C  V  H  Y  L  K  L  P  E  Y  S  
S  E  E  I  M  R  E  R  L  L  A  A  T  M  E  K  G  F  H  L  N  -   
Figure 4.29: The amino acid sequence of ΔN-HECTD1  
Shown is the amino acid sequence of ΔN-HECTD1 (murine HECTD1 truncated at amino acid 
1761). This sequence of ΔN-HECTD1 is 850 amino acids in length and contains to full HECT 
domain, amino acid 2151-2610 (highlighted in blue) and the active site, a cysteine residue at 
amino acid 2587 (C, in red, highlighted in yellow. 
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4.8.1 Site directed mutagenesis (SDM) of ΔN-HECTD1 
Custom oligonucleotide primers were designed to generate a single point mutation in the 
active site of the HECT domain in ΔN-HECTD1 (Table 3.4). The bacterial expression plasmid, 
pET28a-HECTD1-1761, generated via LIC earlier in the chapter (section 4.5.2), was incubated 
with the relevant custom oligonucleotide primers and amplified by PCR. The expected size 
of the pET28a-mutHECTD1-1761 plasmid was 7919 bp, this was confirmed by analysis of the 
PCR DNA products by agarose gel electrophoresis (Figure 4.30). Although additional bands 
were present in the reaction, this would not be expected to interfere with the bacterial 
transformation. However, this analysis could not confirm whether the relevant mutation was 
present within the HECTD1 gene or not. Therefore, following PCR amplification, mutant DNA 
products were DpnI treated to remove DNA methylation and the DNA products purified using 
the QIAquick PCR Purification Kit. Following this, E. coli cells were transformed with the 
pET28a-mutHECTD1-1761 plasmid and grown on selective media containing kanamycin. 
Successful colonies were inoculated into 5 ml of LB media with kanamycin and grown 
overnight at 37°C to amplify the plasmid DNA, which was then purified from bacterial 
contaminants using the QIAprep Spin Miniprep Kit. Confirmation of a successful single point 
mutation, C to G at amino acid 2587, of ΔN-HECTD1 was achieved by DNA sequencing from 
the Sanger Sequencing Service (provided by Source Bioscience Sequencing, Nottingham, UK). 






Figure 4.30: PCR reaction product following site directed mutagenesis of pET28a-HECTD1-
1761 
PCR product of amplification of the pET28a-HECTD1-1761 vector using custom 
oligonucleotide primers designed to generate a single point mutation in the active site of the 
HECT domain in ΔN-HECTD1. PCR reaction product separated by electrophoresis on a 1 % 
agarose gel at 100 V for 1 hour, imaged using the Li-Cor Odyssey Infrared Imaging Analysis 
System. A 1 kb GeneRuler DNA ladder was utilised to identify the size of the PCR product.  
 
4.8.2 Affinity chromatography purification of ΔN-mutHECTD1 
Rosetta2(DE3)pLysS bacterial cells, transformed via heat shock with His-tagged pET28a-
mutHECTD1-1761 were grown until an OD600nm of 0.6 in a 400 ml culture. Protein 
expression of C-terminally His-tagged ΔN-HECTD1 was induced via IPTG addition for 3 hours, 
as previously determined by test expression (section 4.5.2) The bacterial cell lysate was 
purified using a 1 ml HisTrap HP affinity chromatography column and AKTA FPLC. Fractions 
were collected following a linear imidazole elution (5-250 mM) and the UV trace obtained 
from the FPLC with fraction number (Figure 4.31A) is shown in addition to the separation of 
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proteins by SDS-PAGE and analysis by Instant Blue protein staining to detect total protein 
(Figure 4.31B), and by immunoblotting with anti-histidine antibodies to detect His-tagged 
ΔN-mutHECTD1 (Figure 4.31C). The first peak is indicative of an injection peak and second 
protein peak correlated with fractions 1-2 on the UV trace (Figure 5.31A) was associated with 
contaminating bacterial proteins. However, the shoulder on the UV trace from fraction 7 
onwards, contained isolated and purified recombinant ΔN-mutHECTD1. Confirmation by 
SDS-PAGE protein staining (Figure 4.31B) and immunoblotting (Figure 4.31C), revealed the 
presence of ΔN-mutHECTD1 in largely in fractions 7-16, but the protein, as did the wildtype, 
was found to undergo partial degradation to that of a slightly small molecular weight (85 
kDa). Nevertheless, this protein crucially cross-reacts with the His-tagged antibodies, 
suggesting that the protein is being degraded from the N-terminus (as the protein is C-
terminally tagged) and includes the fully intact mutant E3 ligase HECT domain required for 
my investigations. Therefore, relatively pure protein fractions (7-12) were pooled, buffer 
exchanged (50 mM Tris-HCl pH 8, 50 mM KCl, 1 mM EDTA, 10 % glycerol) to remove 
imidazole, the protein concentrated this measured using a Nanodrop ND-1000 spectrometer 
at a wavelength of OD 280 nm with molecular weights and extinction coefficients (ɛ). The 







Figure 4.31: HisTrap HP affinity column chromatography purification of recombinant His-
tagged ΔN-mutHECTD1 
Following protein overexpression in E-coli, ΔN-mutHECTD1 was purified from the bacterial 
cell lysate by a HisTrap HP affinity chromatography column and AKTA FPLC using a linear 5-
250 mM imidazole gradient elution. A UV trace (blue) from the FPLC is shown with the 
fraction number below in red. Corresponding analysis of the fractions by B 10 % SDS-PAGE 
gel stained with Instant blue protein stain and C immunoblotting using His-tag specific 
antibodies. Fraction number and recombinant His-tagged ΔN-HECTD1 indicated, with protein 
marker (10-250 kDa). All gels were electrophoresed at 175 V for 110 minutes and imaged 
using the Li-Cor Odyssey Infrared Imaging Analysis System.  
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4.8.3 In vitro BER activity of APE1 and ΔN-mutHECTD1 on the THF-IN 
mononucleosome substrate 
To determine if it is indeed the E3 ubiquitin ligase activity of HECTD1 that is essential for its 
role in stimulating BER in chromatin. I assessed the ability of ΔN-mutHECTD1 to stimulate 
APE1 activity on THF-IN mononucleosome substrates. This was examined, from three 
independent BER assays, using a titration of ΔN-mutHECTD1, with percentage THF-incision 
calculated by the proportion of cleaved 116 bp THF-IN DNA (P) relative to full length 256 bp 
DNA (S). As when examining the effect of HECTD1 on THF site excision by APE1 within the 
mononucleosome substrate, as a control the incision of the THF site by APE1 alone was 
examined, upon examination of the cleavage product (S) it was determined that 20 % THF-
incision was achieved (Figure 4.32A (blue)), comparable to THF-incision seen in previous in 
vitro BER experiments (section 4.7). Using a titration (0-15 pmol) of the inactive E3 ubiquitin 
ligase HECTD1, ΔN-mutHECTD1, I determined that ΔN-mutHECTD1 was not able to 
significantly stimulate the activity of recombinant APE1 against the THF-IN mononucleosome 
substrate (Figure 4.32B, lanes 3-6 and Figure 4.32A (blue)). Utilising an initial titration of 2 
pmol ΔN-mutHECTD1 no increase in percentage THF-incision was observed, in fact a small 
decrease of 16 % THF-incision was seen at this titration step. Further increases in the 
concentration of ΔN-mutHECTD1 within the BER reactions also failed to stimulate APE1 
activity of the THF-IN mononucleosome, with percentage THF-IN only reaching a maximum 
of 20 % at 5, 10 and 15 pmol ΔN-mutHECTD1 (Figure 4.32B, lanes 3-6 and Figure 4.32A 
(blue)). 
 It was also important to verify that ΔN-mutHECTD1 alone had no impact on the incision of 
the THF-IN mononucleosome. Therefore, except for the absence of APE1, in the same 
reaction conditions the THF-IN substrate was incubated with a titration of recombinant ΔN-
mutHECTD1 (0-15 pmol) alone in the in vitro BER assay. In the absence of APE1 I observed 
no significant incision of the THF site, with percentage THF-incision, as determined by the 
proportion of cleaved 116 bp THF-IN DNA (P) relative to full length 256 bp DNA (S) (Figure 
4.32B). Furthermore, percentage THF-incision largely remained at control levels at all ΔN-
mutHECTD1 titration points, although small variations are seen with 2 % THF-incision seen 
with incubation of 2 pmol ΔN-mutHECTD1 and 3 % THF-incision at 5 and 10 pmol ΔN-
mutHECTD1 incubation, it can be assumed that this variation is due to background signals 
from the Li-Cor Odyssey Infrared Imaging Analysis System and not true 116 bp THF-IN DNA 
cleavage product (Figure 4.32A (orange)). Therefore, I can conclude that there was no impact 
of ΔN-mutHECTD1 alone on incision of the THF-IN substrate (Figure 4.32B, lanes 7-10 and 
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Figure 4.32A (orange)). Thus, providing evidence that the E3 ubiquitin ligase activity of 











Figure 4.32: mutant HECTD1 cannot promote incision of THF-IN mononucleosome 
substrate by recombinant APE1 in vitro 
Stimulation of APE1-dependent incision of the THF-IN mononucleosome substrate by ΔN-
mutHECTD1. A Purified recombinant ΔN-mutHECTD1 concentration titration (0-15 pmol) 
using THF-IN mononucleosome substrate in the presence (blue) and absence (orange) of 
APE1 (50 fmol) and B representative gel with full length 256 bp DNA (S) and cleaved 116 bp 
THF-IN DNA (P) indicated. PAGE gels contained 8 % polyacrylamide, 7 M Urea and 1x TBE and 
were run at 300 V, 20 W for 1.75 hours, gels were imaged and percentage incision quantified 
using the Li-Cor Odyssey Infrared Imaging Analysis System. Shown is the mean percent 
substrate incision ± S.E. from three independent experiments. 
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4.9 Summary  
To investigate the role of HECTD1 as a potential histone modifier or ATP chromatin 
remodeller on BER in chromatin, it was first necessary to generate a THF-IN 
mononucleosome substrate. This substrate was designed to contain a THF site in an occluded 
position within the nucleosome, positioned so that the DNA backbone was facing towards 
the histone octamer, therefore making the site inaccessible to APE1 (Figure 4.1). Previous 
data within the Parsons’ group established in vitro that this THF site was poorly cleaved by 
APE1. However, APE1 present in WCE generated from HeLa cells was found to efficiently 
cleave this THF site due to the presence of histone modifiers or ATP chromatin remodellers 
within the WCE. Following an unbiased purification scheme and mass spectrometry analysis, 
HECTD1 was identified as a strong chromatin remodeller candidate. In this chapter, I have 
demonstrated the generation of a THF-IN mononucleosome substrate, utilised LIC cloning 
and a bacterial expression system to produce recombinant ΔN-HECTD1 and clearly 
established an in vitro role of HECTD1 in BER where it acts to promote APE1 activity at 
occluded THF sites within mononucleosomes.  
The Widom 601 sequence, selected due to its strong nucleosome positioning affinity, was 
amplified from the pGEM-3Z-601 plasmid using 5’-fluorescently labelled primers. Therefore, 
DNA could be quantitatively analysed using the Li-Cor Odyssey Image Analysis System, crucial 
not only for ensuring accurate generation of THF-IN containing DNA substrates, but also for 
ease of visualisation and accurate quantification of incision by APE1. The central 17 bp of the 
601 nucleosome positioning sequence was removed using Van91I and BgII restriction 
enzymes to produce, once purified, two DNA sequence fragments. These were sequentially 
ligated to a pre-prepared 17 bp duplex oligonucleotide containing a THF site on the lower 
strand, resulting in the production of a site specific THF-IN DNA substrate, which when 
complexed with a histone octamer would produce a mononucleosome substrate. The 
histone octamer was successfully prepared, as previously reported [325]. Xenopus Laevis 
recombinant histones were overexpressed in E.coli and purified from inclusion bodies by gel 
filtration and ion-exchange chromatography under denaturing conditions, before unfolding 
and refolding in equimolar ratios to form the histone octamer. The THF-IN mononucleosome 
substrate was reconstituted by incubating THF-IN DNA with the histone octamer in a 1:1 ratio 
with a salt gradient dialysis, consistent with previous reports [325].  
HECTD1 was cloned utilising a LIC strategy (Figure 4.18), this method does not require 
restriction enzymes or DNA ligases used in traditional cloning, rather employs the 
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polymerase/exonuclease activity of T4 DNA polymerase to generate complimentary long 
overhangs between the vector and insert to form stable associations [323]. The murine 
HECTD1 gene, truncated at amino acid 1761, to enable utilisation of a bacterial 
overexpression system, was cloned from the mammalian expression vector and into the 
pET28a bacterial expression vector. Recombinant ΔN-HECTD1 overexpression was optimised 
for 3 hours in E-coli, as determined by test expression, key for generation of the stable 
protein, and purified using affinity chromatography. 
Following successful generation of the THF-IN mononuclesome substrate and ΔN-HECTD1 
protein, I first confirmed the inefficiency of APE1 to access the THF site when the DNA 
backbone is facing inwards towards the histone octamer. I also used this to establish reaction 
conditions for a ΔN-HECTD1 titration, where I decided that 50 fmol APE1 (generating ~20 % 
substrate incision) was sufficient for future in vitro investigations. Furthermore, I 
investigated the ability of ΔN-HECTD1 to stimulate APE1 activity on THF-IN mononucleosome 
substrates and concluded that ΔN-HECTD1 was able to significantly stimulate, in a dose-
dependent manner, the activity of recombinant APE1 against the THF-IN mononucleosome 
substrate from 20 to 57 %. To confirm the requirement of ΔN-HECTD1 to stimulate APE1 
activity on THF-IN mononucleosome substrates, I adopted a SDM approach to mutate the 
active site cysteine (C) residue to a glycine (G) residue within the HECT domain, generating 
ΔN-mutHECTD1, an E3 inactive ligase mutant of ΔN-HECTD1. Following bacterial 
overexpression and affinity purification, a ΔN-mutHECTD1 titration into the in vitro BER assay 
was able demonstrate that ΔN-mutHECTD1 was unable to stimulate APE1 activity against the 
THF-IN mononucleosome, providing evidence that via its E3 ligase activity ΔN-HECTD1 was 
able to stimulate APE1 activity at occluded THF sites. Therefore, confirming HECTD1 as a 
chromatin remodelling enzyme candidate to take forward into future chapters.  
The findings in this chapter, corroborates previously published in vitro studies which found 
that the detection of AP sites by APE1 was dependent on damage orientation within 
mononucleosomes constructed using 150 bp TG motif containing DNA or with 147 bp 601 
DNA. Here, at least a 2-fold (TG sequence) and 3-fold (601 sequence) reduction in cleavage 
of a natural AP site or tetrahydrofluran (THF) by APE1 was observed with inwardly facing 
lesions in comparison to outwardly facing sites [248]. Interestingly, the reduced substrate 
cleavage was demonstrated through gel shift mobility assays to be as a consequence of 
reduced binding of APE1 to the inwardly facing substrate, rather than reduced activity. This 
study was followed by demonstration that two naturally occurring variants of APE1, R237C 
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and G241R, have reduced activity on both inwardly and outwardly facing AP site containing 
147 bp 601 DNA within mononucleosome substrates, but not on naked DNA [249]. This was 
despite the variants not demonstrating any dramatic differences in mononucleosome 
binding. Furthermore, the importance of epigenetics in this stage of BER has been shown in 
vitro with a 15-fold reduction in mononucleosome AP site reactivity with histone proteins 
observed following mutation of five lysine residues (to arginines) in the amino tail region of 
histone H4, predicting the involvement of histone tails and PTMs in DNA strand cleavage 
[250]. Therefore, this data suggests that APE1 itself may not be the target of any PTM or ACR 
involved in chromatin remodelling within BER. Also, of note, is that studies identifying ACRs 
targeting APE1 or AP site incision within BER are limited. An early in vitro study using 227 bp 
601 DNA and recombinant X. laevis histones to generate mononucleosomes containing an 8-
oxoguanine residue, identified yeast SWI/SNF as a factor increasing the efficiency of excision 
of the lesion by OGG1 and APE1 by ~8-fold, which improved processing efficiency similar to 
that of naked DNA alone [241]. Thus, the data presented in this chapter, highlighting a novel 
role of HECTD1 in promoting AP site incision within chromatin, is vital to accelerate our 
understanding of chromatin remodelling in BER.  
All together this suggests that the action of any ACR or PTM, such as ubiquitylation, may not 
be targeting APE1 itself and altering enzyme activity but somehow improving APE1 
accessibility via altering chromatin structure. Furthermore, this may also suggest that 
HECTD1, similarly to SWI/SNF, may play a more general role within BER beyond AP site 
incision. Therefore, when assessing potential mechanistic modes of action of HECTD1 it was 
vital to focus my attentions on assessing multiple targets, including the core histone proteins, 










CHAPTER 5: RESULTS II 
 
Investigation of the E3 ubiquitin ligase activity and targets of HECTD1 
 
5.1  Introduction 
A key way in which cells regulate normal cell physiology is through ubiquitylation which can 
modulate protein-protein or protein-DNA interactions as well as protein stability and activity. 
Ubiquitylation consists of three steps, ubiquitin activation by an E1 ubiquitin-activating 
enzyme, ubiquitin transfer from the E1 enzyme to the E2 active site by a E2 ubiquitin 
conjugating enzyme, before an E3 ubiquitin ligase enzyme catalyses the transfer of ubiquitin 
onto a lysine residue of the substrate protein.  
With over 600 E3 ubiquitin ligases identified in the human proteome, it is assumed that this 
PTM is implicated in every cellular function. This includes the DDR, in particular, a number of 
E3 ubiquitin ligases have been identified to target BER proteins, particularly for 
ubiquitylation-dependent degradation. Multiple DNA glycosylases have been shown to be 
substrates for E3 ubiquitin ligases, for example, CRL4(Cdt2) targets TDG for degradation via 
the proteasomal pathway, during S phase of the cell cycle [328], [329]. Additionally, Mule 
and TRIM26 has been shown to regulate the steady state levels of the DNA glycosylase NEIL1 
[246]. However, TRIM26 has also been shown to polyubiquitylate NTH1, yet this has no 
impact on steady state levels of the protein, instead regulating DNA damage inducible levels 
of NTH1 following oxidative DNA damage [247]. Furthermore, ubiquitylation of MUTYH by 
Mule has been shown to regulate the protein’s cellular steady state levels [330], and the 
same E3 ubiquitin ligase is known to monoubiquitylate Pol β and to control its degradation 
by the proteasome [331]. It is important to highlight the range of biological effects that one 
E3 ligase can have. Furthermore, it has been suggested that steady state levels of BER 
proteins can be modulated by differing cellular states and E3 ligases. For example, UBR3 has 
been shown to ubiquitylate APE1 to regulate the cellular steady state levels [332]. 
Additionally Parkin, which is activated under cellular stress, has been shown to ubiquitylate 
APE1 under mitochondrial or oxidative stress in cells [333]. This further demonstrates the 
complexity and breadth of this PTM particularly in regulating BER. 
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The HECT domain containing E3 ubiquitin ligase, HECTD1 is a 289 kDa protein which was first 
characterised to target heat shock protein 90 (HSP90) for ubiquitylation and control the 
cellular localisation and secretion of the protein necessary for regulation of the behaviour of 
cranial mesenchyme cells [303]. HECTD1 has also been shown to function as a negative 
regulator of the Wnt pathway through catalysing the polyubiquitylation of the adenomatous 
polyposis coli (APC) protein in HEK293 cells, required for its interaction with Axin [308] . This 
is supported by a report observing, via a USP15 stabilisation of HECTD1, downregulation of 
Wnt pathway activity in LN-229 and LN-428 glioblastoma cells associated with HECTD1 
overexpression [318]. Furthermore, it has been demonstrated that HECTD1 negatively 
impacts endothelial-mesenchymal transition in response to silicon dioxide in MML1 mouse 
lung cells, inhibiting cell proliferation and migration [314]. Additionally, in T47D breast cancer 
cells, HECTD1 depletion has been shown to enhance epithelial-mesenchymal transition and 
promotes tumour growth, survival and metastasis due to decreased HECTD1 mediated 
ubiquitylation-dependent degradation of ACF7 [312]. 
In addition to these reports demonstrating roles for HECTD1 in controlling cell signalling, 
proliferation and migration, in the previous chapter I provided new evidence that HECTD1 is 
required to promote efficient repair of synthetic AP sites (THF) by APE1 within 
mononucleosomes, as a model of the chromatin environment. In this chapter, I aimed to 
elucidate the mechanism via which HECTD1 is acting in this novel role. Initially, utilising 
DNase footprinting assays, I examined the ability of HECTD1 to act as a chromatin 
remodelling enzyme via nucleosome sliding. Furthermore, utilising in vitro ubiquitylation 
assays I aimed to identify targets of ubiquitylation by HECTD1. Additionally, in this chapter I 
aimed to examine the specificity of HECTD1 in stimulating BER in chromatin, and specifically 
to assess its ability to also stimulate NTH1 activity on TG mononucleosome substrates. 
 
5.2  Nucleosome sliding by HECTD1 
One theory of the mechanism by which HECTD1 was promoting APE1 activity within 
mononucleosomes, was via altering the accessibility of the occluded synthetic AP site to 
APE1 via nucleosome sliding. This is one mode of chromatin remodelling whereby ATP-
chromatin remodelling enzymes utilise ATP-hydrolysis to relocate histone octamers to 
adjacent DNA segments (‘sliding’) [334]–[336]. In the case of HECTD1, an E3 ubiquitin ligase, 
I theorised that via a ubiquitylation event HECTD1 may be causing sliding or displacement of 
the histones. To examine this, DNase footprinting, where differences in DNA cleavage 
163 
 
patterns between free DNA and protein-bound DNA aid in the identification of DNA-protein 
interactions, was utilised here with the aim of identifying whether sliding of the nucleosome 
led to the increased substrate cleavage following incubation of the nucleosome with 
HECTD1.  
 
5.2.1 DNase footprinting of the free DNA substrate 
Initially, it was important to establish reaction conditions for the DNase footprinting assay 
on free DNA. Therefore, 50 fmol free THF-IN DNA was incubated for 2 minutes with 
increasing concentrations of DNase (0-0.5 units), reactions were stopped with the addition 
of formamide loading dye and denatured at 95°C for 5 minutes. Samples were run on a pre-
warmed 8 % denaturing acrylamide sequencing gel in 0.5x TBE at 1800 V and 42 W for 80 
minutes and gels imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. As can 
be seen in Figure 5.1, incubation with 0.05 units DNase (lane 2) yielded no visible cleavage, 
with the observed pattern identical to that observed in control conditions (lane 1). With the 
increasing DNase titrations, cleavage patterns of the free THF-IN DNA was observed at 0.1-
0.5 units DNase, which indicated that a 2 minute incubation period was sufficient for 
cleavage of the substrate. When optimising DNase dosing, although evidence of the free DNA 
cleavage pattern was visible following incubation with 0.1 units (lane 3), the full banding was 
not evident until incubation with 0.2 units (lane 4). However, as shown in lane 5, an 
optimised clear free THF-IN DNA cleavage pattern is observed with incubation of free DNA 
with 0.5 units DNase. Therefore, 0.5 units per 50 fmol free THF-IN DNA was accepted for 
future investigations. Also, of note, as can be seen in Figure 5.1, a DNA marker was not used 
in these preliminary investigations. This was deemed acceptable as the purpose of these 
experiments was to determine a cleavage pattern of the THF-IN free DNA for use in future 
experiments with the THF-IN mononucleosome substrate, where the free DNA cleavage 





Figure 5.1: DNase titration on THF-IN free DNA 
DNase footprinting assay of THF-IN free DNA. THF-IN free (50 fmol) DNA incubated with 
increasing doses of DNase (0 (lane 1), 0.05 (lane 2), 0.1 (lane 3), 0.2 (lane 4), 0.5 (lane 5) units) 
for 2 minutes at room temperature in DNase buffer. Samples were separated by a 8 % 
denaturing acrylamide sequencing gel in 0.5x TBE at 1800 V and 42 W for 80 minutes and 




5.2.2 DNase footprinting of the THF-IN mononucleosome substrate 
Following the titration of DNase on THF-IN free DNA, it was next essential to establish 
reaction conditions for the footprinting assay on mononucleosome DNA. In the first instance, 
100 fmol of THF-IN mononucleosome substrate was used, where the increase in DNA 
concentration was to allow for loss during DNA extraction. The substrate was then incubated 
for 2 minutes with increasing concentrations of DNase (0-2 units). DNA was extracted initially 
via phenol:chloroform:isoamyl alcohol and Bio-Spin P-30 Gel Columns similar to the in vitro 
BER assay (section 3.18), however, this method resulted in too high a degree of DNA loss, as 
determined by comparison to the optimised THF-IN free DNA reactions (Figure 5.2A; lane 1) 
where the cleavage pattern was clearly visible. This resulted in the inability to quantify the 
THF-IN mononucleosome DNA via a sequencing gel following this DNA extraction technique 
(Figure 5.2A; lanes 2-6). Therefore, I adopted an ethanol precipitation technique to extract 
the THF-IN mononucleosome DNA following incubation of the substrate with increasing 
concentrations of DNase (0-2 units). In the same manner as the free DNA control, DNA 
samples following ethanol precipitation were denatured with the addition of formamide 
loading dye and boiling at 95°C for 5 minutes. Samples were run on a pre-warmed 8 % 
denaturing acrylamide sequencing gel in 0.5x TBE at 1800 V and 42 W for 80 minutes and 
gels imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. This alternative DNA 
extraction method proved successful in retaining a sufficient DNA concentration for analysis 
via a sequencing gel, where a clearly different cleavage pattern can be seen between the 
protein bound DNA (Figure 5.2B lanes 2-6) and the free DNA (Figure 5.2B, lane 1). The 
predicted location of the histone octamer is indicated in Figure 5.2B, where a clear section 
of the cleavage pattern lacks DNA banding, indicative of DNA protection due to protein 
binding from the action of the DNase enzyme. Furthermore, inspection of the THF-IN 
mononucleosome cleavage patterns indicated that 1 unit of DNase (Figure 5.2B, lane 4) was 




Figure 5.2: DNase titration on THF-IN mononucleosome DNA 
DNase footprinting assay of THF-IN mononucleosomes. THF-IN mononucleosome (100 fmol) 
incubated with increasing doses of DNase (0 (lane 2), 0.5 (lane 3), 1.0 (lane 4), 1.5 (lane 5), 
2.0 (lane 6) units) for 2 minutes at room temperature in DNase buffer. As a control, THF-IN 
free (50 fmol) DNA was incubated with 0.5 units DNase (lane 1). DNA was extracted via 
phenol:chloroform:isoamyl alcohol and purified via A Bio-Spin P-30 Gel Columns or B ethanol 
precipitation. Samples were separated by a 8 % denaturing acrylamide sequencing gel in 0.5x 
TBE at 1800 V and 42 W for 80 minutes and gels imaged using the Li-Cor Odyssey Infrared 




5.2.3 DNase footprinting of the THF-IN mononucleosome substrate following 
HECTD1 incubation 
Once reaction conditions for both THF-IN free and mononucleosome DNA had been 
established, the aim was to analyse any differences in the cleavage pattern of the THF-IN 
mononucleosome in the absence versus the presence of incubation with HECTD1 in the in 
vitro BER assay. Therefore, the THF-IN mononucleosome substrate (100 fmol) was incubated 
with either 0 pmol or 10 pmol ΔN-HECTD1 in the in vitro BER assay, reactions were fully 
complemented with one E1 activating enzyme (0.7 pmol), nine combined E2 conjugating 
enzymes (2.5 pmol), and ubiquitin (0.6 nmol). DNA extraction was performed with ethanol 
precipitation before undergoing DNase cleavage in the DNase footprinting assay via 
incubation with 1 unit DNase for 2 minutes. Similarly, THF-IN free DNA (50 fmol) was 
incubated with 0.5 units DNase for 2 minutes as a control. Samples were denatured with the 
addition of formamide loading dye and boiling at 95°C for 5 minutes and run on a pre-
warmed 8 % denaturing acrylamide sequencing gel in 0.5x TBE at 1800 V and 42 W for 80 
minutes. Gels imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. 
Unfortunately following the in vitro BER assay, THF-IN mononucleosomal DNA was not 
successfully visualised on sequencing gels despite multiple attempts. This could be a result 
of unsuccessful ethanol precipitation of DNA or inefficient DNA extraction using 
phenol:chloroform, which is not unexpected given the complexity of this approach. I was not 
able to mitigate this by increasing the concentration of the THF-IN mononucleosome to 200 
fmol (Figure 5.3). Here, samples in both the presence and absence of ΔN-HECTD1, in which 
the DNA had undergone the in vitro BER assay and DNA extraction prior to DNase 
footprinting, I was unable to visualise any DNA cleavage pattern (Figure 5.3 lanes 2 and 3). 
However, the cleavage pattern of the optimised THF-IN free DNA reactions was clearly visible 
(Figure 5.3; lane 1), demonstrating that the electrophoresis of samples was successful. 
Therefore, I am unable to conclude that HECTD1 is or is not altering accessibility of the AP 
site via nucleosome sliding. However, in the following work, I aimed to investigate the 
ubiquitylation activity of HECTD1 against both APE1 and the histone proteins to elucidate the 




Figure 5.3: DNase footprinting on THF-IN mononucleosome following HECTD1 chromatin 
remodelling 
DNase footprinting assay of THF-IN mononucleosomes following in vitro BER assay. THF-IN 
mononucleosome (200 fmol) incubated with 0.7 pmol GST-E1 activating enzyme, 2.5 pmol 
E2 conjugating enzyme (combination of 9 different E2s), 0.6 nmol ubiquitin, 1 µg acetylated 
BSA, 50 fmol APE1 with (lane 2) or without (lane 3) 10 pmol ΔN-HECTD1 for 1 hour at 30°C 
with 800 rpm. DNA was extracted via phenol:chloroform:isoamyl alcohol and ethanol 
precipitation. Following the in vitro BER assay, DNA was incubated with 1 unit DNase for 2 
minutes at room temperature in DNase buffer. As a control, THF-IN free (50 fmol) DNA was 
incubated with 0.5 units DNase (lane 1). Samples were separated by a 8 % denaturing 
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acrylamide sequencing gel in 0.5x TBE at 1800 V and 42 W for 80 minutes and gels imaged 
using the Li-Cor Odyssey Infrared Imaging Analysis System. 
 
5.3  In vitro ubiquitylation of APE1 by HECTD1 
Whilst in the previous section I was unsuccessful in confirming the ability of HECTD1 to cause 
changes to the mononucleosome via altering histone-DNA contact and nucleosome sliding, I 
moved on to investigate the specific targets for HECTD1 ubiquitylation activity. In the first 
instance, I utilised the in vitro ubiquitylation assay with recombinant APE1 and increasing 
concentrations of ΔN-HECTD1 (2.8-14.1 pmol) in the presence of one E1 activating enzyme, 
nine separate E2 conjugating enzymes, and ubiquitin. This was to examine whether APE1 
itself was being ubiquitylated by HECTD1, potentially increasing AP endonuclease enzymatic 
activity. Whilst evidence from the in vitro ubiquitylation assay did suggest E2-dependent 
monoubiquitylation of APE1 in the absence of HECTD1 (Figure 5.4, lane 1), which has 
previously been observed [332], an increasing presence of ΔN-HECTD1 (Figure 5.4, lanes 2-
4) did not stimulate APE1 ubiquitylation. In fact, addition of ΔN-HECTD1 actually supressed 
E2-dependent monoubiquitylation at the highest protein concentration (Figure 5.4, lanes 2-
4). This however confirmed that APE1 protein is not a direct target for HECTD1 ubiquitylation. 
 
Figure 5.4: In vitro ubiquitylation activity of APE1 by HECTD1 
In vitro ubiquitylation assays contained recombinant APE1 (5.9 pmol) in the presence of 
increasing amounts of ΔN-HECTD1 (2.8–14.1 pmol), one E1 activating enzyme (0.7 pmol), 
nine separate E2 conjugating enzymes (2.5 pmol), and ubiquitin (0.6 nmol) (Ub). Reactions 
were incubated at 30°C for 1 hour with shaking. Samples were separated by 10 % SDS-PAGE, 
analysed by immunoblotting using APE1 antibodies, or with antibodies targeting HECTD1 
(lower panel) and imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. 
170 
 
5.4  In vitro ubiquitylation of the histone proteins by HECTD1 
As there was no evidence of APE1 ubiquitylation, as predicted, I went onto examine in vitro 
ubiquitylation of histone proteins within the octamer. Again, I utilised the in vitro 
ubiquitylation assay but with the histone octamer and increasing concentrations of ΔN-
HECTD1 (2.8-14.1 pmol) in the presence of one E1 activating enzyme, nine separate E2 
conjugating enzymes, and ubiquitin. I investigated whether HECTD1 could ubiquitylate the 
individual histone proteins within the histone octamer, in vitro. On examination of histone 
H2A ubiquitylation, it does not appear, at least in vitro, to be a target for ubiquitylation by 
ΔN-HECTD1. In control conditions (Figure 5.5A, lane 1), where just the histone octamer, the 
E1 enzyme, E2 enzymes and ubiquitin (no ΔN-HECTD1) are present, as expected the 14 kDa 
histone H2A is visible, however given the multiple bands detected, especially at higher 
molecular weights (25-50 kDa), any statements drawn from this data cannot be considered 
a definitive conclusion. Yet, with increasing concentrations of ΔN-HECTD1 (Figure 5.5A, lanes 
2-4), there was no difference in the detection of histone H2A (14 kDa) as a slower migrating 
species which would be expected if the protein was being ubiquitylated by ΔN-HECTD1 due 
to the addition of 8 kDa ubiquitin moieties. This indicated that ΔN-HECTD1 does not 
ubiquitylate histone H2A. Again, the poor quality of this antibody is evidenced by the cross-
reactivity seen in control conditions (Figure 5.5A, lanes 5-8), where only the E1 enzyme, E2 
enzymes, ubiquitin and increasing concentrations of ΔN-HECTD1 are present in reactions. 
Therefore, no histone H2A should be detected due to the absence of the histone octamer. 
However, given the visible banding in reactions (Figure 5.5A, lanes 5-8), both off-target and 
at ~14 kDa the apparent evidence that histone H2A is not a target for HECTD1 can not be 
accepted as fully conclusive. Similarly, it does not appear, at least in vitro, that histone H4 is 
a target for ubiquitylation by ΔN-HECTD1. In control conditions (Figure 5.5D, lane 1), where 
just the histone octamer, the E1 enzyme, E2 enzymes and ubiquitin (no ΔN-HECTD1) are 
present, as expected the 11 kDa histone H4 is visible. With increasing concentrations of ΔN-
HECTD1 (Figure 5.5D, lanes 2-4), there is no difference in the detection of histone H4 (11 
kDa) as a slower migrating species which would be expected if the protein was being 
ubiquitylated by ΔN-HECTD1 due to the addition of 8 kDa ubiquitin moieties. Furthermore, 
as histone H4 was not detected in duplicate control reactions (Figure 5.5D, lanes 5-8), where 
only the E1 enzyme, E2 enzymes, ubiquitin and increasing concentrations of ΔN-HECTD1 are 
present, it can be concluded that ΔN-HECTD1 does not ubiquitylate histone H4. 
When examining histone H2B ubiquitylation by ΔN-HECTD1, again in control conditions 
(Figure 5.5B, lane 1), where just the histone octamer, the E1 enzyme, E2 enzymes and 
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ubiquitin (no ΔN-HECTD1) are present, histone H2B (17 kDa) was successfully detected. 
Furthermore, with increasing concentrations of ΔN-HECTD1 (Figure 5.5B, lanes 2-4), a 
gradual increase in a slower migrating species is visible, due to the addition of 8 kDa ubiquitin 
moieties and providing evidence of modest mono/diubiquitylation of histone H2B, this is 
particularly apparent in lanes 3 and 4 (Figure 5.5B, lanes 3-4). Furthermore, as histone H2B 
was not detected in duplicate control reactions (Figure 5.5B, lanes 5-8), where only the E1 
enzyme, E2 enzymes, ubiquitin and increasing concentrations of ΔN-HECTD1 are present. 
Here, evidence of ΔN-HECTD1 mediated in mono/diubiquitylation of histone H2B is revealed. 
In addition, I also present more convincing evidence that ΔN-HECTD1 promotes histone H3 
polyubiquitylation (Figure 5.5C, lanes 2-4). Again, in control conditions (Figure 5.5C, lane 1), 
where just the histone octamer, the E1 enzyme, E2 enzymes and ubiquitin (no ΔN-HECTD1) 
are present, histone H3 (17 kDa) was successfully detected. Also, with increasing 
concentrations of ΔN-HECTD1 (Figure 5.5C, lanes 2-4), a gradual but prominent increase in a 
slower migrating species of 25-35 kDa is visible, due to the addition of 8 kDa ubiquitin 
moieties. Importantly, no significant cross-reactivity in duplicate control reactions (Figure 
5.5C, lanes 5-8), where only the E1 enzyme, E2 enzymes, ubiquitin and increasing 
concentrations of ΔN-HECTD1 are present was observed. Thus, providing evidence of 
polyubiquitylation of histone H3. Therefore, this data suggests that HECTD1 is promoting 
histone H2B/H3 ubiquitylation, and predictably that this is increasing accessibility of APE1 to 






Figure 5.5: In vitro ubiquitylation activity of the histone proteins by HECTD1 
In vitro ubiquitylation assays contained histone octamer (2 pmol) in the presence of 
increasing amounts of ΔN-HECTD1 (2.8–14.1 pmol), one E1 activating enzyme (0.7 pmol), 
nine separate E2 conjugating enzymes (2.5 pmol), and ubiquitin (0.6 nmol) (Ub). Reactions 
were incubated at 30°C for 1 hour with shaking. Samples were separated by 16 % SDS-PAGE, 
analysed by immunoblotting using A histone H2A, B histone H2B, C histone H3, D histone H4 
antibodies and imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. The 
respective control reactions (Control) were performed in the absence of any HECTD1. 
 
5.5 In vivo ubiquitylation of the histone H2B and H3 by HECTD1 
Given the promising in vitro evidence that ΔN-HECTD1 appears to ubiquitylate histones H2B 
and H3 in in vitro ubiquitylation assays, I went on to investigate if HECTD1 dependent 
ubiquitylation of histones H2B and H3 could be seen in a cellular environment. Therefore, I 
adopted an siRNA-mediated approach to effectively deplete the cellular levels of HECTD1. 
Thus, WI-38 cells were grown until 30-50 % confluent before being transfected with HECTD1 
siRNA or Qiagen AllStars non-targeting control siRNA using Lipofectamine RNAiMax 
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transfection reagent. Cells were then incubated at 37°C and 5 % CO2 in a humidified cell 
culture incubator for 48 hours. Following effective knockdown (section 6.2, Figure 6.1), cells 
were incubated on ice for 5 minutes to limit DNA repair activity and irradiated with 10 Gy IR. 
IR was selected as a DNA damaging agent as it is well known to generate a large proportion 
(>95 %) of DNA damage, including DNA base oxidation, AP sites and SSBs, processed by the 
BER pathway and is commonly used to assess the efficiency of BER in cultured cells as well 
overall cell sensitivity [246][337]. Following induction of DNA damage, cells were washed and 
returned to a humidified cell culture incubator set at 37°C and 5 % CO2 for repair along a set 
time course. Repair was stopped at 0- 60-minutes post irradiation via cell harvesting. 
Histones were prepared using acid extraction and analysed via SDS-PAGE and 
immunoblotting.  
On examination of histone H2B ubiquitylation, it does not appear, at least in WI-38 cells, to 
be a target for ubiquitylation by HECTD1. In control conditions (Figure 5.6A, lane 1), where 
WI-38 cells were treated with Qiagen AllStars non-targeting control siRNA, as expected the 
17 kDa histone H2B is visible. Furthermore, in control conditions, immediately following 
induction of DNA damage (Figure 5.6A, lane 2), there appears to be no difference in the 
detection of histone H2B antibody cross-reactivity, perhaps to be expected, due to a lack of 
time available for repair to be initiated. However, along the time course, (Figure 5.6A, lanes 
3-5), at 15- 60-minutes post irradiation, there too appears to be no difference in the 
detection of histone H2B as a slower migrating species which would be expected if the 
protein was being ubiquitylated by HECTD1 due to the addition of 8 kDa ubiquitin moieties. 
A similar profile is detected for histone H2B in conditions where the cellular levels of HECTD1 
had been depleted (Figure 5.6A, lanes 7-11). This data suggests that histone H2B is not a 
target for HECTD1, at least in WI-38 cells. In addition, upon examination of the presence of 
ubiquitin in each sample, this further validates that histone H2B appears to not be a target 
for ubiquitylation by HECTD1. In conditions containing HECTD1, (Figure 6.6B, lanes 1-5), it 
appears that histone H2B is ubiquitylated, however, given that this is detected at 17 kDa, the 
expected molecular weight of unmodified histone H2B, not at 25 kDa, which would be 
expected given the addition of an 8 kDa ubiquitin moiety. This may be indicative of cross-
reactivity of the antibody instead. Additionally, given that there is no increasing shifting of 
ubiquitin to higher molecular weight species across any control conditions post IR (Figure 
6.6B, lanes 2-5), and that a similar detection of ubiquitin is observed in duplicate experiments 
where the cellular levels of HECTD1 had been depleted (Figure 5.6B, lanes 7-11). The 
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conclusion that histone H2B is not ubiquitylated by HECTD1 in WI-38 cells is seemingly 
confirmed.   
However, upon examination of histone H3 ubiquitylation, it does appear, at least in WI-38 
cells, that HECTD1 polyubiquitylates histone H3 (Figure 5.6C, lanes 2-5). In control conditions 
(Figure 5.6C, lane 1), where WI-38 cells were treated with Qiagen AllStars non-targeting 
control siRNA, as expected the 17 kDa histone H3 is visible. In addition to this, background 
levels of histone H3 polyubiquitylation is observed, evidenced by an apparent smearing 
above the unmodified histone H3 band, indicative of slower migrating species, due to the 
addition of 8 kDa ubiquitin moieties. In conditions immediately following induction of DNA 
damage (Figure 5.6C, lane 2), there appears to be a marked induction of histone H3 
polyubiquitylation, above that of background levels (Figure 5.6C, lane 1). Additionally, 
histone H3 polyubiquitylation is sustained at all time points post IR (Figure 5.6C, lanes 3-5). 
Interestingly, although still present at 15-30-minutes post IR, there is a visible gradual 
decrease in the levels of histone H3 ubiquitylation (Figure 5.6C, lanes 3-4). Yet, at 60 minutes 
post IR, an induction of histone H3 polyubiquitylation (Figure 5.6C, lane 5), greater than levels 
seen at 0 minutes post IR (Figure 5.6C, lane 2), is observed. In unirradiated conditions where 
cellular HECTD1 levels are depleted, as expected the 17 kDa histone H3 is visible, and as in 
conditions containing HECTD1 (Figure 5.6C, lane 1), background levels of histone H3 
polyubiquitylation are observed (Figure 5.6C, lane 7). However, immediately following IR 
exposure (Figure 5.6C, lane 8), there is no apparent induction above the background level 
(Figure 5.6C, lane 7) observed in control conditions of histone H3 ubiquitylation in the 
absence of HECTD1. Additionally, across the time course, (Figure 5.6C, lanes 9-11), there is 
no apparent induction of histone H3 ubiquitylation, particularly at 60 min post-IR. This 
suggests that the induction of histone H3 polyubiquitylation (seen in Figure 5.6C, lanes 2-5) 
is HECTD1 dependent.  This is supported by evidence from probing with ubiquitin antibodies 
(Figure 5.6D). In conditions in the presence of HECTD1, it also appears that histone H3 is 
polyubiquitylated, and this polyubiquitylation is induced following IR treatment (particularly 
at time 0 and 60 min), given the detection of slower migrating ubiquitin species, which is 
expected when detecting ubiquitylated protein, due to the addition of 8 kDa ubiquitin 
moieties (Figure 5.6D, lanes 1-5). Additionally, in un-irradiated conditions where cellular 
HECTD1 levels are depleted, evidence of protein ubiquitylation is visible (Figure 5.6D, lane 
7). However, immediately following IR exposure (Figure 5.6D, lane 8-11), there is no apparent 
induction of histone H3 ubiquitylation above the background level (Figure 5.6D, lane 7). 
Given that this detection of ubiquitin appears to mirror that seen when probing for histone 
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H3 in both control (Figure 5.6C, lanes 1-5) and HECTD1 depleted conditions (Figure 5.6C, 
lanes 7-11), it strengthens the evidence of HECTD1 dependent histone H3 polyubiquitylation 
presented. Thus, in combination with evidence from in vitro ubiquitylation assays, I provide 
strong evidence for HECTD1 targeting histone H3 for ubiquitylation in WI-38 cells.  
 
Figure 5.6: In vivo ubiquitylation activity of histone H2B and H3 by HECTD1 
WI-38 cells were treated with 40 nM Qiagen AllStars non-targeting control (NT) siRNA (+ 
HECTD1) or HECTD1 siRNA (- HECTD1) for 48 hours. Cells were then unirradiated (control) or 
irradiated with 10 Gy IR and incubated at 37°C and 5 % CO2 in a humidified cell culture 
incubator for zero (0), 15 (15), 30 (30) or 60 (60) minutes before cells were harvested, WCE 
prepared and analysed via 16 % SDS-PAGE and immunoblotting immunoblotting using A 
histone H2B, B ubiquitin, C histone H3, D ubiquitin antibodies and imaged using the Li-Cor 
Odyssey Infrared Imaging Analysis System. 
 
5.6 Preparation of TG-IN site containing DNA 
To elucidate the specificity of HECTD1 to either APE1 or as playing a more general role within 
BER, I aimed to investigate further stages of BER. To examine the role of HECTD1 within BER 
initiation by DNA glycosylases, in the first instance I generated DNA substrate containing a 
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site specific thymine glycol (TG), which would then be utilised for generating the lesion where 
the DNA backbone is inwardly facing within the nucleosome and therefore resistant to DNA 
glycosylase activity. Adopting the same protocol established in chapter 4, the Widom 601 
nucleosome positioning sequence was amplified from the pGEM-3Z-601 plasmid using PCR 
and the central 17 bp removed using Van91l and BgII restriction enzymes to produce, once 
purified, two DNA sequence fragments. These were sequentially ligated to a pre-prepared 
17 bp duplex oligonucleotide containing a TG site on the lower strand, resulting in the 
production of a site specific TG-IN DNA substrate, which when complexed with a histone 
octamer, generated a TG-IN mononucleosome substrate where the DNA backbone of the TG 
site faced inwards towards the histone octamer and was therefore occluded from excision 
by endonuclease III homologue (NTH1). 
 
5.6.1 Amplification of the 601 nucleosome positioning sequence 
The Widom 601 wild- type strong nucleosome positioning sequence was amplified from the 
pGEM-3Z-601 plasmid using PCR with 5’-fluroescent labelled primers (Section 4.2, Figure 4.2, 
stage 1). For production of TG-IN DNA, the forward primer was labelled with IRDye800 (green 
label) and the reverse with IRDye700 (red label), due to the increased signal intensity of the 
IRDye700 tag so TG incision could be more strongly visualised using the Odyssey Image 
Analysis system. As the DNA marker was not visible due to the use of fluorescently tagged 
primers, successful generation of the 256 bp 601 nucleosome positioning sequence PCR 
product was visualised as yellow, as the product contained both IRDye700 and IRDye800 5’-
labelled ends, and the excess fluorescent primers were also clearly visible underneath each 
of the PCR products (Figure 5.7). The verified 256 bp DNA was subsequently purified using a 






Figure 5.7: Amplification of the 256 bp 601 nucleosome positioning sequence for 
production of TG-IN DNA 
PCR product of the 601 wild-type strong nucleosome positioning sequence containing both 
the IRDye800 and IRDye700 florescent tags and the IRDye800 forward primer IRDye700 
reverse primer separated by electrophoresis on a 1.5 % agarose gel at 100 V for 1 hour, 
imaged using the Li-Cor Odyssey Infrared Imaging Analysis System. 
 
5.6.2 Double restriction digest of the 601 nucleosome positioning sequence 
Following purification of the 256 bp 601 nucleosome positioning sequence, the central 17 bp 
region was removed using Van91l and BgII restriction enzymes (region shown in section 
3.1.1, Figure 3.1). These enzymes produced a IRDye800 tagged 127 bp DNA fragment and a 
IRDye700 tagged 106 bp DNA fragment, both with sticky ends to facilitate subsequent 
ligation (section 4.2, Figure 4.2, stage 2). Completion of the restriction digest was confirmed 
by comparison to the original purified 256 bp PCR product (Figure 5.8A, lane 1), where the 
Van91l and BgII digestion product (Figure 5.8A, lane 2) is absent of the 256 bp PCR product 
and only the 127 bp and 106 bp DNA fragments are present. The 127 bp and 106 bp DNA 
fragments were then purified from each other using PAGE separation and gel extraction. To 
assure efficiency in the production and purification of these digest products, the 106 bp 
(Figure 5.8B, lane 2) and 127 bp (Figure 5.8B, lane 3) DNA products were compared to the 
original PCR product (Figure 5.8B, lane 1). Again, as the DNA is fluorescently labelled, use of 




Figure 5.8: 127bp and 106 bp Van91I/Bg11 restriction digest products 
A. Original 256 bp PCR product (lane 1) against the Van91l and BgII digestion product (lane 
2) following separation by electrophoresis on a 1.5 % agarose gel at 100 V for 1 hour. B. 
Original 256 bp PCR product (lane 1) against the IRDye700 tagged 106 bp DNA digest product 
(lane 2) and IRDye800 tagged 127 bp DNA digest product (lane 3) following PAGE separation 
on an 8 % polyacrylamide gel in 0.5x TBE run at 175 V, 20 W for 3 hours, gel extraction and 
DNA purification. Gels were imaged using the Li-Cor Odyssey Infrared Imaging Analysis 
System. 
 
5.6.3 Sequential ligations to incorporate the TG-IN site 
To maximise ligation efficiency, the 127 bp and 106 bp DNA digest products were ligated 
sequentially to a 17 bp TG-IN containing duplex oligonucleotide with complimentary sticky 
ends (section 3.1.2.1, Table 3.2) (section 4.2, Figure 4.2, stage 3). In the first instance, the 
127 bp segment was ligated to the TG-IN containing duplex oligonucleotide. This was 
successfully observed as a ligated 147 bp DNA ligation product (Figure 5.9A, lane 3) in 
comparison to the original 5’-IRDye800 labelled 127 bp DNA (Figure 5.9A, lane 2). This 
product was purified using the MinElute reaction clean up kit and then ligated to the 106 bp 
DNA digest product. Successful ligation was evidenced by the formation of the full 256 bp 
substrate DNA (Figure 5.9B, lane 3), in comparison to the unligated second ligation mix 
(Figure 5.9B, lane 2). This was purified using PAGE separation and gel extraction, and the 
successful purification of the final 256 bp substrate containing a site specific TG-IN site 
(Figure 5.9C, lane 2) was confirmed via comparison to the original purified PCR product 
(Figure 5.9C, lane 1). As before, the use of a DNA marker was not applicable here, due to the 
DNA being fluorescently labelled. This 256 bp substrate containing a site specific TG-IN site 
now could be used in the nucleosome reconstitution with the prepared histone octamer. 
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This demonstrates that I had successfully transferred this technique to generate a DNA 
substrate containing a site specific TG-IN site, which I could use to examine the effect of 
HECTD1 on NTH1 incision activity rates at occluded TG sites in mononucleosomes. For ease 
of quantification, the DNA substrates were labelled so the IRDye700, the most intense signal 
when imaging with the Li-Cor Odyssey Infrared Imaging Analysis System, was on the lower 
DNA strand, which would be incised by NTH1, therefore the incision rate by NTH1 could be 
better visualised and accurately quantified.  
 
Figure 5.9: Sequential Ligations to generate a 256 bp DNA substrate containing a TG-IN site 
A. Ligation Reaction 1. Original 256 bp PCR product (lane 1), before (lane 2) and after ligation 
(lane 3) of the IRDye800 tagged 127 bp DNA with the 17 bp duplex TG-IN oligonucleotide. B. 
Ligation Reaction 2. Original 256 bp PCR product (lane 1), before (lane 2) and after the second 
ligation (lane 3) using the IRDye800 tagged 147 bp and IRDye700 tagged 106 bp DNA, 
producing a 256 bp product containing a TG-IN site. C. Original 256 bp PCR product (lane 1), 
final 256 bp substrate containing a site specific TG-IN site following purification by PAGE 
separation and gel extraction (lane 2).  All PAGE gels contained 8 % polyacrylamide and 0.5x 
TBE, and were run at 175 V, 20 W for 3 hours, gels were imaged using the Li-Cor Odyssey 




5.7 Generation of the TG-IN mononucleosome substrate  
TG-IN mononucleosomes were reconstituted by incubation of the purified histone octamer 
with the site specific TG-IN DNA substrate, in a 1:1 ratio in a high salt (2 M NaCl) containing 
buffer. The reconstitution was then dialysed using a salt gradient to promote 
mononucleosome formation. This was confirmed by agarose gel electrophoresis, where a 
shift from the lower molecular weight of 256 bp free DNA to a higher molecular weight of 
approximately 750 kDa was observed (Figure 5.10), indicating successful nucleosome 
formation. Near full nucleosome reconstitution was observed (Figure 5.10, lane 3), with a 
reconstitution efficiency of 95 % deemed as acceptable for use of the mononucleosome 
substrate in in vitro BER repair assays to measure NTH1 activity.  
 
Figure 5.10: Generation of a TG-IN Mononucleosome  
Nucleosome reconstitution was compared to free DNA (lane 2), whereby a shift from the 256 
bp free DNA control, to a high molecular weight species (lane 3), approximately 700 bp, was 
observed when the TG-IN nucleosome was successfully formed. A 1:1 DNA: histone octamer 
ratio was used. DNA was separated using a 0.7 % agarose gel and electrophoresed in 0.2x 
TAE at 75 V for 1.5 hours. A 1 kb GeneRuler DNA ladder (lane 1) was utilised to identify the 
size of the DNA.  
 
5.8  In vitro BER activity of NTH1 on the TG-IN mononucleosome substrate 
In the first instance, TG-IN site incision within a mononucleosome substrate by increasing 
concentrations of recombinant NTH1 was examined. The percentage incision from an in vitro 
BER assay using a titration of NTH1 (0-270 pmol) was performed on the TG-IN 
mononucleosome substrate. Surprisingly, the TG-IN mononucleosome substrate (50 fmol) 
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was processed efficiently with 70 % cleavage achieved with 27 pmol NTH1 (a 540-fold excess) 
(Figure 5.11). Therefore, to achieve a comparable baseline incision to that of the THF-IN 
mononucleosome by APE1 of ~20 %, I decided to extrapolate from this titration curve and 
scale down the NTH1 concentration to 1.35 pmol (a 27-fold excess), to establish reaction 
conditions for a ΔN-HECTD1 titration.  
 
Figure 5.11: NTH1 In vitro BER assay titration on TG-IN mononucleosome substrates  
A Purified recombinant NTH1 concentration titration (0-270 pmol) using TG-IN (blue) 
mononucleosome substrate and B representative gel with full length 256 bp DNA (S) and 
cleaved 116 bp TG-IN DNA (P) indicated. PAGE gels contained 8 % polyacrylamide, 7 M Urea 
and 1x TBE and were run at 300 V, 20 W for 1.75 hours, gels were imaged and percentage 
incision quantified using the Li-Cor Odyssey Infrared Imaging Analysis System. Shown is the 
percent substrate incision from one experiment.  
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5.9  In vitro BER activity of NTH1 and HECTD1 on TG-IN mononucleosome substrate 
The ability of ΔN-HECTD1 to stimulate NTH1 activity on a TG-IN mononucleosome substrate 
was examined, from three independent in vitro BER assays using a titration of recombinant 
ΔN-HECTD1. I determined that ΔN-HECTD1 (0-15 pmol) was able to significantly stimulate 
the activity of recombinant NTH1 (1.35 pmol) against the TG-IN mononucleosome (50 fmol) 
substrate (in a substrate to enzyme ratio of 1:27) from 24 to 60 % TG-incision (Figure 5.12B, 
lanes 3-6 and Figure 5.12A (blue)), as determined by the proportion of cleaved 116 bp TG-IN 
DNA (P) relative to full length 256 bp DNA (S) (Figure 5.12B). When examining the effect of 
HECTD1 on TG site excision by NTH1 within the mononucleosome substrate an initial titration 
of 2 pmol ΔN-HECTD1 (a 40-fold excess in comparison to the substrate) resulted in a 
moderate increase in percentage TG-incision, from the observed control levels (24 %) to 33 
% TG-incision. A further increase in the concentration of ΔN-HECTD1 in the reaction to 5 pmol 
(a 100-fold excess in comparison to the substrate), resulted in a similar degree of increase in 
percentage TG-incision from 33 % TG-incision achieved with 2 pmol ΔN-HECTD1 to 40 % TG-
incision. The following incubation with 10 pmol ΔN-HECTD1 (a 200-fold excess in comparison 
to the substrate), resulted in a significant shift in NTH1 incision of the TG-IN 
mononucleosome, reaching 54 % TG-incision, with the final titration step, an incubation of 
15 pmol ΔN-HECTD1 (a 300-fold excess in comparison to the substrate), reaching the 
observed maximum of 60 % TG-incision of the TG-IN mononucleosome by NTH1.  
It was also important to verify that ΔN-HECTD1 alone had no impact on the incision of the 
TG-IN mononucleosome. Therefore, except for the absence of NTH1, in the same reaction 
conditions the TG-IN substrate was incubated with a titration of recombinant ΔN-HECTD1 (0-
15 pmol) alone in the in vitro BER assay. In the absence of NTH1, I observed no significant 
incision of the TG site, with percentage TG-incision, as determined by the proportion of 
cleaved 116 bp TG-IN DNA (P) relative to full length 256 bp DNA (S) (Figure 5.12B), remaining 
at control levels at all ΔN-HECTD1 titration points (Figure 5.12A (orange)). Therefore, I can 
conclude that there was no impact of ΔN-HECTD1 alone on incision of the TG-IN substrate 
(Figure 5.12B, lanes 7-10 and Figure 5.12A (orange)). These data provide evidence that 




Figure 5.12: HECTD1 promotes incision of TG-IN mononucleosome substrate by 
recombinant NTH1 in vitro 
Stimulation of NTH1-dependent incision of the TG-IN mononucleosome substrate by ΔN-
HECTD1. A Purified recombinant ΔN-HECTD1 concentration titration (0-15 pmol) using TG-IN 
mononucleosome substrate in the presence (blue) and absence (orange) of NTH1 (1.35 
pmol) and B representative gel with full length 256 bp DNA (S) and cleaved 116 bp TG-IN 
DNA (P) indicated. PAGE gels contained 8 % polyacrylamide, 7 M Urea and 1x TBE and were 
run at 300 V, 20 W for 1.75 hours, gels were imaged and percentage incision quantified using 
the Li-Cor Odyssey Infrared Imaging Analysis System. Shown is the mean percent substrate 




In the previous chapter, I established an in vitro role of HECTD1 in BER where it acts to 
promote APE1 activity at occluded THF sites. To investigate the mechanism behind this role, 
I initially aimed to examine whether HECTD1 was acting via nucleosome sliding to relocate 
histone octamers to adjacent DNA segments, therefore, altering the accessibility of the 
occluded THF site to APE1. Unfortunately, I was unable to optimise the DNase footprinting 
assay for my needs, despite optimisation on the free DNA substrate using DNase, I was 
unable to examine the in vitro BER reactions. This could be a result of unsuccessful ethanol 
precipitation of DNA or inefficient DNA extraction using phenol:chloroform thus leading to a 
loss of DNA, which is not unexpected given the complexity of this approach. Furthermore, I 
was unable to mitigate this with increasing concentrations of the THF-IN mononucleosome. 
Therefore, I am unable to conclude whether HECTD1 does or does not act via a DNA sliding 
or eviction mechanism.  
Another aim in this chapter was to establish the target/s of ubiquitylation. Firstly, I show 
utilising in vitro ubiquitylation assays that ΔN-HECTD1 does not stimulate APE1 
ubiquitylation, therefore is not increasing AP endonuclease enzymatic activity. This finding is 
corroborated by previously published gel shift mobility assays which observed reduced 
substrate cleavage with inwardly facing lesions, that was as a consequence of reduced 
binding of APE1 to the inwardly facing substrate, rather than reduced APE1 activity [248]. 
Additionally, a further study demonstrated that two naturally occurring variants of APE1, 
R237C and G241R, have reduced activity on both inwardly and outwardly facing AP sites 
containing 147 bp 601 DNA within mononucleosome substrates, but not on naked DNA, 
despite the variants not demonstrating any dramatic differences in mononucleosome 
binding [249]. Furthermore, a 15-fold reduction in mononucleosome AP site reactivity with 
histone proteins was observed with incorporation of mutant histone H4. Of note, these 
mutations (five lysine residues to arginines) were in the amino tail region of histone H4, 
predicting the involvement of histone tails and PTMs in DNA strand cleavage [250]. 
Therefore, this evidence, in support of my own findings, suggests that APE1 itself may not be 
the target of any PTM or ACR involved in chromatin remodelling within BER.  
As there was no evidence of APE1 and HECTD1 interaction, I moved to examine in vitro 
ubiquitylation of histone proteins within the octamer. This revealed evidence that ΔN-
HECTD1 appears to cause a modest increase in mono/diubiquitylation of histone H2B, but 
more convincingly promotes histone H3 polyubiquitylation. Furthermore, I also provide 
185 
 
preliminary evidence of HECTD1 dependent histone H3 ubiquitylation in WI-38 cells. 
Interestingly, a biphasic induction of histone H3 ubiquitylation was observed and could be 
indicative of the repair of DNA damage in less compact regions at the induction of DNA 
damage, seen at 0 minutes post IR. Followed by repair of DNA damage in heterochromatin, 
where there is a requirement for DNA unwinding, and particularly at 60 minutes post IR I 
observed histone H3 ubiquitylation, suggestive of alternative chromatin remodelling events. 
Although preliminary in nature, these findings are exciting given that our general 
understanding of ubiquitylation events that can affect chromatin structure, particularly 
during BER, is unfortunately not well characterised. Currently, the most extensive evidence 
of histone ubiquitylation is histone H2B monoubiquitylation at K120, associated with active 
chromatin and found on 1-1.5 % of total H2B in mammals [338]. My evidence in vitro of ΔN-
HECTD1 dependent mono/diubiquitylation of histone H2B could be indicative of this 
monoubiquitylation event in promoting BER. Utilising a more extensive approach with 
antibodies specific for H2BK120 ubiquitylation and indeed other less well characterised 
histone H2B ubiquitin docking sites (K34, K46, K108, K116, and K125) [339], [340] would 
provide further validation to this claim. However, given the more convincing evidence of 
histone H3 ubiquitylation I present, any future attentions to elucidate the mechanism via 
which HECTD1 is acting should primarily focus on histone H3 ubiquitylation, which appears 
the strongest target. Previous reports have shown an involvement of histone H3 
ubiquitylation in DNA repair, namely, the implication of CUL4–DDB–ROC1 mediated 
ubiquitylation of histone H3 and H4 in NER [341] and the role of NEDD4-mediated 
ubiquitylation of histone H3 at K23/K36/K37 in transcription activation via stimulation of the 
histone acetyltransferase GCN5 [340]. Also, as histone H3 ubiquitylation has only been found 
to occur globally on 0.3 % of H3 histones [340]–[342], this may be suggestive of a specific 
role for histone H3 ubiquitylation in the DDR, therefore a focus on histone H3 ubiquitylation 
may further elucidate a mode of action for HECTD1 in BER. 
A final aim of this chapter was to begin to elucidate the specificity of HECTD1 to either APE1 
or as playing a more general role within BER. Previous studies have established in in vitro 
mononucleosome studies that DNA glycosylase recognition of the DNA base lesion is 
dependent on lesion orientation. Examples, using chicken erythrocyte histones and TG 
nucleosome positioning sequence DNA to generate mononucleosomes, demonstrated a 2-
3-fold increase in excision by UDG and APE1 of the outwardly facing versus the inwardly 
facing mononucleosome substrate [238]. Similarly, an assessment of the activity of UDG and 
APE1 against mononucleosomes containing the 601 DNA sequence present a 3-5-fold more 
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effective excision of the out substrate in comparison to IN mononucleosome substrates 
[239]. Furthermore, compromised incision of inwardly facing TG substrates by NTH1 alone, 
seen by a 2-fold reduction in NTH1 activity against mononucleosomes containing inwardly 
facing TG site in a 184 bp DNA fragment containing the L. variegatus 5S ribosomal DNA 
nucleosome positioning sequence constructed with recombinant X. laevis histones, has also 
previously been presented [244]. This is supported by a comparative study utilising similar 
substrates assessing the activity of NTH1, where only 10 % of the inwardly facing TG sites 
from mononucleosomes were processed [245]. In this chapter, I examined the role of 
HECTD1 within BER initiation by generating a site specific TG-IN DNA substrate, in the same 
manner as established in the previous chapter for THF-IN. I determined that ΔN-HECTD1 was 
able to significantly stimulate the activity of recombinant NTH1 against the TG-IN 
mononucleosome substrate from 24 to 60 %. Although this is a key finding in establishing 
the specificity of HECTD1 in stimulating BER, this needs to be confirmed using multiple 
different DNA lesion-containing mononucleosome substrates reflecting the alternative steps 
of BER and including the appropriate BER enzymes in vitro. Primarily this would involve 
investigations with GAP and NICK mononucleosome substrates, incorporating the end 
processing mechanisms of BER. In the first instance, an assessment of GAP-IN vs OUT 
mononucleosome processing by Pol β would be of interest. Of note, it would be vital to 
incorporate THF, uracil and TG substrates and the respective enzymes (APE1, UDG and NTH1) 
to generate a natural SSB flanked by 5’-dRP ends to more fully assess the action of Pol β 
which necessitates both dRPase and DNA polymerase activity.  Similarly, the impact of 
chromatin on DNA ligation, particularly XRCC1-Lig III complex, should be assessed using the 
appropriate nick-containing substrates. Furthermore, in addition to measuring the impact of 
chromatin on the individual enzymes, and of HECTD1 in stimulating these, it is also vital to 
consider the efficiency of the complete repair process. Therefore, for example, examining 
processing of TG substrates in different locations and/or orientations when supplemented 
with NTH1, APE1, Pol β and XRCC1-LigIIIα and analysing the final product is of significant 
interest. Thus, further elucidation of HECTD1’s mode of action may be gained through these 
more expansive in vitro studies. 
In summary, I have provided evidence that HECTD1 is promoting THF-IN incision within 
mononucleosomes by APE1, via histone H2B/H3 ubiquitylation. Additionally, I have also 
acquired evidence that HECTD1 is able to stimulate the excision of a TG-IN containing 
mononucleosome substrate by NTH1, suggesting that HECTD1 may be able to promote 
multiple stages of BER. Given this in vitro data, demonstrating that HECTD1 is able to 
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promote both NTH1 and APE1 during DNA base excision and strand incision, it would be 
prudent to examine the requirement for HECTD1 in vivo. In the following chapter, I will assess 
the role of HECTD1 in the survival and DNA damage repair kinetics of normal lung fibroblasts 
in response to a variety of DNA damaging agents; x-ray irradiation, H2O2 and MMS, to 























CHAPTER 6: RESULTS III 
 
 
Dependence of HECTD1 in a cellular environment 
 
6.1  Introduction 
Cellular DNA is subject to constant attack by ROS, generating an estimated 10 000 DNA base 
lesions and SSBs per cell per day due to DNA hydrolysis, cellular oxidative metabolism and 
exposure to exogenous sources such as IR, which, if left unrepaired compromise genomic 
integrity [7]. Maintaining genome integrity is essential to ensure competent biochemical 
functions, cellular survival and ultimately the error-free passage of the genome to future 
progeny. BER, a sophisticated cellular mechanism, plays a vital role in repairing DNA base 
damage and SSBs, thus reducing the frequency of cellular mutations threatening genomic 
integrity [167]. Unsurprisingly, it is of the upmost importance to tightly regulate the DNA 
repair proteins involved in BER, ensuring an effective and coordinated response. One such 
mode of regulation is the action of ubiquitylation on BER [177], [343].  
Ubiquitylation mediated regulation of BER has clearly been demonstrated to have wide 
ranging effects on the proteins involved in the repair pathway and, thus impacts the DDR. 
Furthermore, through investigating how E3 ubiquitin ligases alter their target proteins, in a 
multitude of ways, including the steady state levels of the protein, function or enzymatic 
activity and cellular localisation in vivo, we can improve our understanding of BER and the 
DDR within a cellular context. This knowledge can aid with the understanding of 
misregulation of the BER pathway, which can lead to the accumulation of SSBs, AP sites and 
oxidised DNA bases, all of which compromise genomic integrity. This been implicated in 
human disease development including premature ageing, neurodegenerative diseases and 
several cancers. This could form the basis of the development of novel therapeutics, such as 
small molecular inhibitors, to improve current treatment of these diseases (for example, 
radiotherapy) targeting E3 ubiquitin ligases involved in the regulation of BER proteins.  
It must also be highlighted that HECTD1 is known to be mutated, deleted and amplified in a 
variety of cancers, including but not limited to, breast, brain and lung (small lung cell 
carcinoma and lung adenocarcinoma) cancers). Therefore, in addition to reports 
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demonstrating roles of HECTD1 in controlling cell signalling, proliferation and migration 
[303], [308], [312], [314], [318], it is important to examine the role of HECTD1 in the 
promotion of efficient repair of DNA base damage and investigate its function within normal 
cell physiology.  
In previous chapters, I have highlighted the role of HECTD1 in promoting BER in vitro, 
demonstrating the ubiquitylation dependent promotion of APE1 and NTH1 activity on 
occluded THF and TG sites, respectively, via H2B/H3 ubiquitylation. Logically, I also aimed to 
establish this role of HECTD1 in cultured cells in vivo and in the forthcoming chapter will 
investigate the requirement of HECTD1 in normal cell physiology. Utilising siRNA targeting 
HECTD1 to effectively deplete the protein levels in normal lung fibroblasts, I used the 
clonogenic survival assay and the single cell gel electrophoresis (comet) assays to examine 
the requirement of HECTD1 in promoting cell survival and effective DNA repair kinetics to 
elucidate the role of HECTD1 in a cellular context. 
 
6.2 Effect of siRNA knockdown of HECTD1 on steady state levels of HECTD1 
To investigate HECTD1 in a cellular environment, it was essential to firstly test, and if 
necessary optimise, HECTD1 knockdown efficiency. A pool of four siRNA sequences, to 
increase knockdown efficiency, was used to test transfection and HECTD1 knockdown in 
three normal lung fibroblast cell lines; AG06173, AG16409 and WI-38. These cell lines were 
used in future experiments as my aim was to understand the role of HECTD1 in normal cell 
physiology. In particular, the WI-38 cell line was adopted for use in clonogenic survival assays, 
where the AG06173 and AG16409 were not appropriate due to their lack of colony forming 
ability.  
AG06173, AG16409 and WI-38 cells were grown until 30-50 % confluent before being 
transfected with 40 nM HECTD1 siRNA pool using Lipofectamine RNAiMax transfection 
reagent. As a control, duplicate cells were transfected with Qiagen AllStars non-targeting 
control siRNA. Cells were then incubated at 37oC and 5 % CO2 in a humidified cell culture 
incubator for 48 hours. Following this, cells were harvested and WCE generated. Protein 
extracts were then separated by 4-12 % gradient SDS-PAGE and analysed via immunoblotting 
using HECTD1 and tubulin specific antibodies. From the immunoblot analysis, in comparison 
to the Qiagen AllStars non-targeting control, it is clear that the levels of HECTD1 protein has 
been effectively knocked down in all three cell lines. Additionally, equal loading is 
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demonstrated by the equivalent protein levels of tubulin in comparative samples (Figure 
6.1). To confirm this qualitative assessment of HECTD1 knockdown, the HECTD1 and tubulin 
protein bands were quantified using the Li-Cor Odyssey Infrared Imaging Analysis System. 
Levels of HECTD1 relative to tubulin quantified and shown in Figure 6.1D is the 
HECTD1/tubulin ratio normalised to the Qiagen AllStars non-targeting control transfected 
control cells, which was set to 1.0.  All three cell lines exhibited sufficient HECTD1 knockdown 
following HECTD1 siRNA treatment, with a relative knockdown efficiency of 84 % in the 









Figure 6.1: Knockdown of HECTD1 using siRNA pool in normal lung fibroblast cell lines  
A AG06173, B AG16409, C WI-38 cells grown until 30-50 % confluent and then treated with 
Lipofectamine RNAiMax transfection reagent in the presence of Dharmacon HECTD1 siRNA 
or Qiagen AllStars non-targeting control (40 nM) for 48 hours. Cells were harvested and WCE 
prepared and analysed via 4-12 % gradient SDS-PAGE and immunoblotting using HECTD1 and 
tubulin specific antibodies. Membranes were imaged and quantified using the Li-Cor Odyssey 
Infrared Imaging Analysis System. D Levels of HECTD1 relative to tubulin, from one 
experiment, was quantified and shown as the HECTD1/tubulin ratio normalised to the 
Qiagen AllStars non-targeting control transfected control cells, which was set to 1.0.  
 
6.3  Analysis of cell survival following HECTD1 siRNA knockdown 
After demonstrating the involvement of HECTD1 in promoting efficient BER in vitro (Chapter 
4 and 5), I hypothesised that this had an impact on overall cell survival. This was investigated 
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in the normal lung fibroblast cell line, WI-38, due to its colony forming ability, using the 
clonogenic survival assay, which assesses a cells ability to grow and form a colony of >50 
cells, following induction of DNA damage. To induce DNA damage, cells were treated with 
increasing doses of either IR, H2O2 or MMS to investigate the full range of DNA base lesions 
and SSBs repaired by the BER pathway. Relative colony forming units (surviving fraction) 
were expressed as colonies per treatment relative to colonies observed in the untreated 
control for each treatment. Statistical analysis was performed by the CFAssay for R package 
[326]. 
 
6.3.1 Clonogenic cell survival following IR 
WI-38 cells were grown until 30-50 % confluent before being transfected with HECTD1 siRNA 
or Qiagen AllStars non-targeting control siRNA using Lipofectamine RNAiMax transfection 
reagent. Cells were then incubated at 37oC and 5 % CO2 in a humidified cell culture incubator 
for 48 hours. Following effective knockdown (Figure 6.1), cells were incubated on ice for 5 
minutes to limit DNA repair activity and irradiated with increasing doses of IR (0-4 Gy). IR was 
selected as a DNA damaging agent as it is well known to generate a large proportion (>95 %) 
of DNA damage, including DNA base oxidation, AP sites and SSBs, processed by the BER 
pathway and is commonly used to assess the efficiency of BER in cultured cells as well overall 
cell sensitivity [246][337].  After induction of DNA damage, the cells were trypsinised and 
counted. A defined number of cells (Table 3.9) were then seeded into six-well plates and 
incubated for 7 days at 37oC and 5 % CO2 in a humidified cell culture incubator to allow colony 
growth (Figure 6.2B). As a control, unirradiated WI-38 cells treated with either HECTD1 siRNA 
or Qiagen AllStars non-targeting control siRNA was used. The colonies were fixed with 6 % 
glutaraldehyde, stained with 0.5 % crystal violet and counted using the GelCount colony 
counter from Oxford Optronix (Oxford, UK). From three independent experiments, colonies 
were calculated and normalised to that of the untreated control, which was set to 1.0 (Figure 
6.2). 
From the analysis of the clonogenic assay I was able to show significantly decreased survival, 
at 4 Gy IR of HECTD1 depleted WI38 cells (16.7-fold reduction versus unirradiated cells) 
compared to NT siRNA treated cells (10-fold reduction in survival) in response to x-ray 
irradiation (Figure 6.2A). The decrease in survival associated with HECTD1 depletion is most 
apparent at an IR dose of 1 Gy where a 2.2-fold decrease in survival is observed in HECTD1 
depleted WI38 cells compared to a 1.1-fold decrease in survival of NT siRNA treated cells. 
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The decrease in survival associated with increasing IR dose to 2 Gy, again was more apparent 
in HECTD1 depleted WI38 cells, where a further 2.3-fold reduction is survival was observed 
in comparison to a 1.7-fold decrease in survival of NT siRNA treated cells. A further 3.3-fold 
reduction in survival was seen with increased IR dose from 2 Gy to 4 Gy is HECTD1 siRNA 
treated cells. However, a 5.4-fold reduction in survival was observed with increased IR dose 
from 2 Gy to 4 Gy in NT siRNA control cells. However, this greater dose effect at 4 Gy is most 
likely indicative of the cytotoxicity associated with higher doses of X-ray IR and not an effect 
of the Qiagen NT siRNA on the WI-38 cells. Furthermore, as the overall decrease in cell 
survival was greater in HECTD1 depleted cells (16.7-fold) than NT control cells (10-fold), I 
concluded that HECTD1 knockdown resulted in reduced survival following X-ray IR exposure. 
This is verified by statistical analysis of the surviving fraction following irradiation, which 
revealed that a HECTD1 knockdown caused a statistically significant (p<0.001) increase in 






Figure 6.2: HECTD1 depletion enhances cellular radiosensitivity to ionising radiation 
A Clonogenic survival of WI-38 cells treated with 40 nM Qiagen AllStars non-targeting control 
(NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells were then unirradiated 
(control) or irradiated with increasing doses of x-ray irradiation (0-4 Gy), trypsinised, counted 
and a defined number plated into 6 well plates. Increasing cell numbers were used for 
increasing doses of x-ray irradiation to account for cellular plating efficiencies. Colonies were 
allowed to grow for 7 days prior to staining. Colonies were counted using the GelCount 
colony counter (Oxford Optronix, Oxford, UK). Shown are the mean surviving fractions with 
standard error from at least three independent experiments. p<0.001 as analysed by the 
CFAssay for R package. B Representative clonogenic plate images of cells treated with NT 
siRNA or HECTD1 siRNA following irradiation treatment (control, 2 or 4 Gy). 
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6.3.2 Clonogenic cell survival following H2O2 
WI-38 cells were grown until 30-50 % confluent before being transfected with HECTD1 siRNA 
or Qiagen AllStars non-targeting control siRNA using Lipofectamine RNAiMax transfection 
reagent. Cells were then incubated at 37oC and 5 % CO2 in a humidified cell culture incubator 
for 48 hours. Following effective knockdown (Figure 6.1), cells were incubated with 
increasing does of H2O2 (0-300 µM) at 37oC and 5 % CO2 in a humidified cell culture incubator. 
H2O2 was selected as a DNA damaging agent as it is well known to generate oxidative DNA 
damage processed by BER. After induction of DNA damage, the cells were trypsinised and 
counted. A defined number of cells (Table 3.9) were then seeded into six-well plates and 
incubated for 7 days at 37oC and 5 % CO2 in a humidified cell culture incubator to allow colony 
growth (Figure 6.3B). As a control, WI-38 cells treated with either HECTD1 siRNA or Qiagen 
AllStars non-targeting control siRNA but untreated with H2O2 was used. The colonies were 
fixed with 6 % glutaraldehyde, stained with 0.5 % crystal violet and counted using the 
GelCount colony counter from Oxford Optronix (Oxford, UK). From three independent 
experiments, colonies were calculated and normalised to that of the untreated control, 
which was set to 1.0 (Figure 6.3). 
From the analysis of the clonogenic assay I was able to also show HECTD1 depleted WI38 
cells compared to NT siRNA treated cells were more sensitive to the cell killing effects of H2O2 
(Figure 6.3A). Overall, in comparison to control conditions, I observed a 50-fold reduction in 
survival associated with a HECTD1 depletion, compared to a 9-fold decrease in NT siRNA 
treated cells following exposure to 300 µM H2O2. At all H2O2 doses investigated, the fold 
decrease in survival was greater in HECTD1 siRNA treated cells with the cell killing effects of 
H2O2 increasing with dose. Fold decrease in survival between control and 50 µM H2O2 treated 
HECTD1 depleted cells was 1.5-fold, with a 2.2-fold, 3-fold and 5-fold decrease in survival at 
100, 200 and 300 µM H2O2, respectively. This trend was not seen in NT siRNA treated cells, 
with a fold decrease in survival of ~2-fold between each dose increase. Furthermore, 
statistical analysis shows a significant (p<0.001) decrease in the surviving fraction of a 
HECTD1 knockdown cells following H2O2 exposure compared to that of NT siRNA treated 
cells, demonstrating an increase in sensitivity to H2O2-induced cell killing associated with 





Figure 6.3: HECTD1 depletion enhances cellular radiosensitivity to hydrogen peroxide 
A Clonogenic survival of WI-38 cells treated with 40 nM Qiagen AllStars non-targeting control 
(NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells were then untreated (control) 
or incubated with increasing doses of H2O2 (0-300 µM) at 37oC and 5 % CO2 in a humidified 
cell culture incubator, trypsinised, counted and a defined number plated into 6 well plates. 
Increasing cell numbers were used for increasing doses of H2O2 to account for cellular plating 
efficiencies. Colonies were allowed to grow for 7 days prior to staining. Colonies were 
counted using the GelCount colony counter (Oxford Optronix, Oxford, UK). Shown are the 
mean surviving fractions with standard error from at least three independent experiments. 
P <0.001 as analysed by the CFAssay for R package[326]. B Representative clonogenic plate 
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images of cells treated with NT siRNA or HECTD1 siRNA following H2O2 treatment (control, 
200 or 300 µM). 
 
6.3.3 Clonogenic cell survival following MMS 
WI-38 cells were grown until 30-50 % confluent before being transfected with HECTD1 siRNA 
or Qiagen AllStars non-targeting control siRNA using Lipofectamine RNAiMax transfection 
reagent. Cells were then incubated at 37oC and 5 % CO2 in a humidified cell culture incubator 
for 48 hours. Following effective knockdown (Figure 6.1), cells were incubated with 
increasing doses of MMS (0-1.5 mM) at 37oC and 5 % CO2 in a humidified cell culture 
incubator. MMS was selected as a DNA damaging agent as it is well known to generate DNA 
base alkylation, which is processed by BER. After induction of DNA damage, the cells were 
trypsinised and counted. A defined number of cells (Table 3.9) were then seeded into six-
well plates and incubated for 7 days at 37oC and 5 % CO2 in a humidified cell culture incubator 
to allow colony growth (Figure 6.4B). As a control, WI-38 cells treated with either HECTD1 
siRNA or Qiagen AllStars non-targeting control siRNA but untreated with MMS was used. The 
colonies were fixed with 6 % glutaraldehyde, stained with 0.5 % crystal violet and counted 
using the GelCount colony counter from Oxford Optronix (Oxford, UK). From three 
independent experiments, colonies were calculated and normalised to that of the untreated 
control, which was set to 1.0 (Figure 6.4). 
From the analysis of the clonogenic assay I was able to also show HECTD1 depleted WI38 
cells compared to NT siRNA treated cells were more sensitive to the cell killing effects of 
MMS (Figure 6.4A). Overall, in comparison to untreated conditions, I observed a 50-fold 
reduction in survival associated with a HECTD1 depletion, compared to a 20-fold decrease in 
NT siRNA treated cells following exposure to 1.5 mM MMS. Although, initially at 0.25 mM 
MMS a greater reduction in survival is seen in NT siRNA treated cells (1.5-fold) versus HECTD1 
siRNA treated cells (1.1-fold), at all other dose increments the fold decrease in survival is 
greater in HECTD1 depleted cells; 2.3-fold (0.5 mM MMS), 2.7-fold (0.75 mM MMS), 1.7-fold 
(1 mM MMS) and 4.5-fold (1.5 mM MMS), in comparison to NT siRNA control conditions; 1.5-
fold (0.5 mM MMS), 1.6-fold (0.75 mM MMS), 1.8-fold (1 mM MMS) and 3-fold (1.5 mM 
MMS). Furthermore, statistical analysis shows a significant (p<0.001) decrease in the 
surviving fraction of a HECTD1 knockdown cells following MMS exposure compared to that 
of NT siRNA treated cells, demonstrating an increase in sensitivity to MMS-induced cell killing 





Figure 6.4: HECTD1 depletion enhances cellular radiosensitivity to MMS 
A Clonogenic survival of WI-38 cells treated with 40 nM Qiagen AllStars non-targeting control 
(NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells were then untreated (control) 
or incubated with increasing doses of MMS (0-1.5 mM) at 37oC and 5 % CO2 in a humidified 
cell culture incubator, trypsinised, counted and a defined number plated into 6 well plates. 
Increasing cell numbers were used for increasing doses of MMS to account for cellular plating 
efficiencies. Colonies were allowed to grow for 7 days prior to staining. Colonies were 
counted using the GelCount colony counter (Oxford Optronix, Oxford, UK). Shown are the 
mean surviving fractions with standard error from at least three independent experiments. 
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p<0.001 as analysed by the CFAssay for R package[326]. B Representative clonogenic plate 
images of cells treated with NT siRNA or HECTD1 siRNA following MMS treatment (control, 
0.75 or 1.5 mM). 
 
6.4 Analysis of SSB repair kinetics following HECTD1 siRNA knockdown 
As the results in previous chapters 4 and 5 show, HECTD1 plays a role within BER, promoting 
access to occluded AP and TG sites via histone H2B/H3 ubiquitylation. It can therefore be 
assumed that HECTD1 is also required within cultured cells to promote efficient DNA repair. 
Furthermore, as HECTD1 appears to be required for normal lung fibroblast cell survival 
following IR, H2O2 and MMS exposure (Section 6.3), I aimed to examine whether this is 
caused by changes to the DNA damage repair kinetics in three normal lung fibroblast cell 
lines; AG01673, AG16409 and WI-38, by utilising the alkaline comet assay, following IR, H2O2 
and MMS exposure. The alkaline comet assay measures collectively alkali-labile sites and 
DNA SSBs. 
 
6.4.1 Cell dose titrations for the alkaline comet assay 
In the first instance, it was important to establish the correct doses of IR, H2O2 and MMS 
required to generate an appropriate level of initial DNA damage (~40 % tail DNA) for use in 
studying cell repair kinetics, and which doesn’t exceed the cellular DNA repair capacity. 
Therefore, WI-38 cells were individually grown until 30-50 % confluent before being 
transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), DNA damage was induced with increasing doses of either IR (0-4 Gy), H2O2 (0-30 µM) or 
MMS (0-1 mM). After induction of DNA damage, cells were embedded in agarose on 
microscope slides, immediately lysed for 1 hour, and the DNA electrophoresed in alkaline 
conditions. SYBR gold stained cells were imaged using the BX61 Olympus microscope and 
10x magnification. Images were analysed using Komet 6.0 software and % tail DNA values 
calculated. 
Following induction of DNA damage in WI-38 cells via IR (Figure 6.5A), H2O2 (Figure 6.5B) and 
MMS (Figure 6.5C), in both HECTD1 depleted and control cells, I demonstrated a clear dose 
response, with the amount of DNA damage increasing linearly in HECTD1 siRNA and NT siRNA 
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treated cells following exposure to all three DNA damaging agents. Also, of note, the levels 
of DNA damage are comparable in HECTD1 siRNA and NT siRNA treated cells, which is of 
importance to confirm prior to DNA repair kinetics analysis. Furthermore, these cell dose 
titrations also verify dosage for repair kinetic studies. Within Jason Parsons’ laboratory, and 
as indicated above, it has been well established that 40 % tail DNA is required as an initial 
level of DNA damage to effectively assess the cellular repair of alkali-labile sites and DNA 
SSBs using the alkaline comet assay, and which limits cells going into apoptosis. Upon 
examination of DNA damage induced by IR, it was shown that 1 Gy IR generated ~35 % tail 
DNA whereas 2 Gy produced ~55 % tail DNA (Figure 6.5A), therefore 1.5 Gy IR was decided 
upon as the dose for use in DNA repair studies to ensure 40 % tail DNA was achieved as an 
initial level of DNA damage. Assessment of H2O2 induced DNA damage demonstrates that 10 
µM H2O2 generated 45 % and 41 % tail DNA in Qiagen NT control and HECTD1 siRNA cells, 
respectively (Figure 6.5B), therefore this H2O2 dose was accepted for use in further work. 
Finally, MMS induced DNA damage was shown to generate approximately 45 % tail DNA in 
both conditions when WI-38 cells were incubated with 0.5 mM MMS (Figure 6.5C), thus, this 
was agreed upon for use in DNA damage repair kinetic studies. These cell doses; 1.5 Gy IR, 
10 µM H2O2 and 0.5 mM MMS were established in the WI-38 cell line, however as all three 
cell lines used in future work are normal lung fibroblasts, these doses were deemed generally 







Figure 6.5: Establishing IR, H2O2 and MMS alkaline comet assay doses for induction of DNA 
damage following siRNA knockdown of HECTD1 in WI-38 cells 
Alkaline comet assay cell dose titration of A IR B H2O2 and C MMS in WI-38 cells treated with 
40 nM Qiagen AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 
48 hours. DNA damage was induced with increasing doses of A IR (0-4 Gy) B H2O2 (0-30 µM) 
or C MMS (0-1 mM) and the resulting alkali labile sites and DNA SSBs measured by the 
alkaline comet assay. Cells were stained with SYBR gold, imaged using the BX61 Olympus 
microscope and 10x magnification and analysed using Komet 6.0 software. Shown is % tail 
DNA values from one experiment. 
 
6.4.2 Alkaline comet assay following IR 
AG06173, AG16409 or WI-38 cells were individually grown until 30-50 % confluent before 
being transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), cells were trypsinised, incubated on ice for 5 minutes to prevent DNA repair and 
irradiated in a cell suspension with 1.5 Gy IR, as determined by cell dose titrations (Figure 
6.5A). After induction of DNA damage, cells were embedded in agarose on a microscope 
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slide, and then allowed to repair for a defined time point (0-60 minutes) at 37oC in a 
humidified chamber. Following repair, the cells were lysed and the DNA electrophoresed in 
alkaline conditions. As a control, unirradiated cells treated with either HECTD1 siRNA or 
Qiagen AllStars non-targeting control siRNA was used. SYBR gold stained cells were imaged 
using the BX61 Olympus microscope and 10x magnification. Images were analysed using 
Komet 6.0 software, % tail DNA values calculated and normalised to that of the irradiated 
unrepaired timepoint, which was set to 100 %. 
From at least three independent experiments, and for all cell lines, NT siRNA control treated 
cells (blue) repaired IR-induced DNA damage by 60 minutes. The majority of repair events 
occurred from 10-60 minutes post-irradiation in AG06173’s (Figure 6.6A) and WI-38’s (Figure 
6.6C) and from 20-60 minutes post-irradiation in the AG16409’s (Figure 6.6B). Furthermore, 
in all three cell lines, depletion of HECTD1 caused a significant delay in the repair of SSBs and 
alkali-labile sites versus NT siRNA treated cells. This is evidenced by significantly higher levels 
of DNA damage, as analysed by a two sample t-test, in the AG06173 cells (Figure 6.6A) at all 
time points post-irradiation and a 4.7-fold difference in DNA damage levels at 60 minutes 
post-irradiation. Significantly higher levels (two sample t-test) of DNA damage are also seen 
in the WI-38 cells (Figure 6.6C) at all time points post-irradiation, with a 3.2-fold increase in 
DNA damage levels at 60 minutes post-irradiation. Additionally, significantly higher levels 
(two sample t-test) of DNA damage are seen at 20-, 30- and 60-minutes post-irradiation in 
the AG16409 cells (Figure 6.6B), and at 60-minutes post-irradiation a 2.9-fold difference in 




Figure 6.6: Analysing IR-induced DNA damage repair kinetics following siRNA knockdown 
of HECTD1 in normal lung fibroblasts 
Alkaline comet assay of A AG06173 B AG16409 and C WI-38 cells treated with 40 nM Qiagen 
AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells 
were then unirradiated (control) or irradiated (1.5 Gy) and alkali labile sites and DNA SSBs 
measured at various time points post-irradiation (0-60 min) by the alkaline comet assay. Cells 
were stained with SYBR gold, imaged using the BX61 Olympus microscope and 10x 
magnification and analysed using Komet 6.0 software. Shown is % tail DNA values normalised 
to that of the 0 minutes timepoint, which was set to 100 % with standard errors from at least 
three independent experiments. *p<0.05, **p<0.02, ***p<0.005, ****p<0.001 as analysed 
by a two sample t-test. 
 
6.4.3 Alkaline comet assay following H2O2 
AG06173, AG16409 or WI-38 cells were individually grown until 30-50 % confluent before 
being transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
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Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), cells were trypsinised, incubated on ice for 5 minutes to prevent DNA repair and 
incubated on ice in a cell suspension with 10 µM H2O2 for 5 minutes, as determined by cell 
dose titrations (Figure 6.5B). After induction of DNA damage, cells were embedded in 
agarose on a microscope slide, and then allowed to repair for a defined timepoint (0-60 
minutes) at 37oC in a humidified chamber. Following repair, the cells were lysed and the DNA 
electrophoresed in alkaline conditions. As a control, untreated cells treated with either 
HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA was used. SYBR gold stained 
cells were imaged using the BX61 Olympus microscope and 10x magnification. Images were 
analysed using Komet 6.0 software, % tail DNA values calculated and normalised to that of 
the H2O2 treated unrepaired timepoint, which was set to 100 %. 
From at least three independent experiments, and for all cell lines, NT siRNA cells (blue) 
repaired almost all H2O2-induced DNA damage by 60 minutes post-treatment. Repair was 
most proficient from 10-60 minutes post H2O2 incubation observed in WI-38’s (Figure 6.7C) 
and from 20-60 minutes post H2O2 incubation in the AG06173’s (Figure 6.7A) and AG16409’s 
(Figure 6.7B). Furthermore, in all three cell lines, depletion of HECTD1 caused a significant 
delay in the repair of SSBs and alkali-labile sites versus NT siRNA treated cells. This is 
demonstrated by significantly higher levels of DNA damage in the AG06173’s (Figure 6.7A) 
at 20-60 minutes post treatment, with a 3.9-fold difference in DNA damage levels at 60 
minutes post treatment. This is less evident in the AG16409’s, nevertheless significant 
differences between the HECTD1 depleted and NT control cells is observed at 30 and 60 
minutes post treatment, and a 1.9-fold difference in DNA damage levels is evident 60 
minutes post treatment (Figure 6.7B). The greatest significantly delayed repair of oxidative 
DNA base damage associated with HECTD1 depletion is seen WI-38 cells (Figure 6.7C), where 
significance, as determined by a two sample t-test, is seen at all time points post-H2O2 
incubation, and at 60-minutes post treatment a 4.5-fold difference in the levels of DNA 




Figure 6.7: Analysing H2O2-induced oxidative DNA damage repair kinetics following siRNA 
knockdown of HECTD1 in normal lung fibroblasts 
Alkaline comet assay of A AG06173 B AG16409 and C WI-38 cells treated with 40 nM Qiagen 
AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells 
were then untreated (control) or incubated with H2O2 (10 µM) and oxidative DNA damage 
measured at various time points post-treatment (0-60 min) by the alkaline comet assay. Cells 
were stained with SYBR gold, imaged using the BX61 Olympus microscope and 10x 
magnification and analysed using Komet 6.0 software. Shown is % tail DNA values normalised 
to that of the 0 minutes timepoint, which was set to 100 % with standard errors from at least 
three independent experiments. *p<0.05, **p<0.005, ***p<0.002, ****p<0.001 as analysed 
by a two sample t-test. 
 
6.4.4 Alkaline comet assay following MMS 
AG06173, AG16409 or WI-38 cells were individually grown until 30-50 % confluent before 
being transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
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Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), cells in a monolayer were incubated at 37oC and 5 % CO2 in a humidified cell culture 
incubator with 0.5 mM MMS for 1 hour, as determined by cell dose titrations (Figure 6.5C). 
After induction of DNA damage, cells were trypsinised, embedded in agarose on a 
microscope slide, and then allowed to repair for a defined timepoint (0-60 minutes) at 37oC 
in a humidified chamber. Following repair, the cells were lysed and the DNA was 
electrophoresed in alkaline conditions. As a control, untreated cells treated with either 
HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA was used. SYBR gold stained 
cells were imaged using the BX61 Olympus microscope and 10x magnification. Images were 
analysed using Komet 6.0 software, % tail DNA values calculated and normalised to that of 
the MMS treated unrepaired timepoint, which was set to 100 %. 
From at least three independent experiments, and for all cell lines, NT siRNA cells (blue) 
repaired the majority of MMS-induced DNA damage by 60 minutes post-treatment. This was 
most evident in the AG16409’s where repair was seen from 10-60 minutes post MMS 
incubation (Figure 6.8B). Repair from 10-60 minutes was also observed in the WI-38’s (Figure 
6.8C) and from 20-60 minutes in the AG06173’s (Figure 6.8A). Furthermore, in all three cell 
lines, depletion of HECTD1 caused a significant delay in the repair of MMS-induced DNA base 
damage in comparison to NT siRNA treated cells. This is demonstrated by significantly higher 
levels, as determined by a two sample t-test, of DNA damage in the AG06173’s 20-60 minutes 
post treatment, where at 60 minutes post treatment a 2.5-fold difference in the levels of 
DNA damage is observed (Figure 6.8A). Again, in AG16409’s at 20-60 minutes post treatment, 
significantly higher levels (two sample t-test) of DNA damage are observed, with a 2.2-fold 
difference in the levels of DNA damage at 60-minutes post treatment (Figure 6.8B). In the 
WI-38’s this difference between the HECTD1 depleted and NT control cells is only observed 
at 30 (1.8-fold) and 60 (2.2-fold) minutes post treatment (Figure 6.8C). However, this displays 




Figure 6.8: Analysing MMS-induced DNA damage repair kinetics following siRNA 
knockdown of HECTD1 in normal lung fibroblasts 
Alkaline comet assay of A AG06173 B AG16409 and C WI-38 cells treated with 40 nM Qiagen 
AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells 
were then untreated (control) or incubated with MMS (0.5 mM) and alkylated DNA base 
damage measured at various time points post-treatment (0-60 min) by the alkaline comet 
assay. Cells were stained with SYBR gold, imaged using the BX61 Olympus microscope and 
10x magnification and analysed using Komet 6.0 software. Shown is % tail DNA values 
normalised to that of the 0 minutes timepoint, which was set to 100 % with standard errors 
from at least three independent experiments. *p<0.05, **p<0.02, ***p<0.002, ****p<0.001 
as analysed by a two sample t-test. 
 
Cumulatively, this data demonstrates the importance of HECTD1 in the efficient processing 
of DNA base damage and single strand breaks through the BER pathway, which is required 
for maintaining cell survival in response to exogenous DNA damaging agents.  
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6.5 Analysis of DSB repair kinetics following HECTD1 siRNA knockdown 
Following successful investigations into the observed delayed SSB repair kinetics of HECTD1 
depleted normal lung fibroblast cells, which demonstrate a requirement of HECTD1 in 
promoting efficient DNA repair following induction of DNA damage via IR, H2O2 and MMS, 
the next step was to begin to assess the specificity of HECTD1 within DNA repair. Therefore, 
DSB repair kinetics of HECTD1 depleted normal lung fibroblast cells were elucidated. Utilising 
the neutral comet assay, which detects DNA DSB breaks repaired by the HR and NHEJ 
pathways, I aimed to determine if HECTD1 plays a role within these DNA repair pathways. 
Similarly to alkaline comet assay experiments, the three normal lung fibroblast cell lines; 
AG06173, AG16409 and WI-38 were used and DNA damage induced via IR and H2O2, which 
both have been characterised to induce DNA DSBs, albeit at higher doses than those required 
for induction of DNA SSBs. 
  
6.5.1 Cell dose titrations for the neutral comet assay 
As for examining the repair of alkali-labile sites and DNA SSBs, when assessing DSB repair 
kinetics it was firstly essential to establish the correct doses of IR and H2O2 required to 
generate an appropriate level of initial DNA damage for use in neutral comet assays. 
Therefore, WI-38 cells were individually grown until 30-50 % confluent before being 
transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), DNA damage was induced with increasing doses of either IR (0-8 Gy) or H2O2 (0-40 µM). 
After induction of DNA damage, cells were embedded in agarose on microscope slides, 
immediately lysed for 1 hour, and DNA electrophoresed in neutral conditions. SYBR gold 
stained cells were imaged using the BX61 Olympus microscope and 10x magnification. 
Images were analysed using Komet 6.0 software and % tail DNA values calculated. Within 
Jason Parsons’ laboratory, it has been well established that approximately 30 % tail DNA is 
required as an initial level of DNA damage to effectively assess the repair of DNA DSBs using 
the neutral comet assay, and which doesn’t exceed the cellular capacity for repair. Following 
induction of DNA damage in WI-38 cells via IR in both HECTD1 depleted and control cells, 4 
Gy IR generated approximately 30 % tail DNA (Figure 6.9A) and was therefore agreed upon 
for use in DNA damage repair kinetic studies. Assessing induction of DNA damage via H2O2 
indicated that 30 µM H2O2 generated approximately 30 % tail DNA (Figure 6.9B) in both 
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conditions and was accepted as the H2O2 dose for use in further work. These cell doses; 4 Gy 
IR and 30 µM H2O2 were established in the WI-38 cell line, however as all three cell lines used 
in future work are normal lung fibroblasts, these doses were deemed generally appropriate 
for use in neutral comet assays using AG06173 and AG16409 cells.  
 
Figure 6.9: Establishing IR and H2O2 neutral comet assay doses for induction of DNA damage 
following siRNA knockdown of HECTD1 in WI-38 cells 
Neutral comet assay cell dose titration of A IR and B H2O2 in WI-38 cells treated with 40 nM 
Qiagen AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 
hours. DNA damage was induced with increasing doses of A IR (0-8 Gy) or B H2O2 (0-40 µM) 
and the resulting DNA DSBs measured by the neutral comet assay. Cells were stained with 
SYBR gold, imaged using the BX61 Olympus microscope and 10x magnification and analysed 




6.5.2 Neutral comet assay following IR 
AG06173, AG16409 or WI-38 cells were individually grown until 30-50 % confluent before 
being transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), cells were trypsinised, incubated on ice for 5 minutes to prevent DNA repair and 
irradiated in a cell suspension with 4 Gy IR, as determined by cell dose titrations (Figure 6.9A). 
After induction of DNA damage, cells were embedded in agarose on a microscope slide, and 
allowed to repair for a defined timepoint (0-120 minutes) at 37oC in a humidified chamber. 
Following repair, the cells were lysed and the DNA electrophoresed in neutral conditions. As 
a control, unirradiated cells treated with either HECTD1 siRNA or Qiagen AllStars non-
targeting control siRNA was used. SYBR gold stained cells were imaged using the BX61 
Olympus microscope and 10x magnification. Images were analysed using Komet 6.0 
software, % tail DNA values calculated and normalised to that of the irradiated unrepaired 
timepoint, which was set to 100 %. 
From at least three independent experiments, and for all cell lines, both HECTD1 (orange) 
and NT (blue) siRNA cells repaired IR-induced DSBs gradually from 30-120 minutes, and by 
120 minutes post-irradiation all the damage had been repaired and was similar to that 
observed in control, unirradiated cells (Figure 6.10). Furthermore, and again in all three cell 
lines, the kinetics of repair of DNA DSBs was comparable between HECTD1 depleted and non-
targeting control cells with no statistical difference, as analysed by a two sample t-test in the 




Figure 6.10: Analysing IR-induced DSB DNA damage repair kinetics following siRNA 
knockdown of HECTD1 in normal lung fibroblasts 
Neutral comet assay of A AG06173 B AG16409 and C WI-38 cells treated with 40 nM Qiagen 
AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells 
were then unirradiated (control) or irradiated (4 Gy) and DNA DSBs measured at various time 
points post-irradiation (0-120 min) by the neutral comet assay. Cells were stained with SYBR 
gold, imaged using the BX61 Olympus microscope and 10x magnification and analysed using 
Komet 6.0 software. Shown is % tail DNA values normalised to that of the 0 minutes 
timepoint, which was set to 100 % with standard errors from at least three independent 
experiments. No statistical significance as analysed by a two sample t-test. 
 
6.5.3 Neutral comet assay following H2O2 
AG06173, AG16409 or WI-38 cells were individually grown until 30-50 % confluent before 
being transfected with HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA using 
Lipofectamine RNAiMax transfection reagent. Cells were then incubated at 37oC and 5 % CO2 
in a humidified cell culture incubator for 48 hours. Following effective knockdown (Figure 
6.1), cells were trypsinised, incubated on ice for 5 minutes to prevent DNA repair and 
212 
 
incubated on ice in a cell suspension with 30 µM H2O2 for 5 minutes, as determined by cell 
dose titrations (Figure 6.9B). After induction of DNA damage, cells were embedded in 
agarose on a microscope slide, and allowed to repair for a defined timepoint (0-120 minutes) 
at 37oC in a humidified chamber. Following repair, the cells were lysed and the DNA 
electrophoresed in neutral conditions. As a control, untreated cells treated with either 
HECTD1 siRNA or Qiagen AllStars non-targeting control siRNA was used. SYBR gold stained 
cells were imaged using the BX61 Olympus microscope and 10x magnification. Images were 
analysed using Komet 6.0 software, % tail DNA values calculated and normalised to that of 
the H2O2 treated unrepaired timepoint, which was set to 100 %. 
From at least three independent experiments, and for all cell lines, both HECTD1 (orange) 
and NT (blue) siRNA cells repaired H2O2-induced DNA damage gradually from 30-120 
minutes, and by 120 minutes post-treatment all the damage had been repaired and was 
similar to that observed in control, untreated cells (Figure 6.11). Furthermore, in all three 
cell lines, depletion of HECTD1 caused no significant delay in the repair of H2O2-induced DNA 
DSBs. This is evidenced by comparable levels of DNA damage at all time points between 
HECTD1 depleted and NT control cells, where significance, as determined by a two sample t-







Figure 6.11: Analysing H2O2-induced DSB DNA damage repair kinetics following siRNA 
knockdown of HECTD1 in normal lung fibroblasts 
Neutral comet assay of A AG06173 B AG16409 and C WI-38 cells treated with 40 nM Qiagen 
AllStars non-targeting control (NT) siRNA (blue) or HECTD1 siRNA (orange) for 48 hours. Cells 
were then untreated (control) or incubated with H2O2 (30 µM) and DNA DSBs measured at 
various time points post-irradiation (0-120 min) by the neutral comet assay. Cells were 
stained with SYBR gold, imaged using the BX61 Olympus microscope and 10x magnification 
and analysed using Komet 6.0 software. Shown is % tail DNA values normalised to that of the 
0 minutes timepoint, which was set to 100 % with standard errors from at least three 
independent experiments. No statistical significance as analysed by a two sample t-test. 
 
This data on the DSB repair kinetics of normal lung fibroblasts following exposure to x-ray 
irradiation and H2O2, suggests that HECTD1 does not play a key role in the processing of DNA 
DSBs. This implies that the protein is not directly involved in promoting the efficiency of the 





6.6  Summary  
In previous chapters 4 and 5, I established an in vitro role of HECTD1 in BER where it acts to 
promote accessibility of occluded sites of DNA damage to BER repair proteins in a 
ubiquitylation dependent manner via H2B/H3 ubiquitylation. The next logical step in the 
development of this project was to examine the requirement for HECTD1 in cultured cells in 
vivo. Therefore, I aimed to determine the impact of HECTD1 knockdown on overall cell 
survival and the DNA repair kinetics within normal cell physiology. As my aim was to 
understand the role of HECTD1 in normal cell physiology, I used the normal lung fibroblast 
cell lines; AG06173, AG16409 and WI-38 for these investigations.  
In the first instance to examine the requirement of HECTD1 in a cellular context, it was 
essential to develop a method to knockdown HECTD1 efficiently. I adopted a siRNA mediated 
approach and transfected the three normal lung fibroblast cell lines with a pool of four siRNA 
sequences, to increase knockdown efficiency, using Lipofectamine RNAiMax as a transfection 
reagent. Following a 48 hour incubation, I analysed HECTD1 protein levels via 
immunoblotting and achieved a depletion of at least 80 % in the cellular levels of the proteins 
in all the cell lines, an acceptable level of depletion for analysing the impact of HECTD1 loss 
on survival and DNA damage repair.  
Following this, I utilised the clonogenic survival assay to investigate the contribution of 
HECTD1 to overall cell survival, which HECTD1 was hypothesised to impact due to its 
involvement in promoting efficient BER in vitro. Analysis of the clonogenic assays in WI38 
cells, used as these were the only normal lung fibroblast cell line which could be optimised 
for this technique, showed that HECTD1 depleted WI38 cells compared to NT siRNA treated 
cells were more sensitive to the cell killing effects of IR, H2O2 and MMS. This clearly 
demonstrated that HECTD1 is vital for the effective processing of DNA damage (particularly 
DNA base damage, AP sites and SSBs) repaired by the BER pathway and which promotes cell 
survival.  
As HECTD1 appears to be required for cell survival following IR, H2O2 and MMS exposure, I 
aimed to examine whether this is predictably caused by changes to the DNA damage repair 
kinetics in three normal lung fibroblast cell lines; AG01673, AG16409 and WI-38. This was 
based on the assumption that HECTD1 is required to promote BER within a cellular context, 
as well as in vitro, improving accessibility of APE1 and NTH1 to occluded AP and TG sites via 
histone H2B/H3 ubiquitylation (shown in chapter 4). A key approach in examining DNA repair 
kinetics in a cellular environment is via the comet assay, which assesses directly the levels of 
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DNA strand breaks. Indeed, this technique has been previously adopted when establishing 
the role of Mdm2/USP7 in chromatin remodelling via H2B ubiquitylation [253], and to define 
a role for the chromatin remodeller, ALC1, in BER in chicken DT40 and human TK6 cell lines 
[263], [264], [344]. Similarly in this project I utilised the alkaline comet assay, and 
investigated the effects of HECTD1 depletion on the repair of alkali-labile sites and DNA SSBs. 
I demonstrated a significant delay in the repair of alkali-labile sites and DNA SSBs associated 
with a HECTD1 depletion in all three cell lines, following induction of DNA damage by IR, H2O2 
and MMS. Cumulatively, this demonstrates the importance of HECTD1 in the efficient 
processing of a variety of DNA damage processed by the BER pathway including; DNA base 
oxidation, AP sites and SSBs generated by IR, oxidative DNA damage and SSBs produced by 
exposure to H2O2 and DNA base alkylation, a product of MMS exposure. This complements 
previous in vitro data showing a promotion of both APE1 and NTH1 on THF-IN and TG-IN 
mononucleosome substrates by HECTD1 via histone H2B/H3 ubiquitylation (chapter 5). The 
data in this chapter further suggests that HECTD1 may not be recruited to specific DNA 
damage intermediates, given the range of DNA damage types HECTD1 appears to be 
essential for the efficient processing of. Instead, this data supports the theory of HECTD1 
being actively recruited and associating with the chromatin itself. 
In addition to this evidence, it was also prudent to begin to examine the requirement of 
HECTD1 within other repair pathways. As a first step towards this, I examined DSB repair 
pathways (NHEJ and HR) by assessing the repair kinetics of DNA DSBs following HECTD1 
depletion in the normal lung fibroblast cell lines; AG01673, AG16409 and WI-38 using the 
neutral comet assay. When assessing DSB repair, DNA damage was induced via IR and H2O2, 
which have been characterised to induce DNA DSBs, albeit at higher doses than required for 
induction of DNA SSBs. In this assessment, in all three cells lines I observed no significant 
difference in the repair kinetics of DSB induced by IR or H2O2 between HECTD1 depleted and 
control cells. This indicated that HECTD1 does not play a significant role in the NHEJ pathway, 
given that cells are largely in resting phase (G0/G1), this technique will mainly examine NHEJ 
efficiency and not HR, which is S-phase specific. However, this data does provide some 
evidence of the specificity of HECTD1 in promoting BER. Yet, although promising, this is 
preliminary data and gathering further evidence as to whether HECTD1 is responsive to other 
types of DNA damage, such as UV-induced bulky DNA lesions processed by nucleotide 
excision repair, DNA crosslinks induced by crosslinking agents such as cisplatin, or DNA DSBs 
is essential. Furthermore, it would be interesting to extend the comet assay based studies in 
the project by adopting a similar approach as recently used in the Parsons laboratory, which 
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examined unrepaired OGG1-dependent sites using enzyme modification in alkaline comet 
assays [345]. Utilising this technique to assess NTH1 and OGG1-dependent unrepaired DNA 
base damage, would be of particular relevance, and predictably, in the absence of HECTD1, 
there would be delayed or unrepaired oxidised pyrimidines processed by NTH1 (and possibly 
8-oxoguanine residues recognised by OGG1), whereas overexpression of HECTD1 should 
stimulate repair.  
In this chapter, I have provided evidence that HECTD1 is required to promote efficient repair 
of DNA base damage in cultured cells. Also, of note, this is the first reporting of a role of 
HECTD1 within DNA repair. Previously, reports have demonstrated roles of HECTD1 in 
controlling cell signalling, proliferation and migration, implicating the protein in several 
biological processes [303], [308], [312], [314], [318]. These include, targeting HSP90 for K63-
linked polyubiquitylation [301], [303], ubiquitylation of PIPKIγ90 at K97 [304]–[306] and K63 
linked polyubiquitylation of APC [308]–[311]. Furthermore, HECTD1 has also been well 
characterised to have a role within EMT, through a ubiquitylation triggered degradation of 
the EMT transcription factor SNAIL [299] and by regulation of K48 polyubiquitylation of ACF7 
[312]. More recently, the DUB TRABID has been shown to target HECTD1, controlling the 
substrate’s stability [346], which provides an interesting avenue for future investigations into 
whether TRABID is involved in controlling HECTD1 stability, required for promoting DNA 
repair. However, currently, I highlight a novel essential role for HECTD1 in the cellular DNA 
damage response. This data cumulatively supports the vital function that HECTD1 plays in 











CHAPTER 7: Discussion 
 
7.1 Overview 
DNA is under constant attack both endogenously, including ROS generated from normal 
cellular metabolism, and from exogenous sources, such as UV radiation. By design, the 
double helical structure of DNA provides a degree of protection, but DNA is still susceptible 
to damage from spontaneous chemical reactions [6]. In fact, it has been estimated that over 
10,000 DNA base lesions and SSBs are generated per cell per day due to the instability of the 
DNA molecule. This is largely a result of DNA hydrolysis, cellular oxidation and environmental 
factors, such as ionising radiation. BER, a sophisticated cellular mechanism first reported in 
the 1970s by Thomas Lindahl, detects small, non-helical distorting lesions, and is essential 
for the repair of the majority of endogenously generated DNA base damages, and thus in 
maintaining genomic stability [167]. If left unrepaired, accumulation of DNA damage can lead 
to mutations, blocked transcription and translation, incomplete DNA replication or 
segregation of chromosomes leading to chromosomal abnormalities and cell cycle delay, 
arrest or even apoptosis [6]. This resulting genomic instability is well established to be a 
hallmark of all forms of cancer [2] and has been implicated in the development of 
neurodegenerative diseases including Huntington’s and Alzheimer’s disease [9], as well as 
premature ageing [10]. This further highlights the importance of our understanding of the 
global BER process, including the mechanism of action within the complex chromatin 
structure. This would provide an increasingly complete view of the repair of DNA lesions by 
BER, vital, especially as proteins associated with DNA repair have previously been utilised as 
targets for novel therapies for diseases, such as cancer. Perhaps the most well-known 
example being the use of PARP-1 inhibitors for treating BRCA-deficient breast and ovarian 
tumours in a synthetic lethal context [347]–[349]. Therefore, it is of specific interest to 
determine the mode of action of BER within chromatin and to discover novel ACR complexes 
and their role within BER. 
Within the cell, DNA is condensed and packaged into a highly ordered structure, called 
chromatin, which consists of a number of loops and coils, organised by histones and non-
histone chromosomal proteins which bind to DNA and structure chromosomes. At its most 
basic level, chromatin is arranged in nucleosomes, a histone-DNA complex, which link to 
form nucleosome arrays [200]. The nucleosome consists of ∼145-147 base pairs of DNA 
wrapped ∼1.7 times around a histone octamer, composed of two copies of the four core 
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histone proteins, H2A, H2B, H3 and H4 [201]. Nucleosomal arrays are further folded on top 
of one another to condense DNA to form chromatin fibres, which are coiled and condensed 
to form chromosomes. This compaction into chromatin allows DNA to be packaged into small 
regions, but also serves to protect it from damage, control gene expression and 
strengthen DNA to allow for mitosis or meiosis when entering anaphase. Via multiple 
mechanisms, DNA within compacted regions is made accessible to the complex machinery 
of essential biological processes, including gene transcription, DNA replication, and 
importantly for this work, DNA repair. 
This dynamic nature of chromatin is facilitated by the nature of histones, which can be 
regulated to either repress or stimulate biological functions via PTMs. These PTMs, which 
include phosphorylation, ubiquitylation, acetylation, methylation, SUMOylation and 
PARylation, target the N-terminal tails of the histones, which protrude out from the 
nucleosomes. The histone tails present lysine residues to be targeted for the addition, but 
also removal, of chemical moieties that alter chromatin composition and function [204], 
[205]. In particular, these function to promote DNA accessibility either through direct 
destabilisation of the chromatin structure, or via stimulation of the recruitment of ACR 
enzymes. Increasing evidence, at least acquired in vitro, suggests that histone PTMs and/or 
recruitment of ACR factors may be integral in the processing of DNA damage through the 
BER pathway.  
The dominating view on how BER operates within chromatin is that chromatin remodelling 
events are required to facilitate accessibility of BER enzymes to sites of DNA base damage 
and SSBs, particularly in occluded regions within the DNA. Indeed, in vitro studies utilising 
mononucleosome substrates containing site-specific DNA damage sites have clearly 
demonstrated that individual stages of the BER process can be inhibited to a significant 
degree depending on orientation of the damage relative to the histone core, but also relative 
to its proximity to the histone dyad [236]–[241], [243]–[245], [251]. Yet despite this evidence, 
how BER functions within a chromatin environment in vivo still remains elusive. Some 
promising progress has been made with identifying potential ACRs which facilitate BER from 
in vitro studies (e.g. RSC [242]) and from those conducted in cultured cells (e.g. ALC1 [344]). 
However, there are still clear gaps in knowledge as to how these, or other potential ACR 
complexes, mechanistically orchestrate chromatin remodelling during BER in vivo.  
The study presented in this thesis builds upon previous work in the Parsons laboratory, 
where using mononucleosome substrates, it was demonstrated that a sterically occluded 
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THF-IN site was more efficiently processed by APE1 present in HeLa WCE in a largely 
ubiquitylation-dependent manner, than by recombinant APE1 protein alone. The factor 
promoting THF-IN incision was therefore predicted to be a E3 ubiquitin ligase, and a 
sequential chromatography approach of proteins purified from HeLa WCE identified the E3 
ubiquitin ligase HECTD1 as a candidate enzyme facilitating BER via chromatin remodelling 
events [293], [294]. Here, I have successfully demonstrated that the E3 ubiquitin ligase 
activity of a recombinant truncated form of HECTD1 can stimulate incision of THF-IN and TG-
IN by APE1 in vitro by promoting histone H2B/H3 ubiquitylation. Furthermore, depletion of 
HECTD1 in normal lung fibroblasts lead to significant deficiencies in SSB DNA damage repair, 
and decreased cell survival following x-ray IR, H2O2 and MMS treatment. Thus, I have now 
identified and characterised HECTD1 as a novel and important factor in promoting BER in 
chromatin. 
 
7.2 Role of HECTD1 in BER where it acts to promote enzyme activity at 
occluded DNA lesions in vitro 
Nucleosomal studies are the current major focus for investigating chromatin remodelling 
events occurring in BER, as they are relatively straightforward to perform. Several in vitro 
studies have utilised mononucleosome substrates with site specific DNA lesions as a 
representation of the chromatin environment.  These studies have provided strong evidence 
for altered BER efficiency in chromatin, in particular, they have highlighted proximity to the 
dyad axis and orientation relative to the histone core as major factors effecting BER efficacy 
[236]–[241], [243]–[245], [251]. However, relatively little attention has been given to the 
assessment of the efficiency of repair of these substrates by BER proteins present within cell 
extracts, which contain stimulatory histone modifiers and chromatin remodellers. Although 
an approach utilising size exclusion chromatography to isolate factors promoting chromatin 
remodelling within WCE has been previously attempted, this only isolated the proteins into 
four size pools. Therefore, this study could only conclude that the NTH1 enhancing activity 
co-fractionates in pool three, with proteins of 6.5-45 kDa, and failed to provide sufficient 
information to isolate individual ACR candidates [350]. Further efforts into the isolation of 
candidates, via more extensive fractionation of proteins within this protein pool by 
chromatography, and MS analysis of the most active fractions is essential to identify 
candidates with any confidence. Therefore, utilising a more extensive approach, a previous 
PhD student (Laura Bennett) in the Parsons laboratory performed an unbiased purification 
scheme involving the separation of proteins in HeLa cell extracts by different ion-exchange 
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and size exclusion chromatography columns, and following MS analysis identified HECTD1 as 
a candidate enzyme involved in chromatin remodelling within BER [293], [294]. In this Thesis, 
I present data characterising a previously unpublished role for HECTD1 in DNA repair, 
expanding the breadth of current mononucleosomal studies.  
THF-IN and TG-IN mononucleosomal substrates were prepared using the Widom 601 
sequence, chosen due to its strong nucleosome positioning affinity. The DNA sequence was 
amplified using 5’-fluorescently labelled primers, to allow for DNA to be quantitatively 
analysed using the Odyssey Image Analysis System. This was crucial for accurate 
quantification of incision by APE1 or NTH1, but also to ensure successful generation of THF-
IN or TG-IN containing DNA substrates. Here, the Widom 601 positioning sequence was 
modified via restriction enzyme digestion, then sequential DNA ligation employed using a 
pre-prepared duplex oligonucleotide containing either a THF or TG site on the lower strand, 
resulting in the production of a site specific THF-IN or TG-IN DNA substrate. A THF site was 
chosen as an alternative to a natural AP-site, as it is significantly more stable and exhibits 
virtually no difference in being recognised and cleaved by the activity of APE1, compared to 
AP-sites generated directly by DNA glycosylases [248]. The histone octamer was successfully 
prepared using Xenopus Laevis recombinant histones, and the THF-IN and TG-IN 
mononucleosome substrates produced by incubating the THF-IN or TG-IN DNA with the 
histone octamer in a 1:1 ratio with a salt gradient dialysis, consistent with previous reports 
[325]. Mononucleosome substrates were chosen over free DNA as it is a commonly used in 
vitro representation of chromatin, as previously stated, and the system has been utilised in 
many studies as it provides an insight into nucleosome dynamics during DNA repair. 
However, there are draw backs to this single nucleosome system, as they lack the full 
chromatin structure found in a cellular environment which may provide different chromatin 
remodelling events and histone dynamics. There are reports of more complex chromatin 
structures being developed, including dinucleosomes and nucleosome arrays [242], [351]. 
However, at present, the most common and popular model for investigating chromatin 
dynamics during BER continues to be the mononucleosome substrate.  
Previously in the Parsons laboratory, immunoprecipitation of HECTD1 from the 
chromatography fraction purified from HeLa WCE displaying potential ACR activity, was 
attempted to confirm that HECTD1 was indeed responsible for stimulating APE1 activity 
against the THF-IN mononucleosome. However, most probably due to the size of the protein 
(289 kDa), it was not possible to optimise this strategy. Promisingly though, a partial 
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depletion of the protein was achieved and corresponded to a small decrease in the 
promotion of THF-IN mononucleosome repair by recombinant APE1 [293], [294]. Therefore, 
I adopted a LIC strategy to clone HECTD1, as this method does not require restriction 
enzymes or DNA ligases used in traditional cloning, but rather employs the 
polymerase/exonuclease activity of T4 DNA polymerase to generate complimentary long 
overhangs between the vector and insert to form stable associations [323]. Using this 
method, I opted to use the murine HECTD1 protein (mHECTD1), as this had already been 
cloned and was kindly provided by Prof Irene Zohn (Center for Neuroscience Research, 
Children's Research Institute, Washington, DC, USA). Using the murine protein was also 
deemed acceptable, as it displays very high homology (98.2 % by amino acid sequence) to 
the human HECTD1 protein. Also, this enabled the use of a bacterial overexpression system 
to purify the protein, which would be extremely difficult for the full length protein given that 
the full length mHECTD1 consists of 2612 amino acids and is 289 kDa in size. I choose to clone 
a truncated version containing the active E3 ubiquitin ligase (HECT) domain (amino acids 
2156-2612), which is required for ubiquitylation of the target protein, plus an additional 389 
amino acids immediately N-terminal to this domain (diagrammatic representation shown in 
Figure 4.21). This allowed for the protein to be expressed and purified from E coli cells.  
I first utilised the in vitro BER assay, to confirm the inefficiency of APE1 to access the THF site 
when the DNA backbone is facing inwards towards the histone octamer. These preliminary 
investigations also established conditions (50 fmol APE1 generated ~20 % THF-IN substrate 
incision) for the in vitro BER assay in which to assess the ability of ΔN-HECTD1 in promoting 
APE1 activity against the THF-IN mononucleosome. I concluded that ΔN-HECTD1 was able to 
significantly stimulate, in a dose-dependent manner, the activity of recombinant APE1 
against the THF-IN mononucleosome substrate. In a similar fashion, I also utilised the in vitro 
BER assay in which to assess the ability of ΔN-HECTD1 in promoting NTH1 activity against the 
TG-IN mononucleosome. Again, I demonstrated that ΔN-HECTD1 was able to significantly 
stimulate, in a dose-dependent manner, the activity of recombinant NTH1 against the TG-IN 
mononucleosome substrate. This provided evidence that HECTD1, at least in vitro, was 
functioning actively within the first two stages of BER. Validation of this conclusion was 
achieved by adopting a SDM approach to mutate the active site cysteine (C) residue to a 
glycine (G) residue within the HECT domain, generating ΔN-mutHECTD1, an E3 inactive ligase 
mutant of ΔN-HECTD1. Comparison of ΔN-mutHECTD1 and ΔN-HECTD1 supplemented in 
vitro BER assays measuring APE1 activity against the THF-IN mononucleosome, 
demonstrated that ΔN-mutHECTD1 was unable to stimulate APE1 activity. Firstly, this 
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strengthened my conclusion that HECTD1 is a candidate chromatin remodelling enzyme 
functioning to promote BER, but also provided evidence that the stimulatory activity of ΔN-
HECTD1 was dependent on its E3 ligase activity. 
These findings corroborate with previous studies, where it is well established using in vitro 
mononucleosome substrates that DNA glycosylase recognition of the DNA base lesion is 
efficient when the sugar phosphate backbone is outwardly facing away from the histone 
octamer, as this positioning is optimal for the enzyme to utilise its “base-flipping” 
mechanism. In contrast where the sugar phosphate backbone is inwardly facing, it is 
predicted that sufficient DNA glycosylase access is enabled by the action of ACRs or histone 
PTMS, to dissociate DNA from histones. For example, studies using chicken erythrocyte 
histones and TG nucleosome positioning sequence DNA to generate mononucleosomes, a 2-
3-fold increase in excision by UDG and APE1 of the outwardly facing versus the inwardly 
facing mononucleosome substrate was observed [238]. Similarly, an assessment of the 
activity of UDG and APE1 against mononucleosomes containing the 601 DNA sequence 
present a 3-5-fold more effective excision of the out substrate in comparison to IN 
mononucleosome substrates [239]. These approaches compliment the reactions with APE1, 
as APE1 is essential for quantification of UDG activity given its monofunctional activity. 
However, other studies, in support of the data presented in this Thesis, have demonstrated 
compromised incision of inwardly facing TG substrates by NTH1 alone, seen by a 2-fold 
reduction in NTH1 activity against mononucleosomes containing inwardly facing TG site in a 
184 bp DNA fragment containing the L. variegatus 5S ribosomal DNA nucleosome positioning 
sequence constructed with recombinant X. laevis histones [244]. This is supported by a 
comparative study utilising similar substrates assessing the activity of NTH1, where only 10 
% of the inwardly facing TG sites from mononucleosomes were processed [245]. Yet, these 
approaches, and the one used for this project only assessed the activity of NTH1 alone 
against TG mononucleosome substrates. Therefore, a more stringent approach going 
forward would be to also assess NTH1 activity when reactions are supplemented with APE1. 
As in a cellular environment, due the cellular abundance of APE1 and relatively low activities 
of bifunctional glycosylases, it is generally thought, that although NTH1 possesses the ability 
to cleave the DNA backbone, APE1 circumvents this step and directly cleaves the AP site itself 
[175]. This would provide a more accurate assessment of NTH1 activity against TG 
mononucleosomes, reducing the limitations of in vitro studies.  
Similarly, in support of the findings presented here, previously published data concludes that 
AP site detection by APE1 is dependent on damage orientation within both a natural AP site, 
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and a THF-containing mononucleosome. At least a 2-fold (AP site) and 3-fold (THF) reduction 
in cleavage by APE1 was observed with inwardly facing lesions in comparison to outwardly 
facing sites [248]. Interestingly, this study chose to investigate incision of both a natural AP 
and artificial THF site. Using a THF site as an alternative to a natural AP-site is often chosen, 
as in this project, it is significantly more stable and exhibits virtually no difference in being 
recognised and cleaved by APE1. However, this may place further limitations on an in vitro 
system and a more realistic option may be to use natural AP sites despite them being less 
stable than the THF alternative. Also of interest, gel shift mobility assays demonstrated that 
reduced substrate cleavage, observed with inwardly facing lesions, was as a consequence of 
reduced binding of APE1 to the inwardly facing substrate, rather than reduced APE1 activity 
[248]. Following on from this study, it was demonstrated that two naturally occurring 
variants of APE1, R237C and G241R, have reduced activity on both inwardly and outwardly 
facing AP sites containing 147 bp 601 DNA within mononucleosome substrates, but not on 
naked DNA, despite the variants not demonstrating any dramatic differences in 
mononucleosome binding [249]. Furthermore, the importance of mononucleosome 
composition has been highlighted within in vitro studies, where a 15-fold reduction in 
mononucleosome AP site reactivity with histone proteins was observed with incorporation 
of mutant histone H4. Of note, these mutations (five lysine residues to arginines) were in the 
amino tail region of histone H4, predicting the involvement of histone tails and PTMs in DNA 
strand cleavage [250]. Therefore, this evidence suggests that APE1 itself may not be the 
target of any PTM or ACR involved in chromatin remodelling within BER. Indeed, my own in 
vitro ubiquitylation investigations demonstrated that HECTD1 did not appear to directly 
ubiquitylate APE1.   
Also, of importance to note is the lack of previous studies identifying ACRs or PTMs 
promoting APE1 or AP site incision within BER. Data is limited to an early in vitro study using 
227 bp 601 DNA and recombinant X. laevis histones to generate mononucleosomes 
containing an 8-oxoguanine residue, which identified yeast SWI/SNF as a factor increasing 
the efficiency of excision of the lesion by OGG1 and APE1 by ~8-fold, which improved 
processing efficiency similar to that of naked DNA alone [241]. More extensive evidence both 
in vitro using WCE containing SWI/SNF, or the purified SWI-SNF complex itself, in 
combination with recombinant OGG1 and APE1, as used previously in the Parsons laboratory 
[293], [294] is necessary to see the impact on mononucleosome activity. These data should 
also be supplemented with investigations in cells. Adopting an siRNA screening approach to 
assess the impact of individual SWI/SNF ACRs on cellular survival post-DNA damaging 
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treatment would initially aid in the identification of whether SWI/SNF plays an active role in 
the cellular DDR, which could then be more thoroughly characterised. Of importance would 
be to examine the effect of protein depletion, either through an siRNA or CRISPR/Cas9 
approach and protein overexpression with a mammalian plasmid delivery technique, on the 
DNA damage repair kinetics of cells in response to specific treatments (e.g. IR, MMS and 
H2O2). However currently, the data presented in this thesis, highlighting a novel role of 
HECTD1 in promoting TG and AP site incision within chromatin, is unique in characterisation 
of a specific enzyme acting to remodel chromatin within BER and is vital to accelerate our 
understanding of chromatin remodelling in BER.  
An exciting extension of this would be to further characterise HECTD1 within BER, namely 
through investigating DNA end processing and ligation. This would be of particular interest 
for further study as reports on the constraints of Pol β activity within chromatin are varied. 
One study investigating the individual steps co-ordinated by Pol β in the form of gap filling 
and 5’-dRP lyase activity, found that removal of the 5’dRP residue within the 
mononucleosome at positions 35 (outward facing) and 49 (inward facing) were cleaved with 
the same efficiency as free DNA. When assessing DNA synthesis activity though, there was 
strong inhibition (~2600-fold) when the gap was close to the dyad (position 10) in 
comparison to free DNA. At positions 49 (inward facing) and 35 (outward facing), the 
difference in kinetics was 277-fold and 4-fold, respectively versus the free DNA [251]. This 
suggests that of the two enzymatic steps that Pol β catalyses, the DNA synthesis stage is most 
greatly impacted by the presence of histone proteins within the mononucleosome. Other 
reports conclude a complete inhibition of Pol β DNA synthesis activity caused by the presence 
of the histone octamer in natural GAP mononucleosomes, generated from processing of both 
a uracil and 8-oxoG site [238] [241]. This data indicates that irrespective of rotational setting, 
this stage of the pathway is a major restriction on BER in chromatin, demonstrating 
nucleosome remodelling as an essential step for promoting Pol β activity. In contrast, a study 
utilising 184 bp DNA fragment containing the L. variegatus 5S ribosomal DNA nucleosome 
positioning sequence and mononucleosomes constructed with recombinant X. laevis 
histones, demonstrated that Pol β was ~3-fold more active on a gap where the DNA 
backbone was outwardly facing versus inwardly facing. It was hypothesised that this 
difference observed with rotational positioning was a result of the inherent bending of the 
outward substrate, facilitating the 90 degree bend required for Pol β activity [244]. 
Furthermore, translational positioning has been suggested to have a greater impact of 
efficiency of Pol β [244]. In mononucleosomes constructed utilising chicken erythrocyte 
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histone octamers and a 146 bp DNA fragment containing the L. variegatus 5S rRNA gene 
sequence, Pol β was able to extend at greater efficiency the 3’-hydroxyl terminus generated 
by UDG and APE1 incision of uracil (in position 22) than the uracil placed (in position 51) 
closer to the dyad axis [236]. Again, this apparent difference was theorised to be linked to 
kink formation required for Pol β activity, the result of increased energetic cost associated 
with introducing a 90 degree kink into the DNA at these locations. The mixed reports on the 
efficiency of Pol β on mononucleosome substrates again could be a result of the limitations 
of in vitro reactions and supplementing either with WCE for a full complement of the 
pathway, or at least with XRCC1-Lig III which is known to stabilise  and form a complex on 
DNA with Pol  β is required for efficient BER [352], would help mitigate this. This issue could 
also be rectified via conducting a full pathway reconstitution in mononucleosomes, for 
example, TG substrates in different locations/orientations could be supplemented with 
NTH1, APE1, Pol β and XRCC1-LigIIIα and the final product analysed. However, as Lig IIIα is 
not the only ligase to function within BER (Lig I is predominantly employed in LP-BER), the 
effect of ligase competition will be missed when only using XRCC1-LigIIIα in reactions. As is 
the case in current studies investigating DNA ligation within BER, only ligation of the nick 
substrate by XRCC1-LigIIIα has been examined [244] [252]. Consequently, fully 
complemented reactions with WCE would also be vital in these investigations, as current 
evidence suggests that occluded nicked DNA mononucleosomes can only be ligated by 
XRCC1-LigIIIα, when it is exposed by periodic, spontaneous partial unwrapping of the DNA 
from the histone octamer [252]. More complex reactions involving mononucleosome 
substrates that promote SP-BER (XRCC1-LigIIIα-dependent) versus LP-BER (Lig I-dependent) 
would also be of significant interest for future studies. 
 
7.3 HECTD1 acts via a H2B/H3 ubiquitylation mechanism to promote BER 
A major form of cellular regulation is achieved via ubiquitylation, which can modulate 
protein-protein or protein-DNA interactions, as well as being more commonly involved in 
protein stability and activity. Ubiquitylation occurs in a three step ATP-dependent process by 
an enzyme cascade involving ubiquitin activation by an E1 ubiquitin-activating enzyme, 
ubiquitin transfer from the E1 enzyme to the E2 active site by a E2 ubiquitin conjugating 
enzyme, before an E3 ubiquitin ligase enzyme catalyses the transfer of ubiquitin onto a lysine 
residue of the substrate protein [266]. Ubiquitylation and the UPP has been demonstrated 
to mediate protein-protein interactions, play a regulatory role in protein localisation, 
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conformation and activity as well as have an involvement in signalling networks and 
transcriptional regulation of a range of pathways including the cellular DDR, the cell cycle 
and apoptosis [265].  
Our general understanding of ubiquitylation events that can affect chromatin structure, 
particularly required for enhancing BER efficiency, is unfortunately not well characterised. 
The strongest evidence for such events is through histone H2B monoubiquitylation at K120, 
associated with active chromatin and found on 1-1.5 % of total H2B in mammals [338]. The 
data reported here could be indicative of this monoubiquitylation event in promoting BER, 
given the evidence that ΔN-HECTD1 appeared to cause a modest increase in mono/di-
ubiquitylation of histone H2B in vitro. However, as I could not reveal preliminary evidence of 
a HECTD1 dependence of histone H2B ubiquitylation in WI-38 cells, the strength of this 
argument could be reduced. Yet, a more extensive approach utilising antibodies specific for 
H2BK120 ubiquitylation and indeed other less well characterised histone H2B ubiquitin 
docking sites (K34, K46, K108, K116, and K125) is worthwhile, given the preliminary nature 
of my data from WI-38 cells, for these accurate conclusions to be definitively drawn [339], 
[340]. Furthermore, given my evidence presented in this thesis, it appears at least in vitro, 
that HECTD1 does not act on histone H2A or H4. In fact, histone H2A ubiquitylation at K119 
appears to play a primarily chromatin repressive role, in X inactivation, stabilisation of 
histone H1 and inhibition of histone H3 methylation. In addition to this, it is the most 
abundant site of ubiquitylation on histone H2A (5-15 % total H2A in higher eukaryotes) [338], 
[340]. It therefore appears unlikely that HECTD1 would target histone H2A for ubiquitylation 
as this at least in theory, this would be counterintuitive to the promotion of DNA repair I 
have seen in this research project. However, less common H2A ubiquitylation sites, including 
K13/15 and K127/129 have been reported to be involved in DNA damage signalling and 
homologous DNA pairing [339], and therefore perhaps histone H2A ubiquitylation cannot 
fully be dismissed as a HECTD1-dependent mechanism. 
In the first instance though, any future attentions to elucidate the mechanism via which 
HECTD1 is acting should primarily focus on histone H3 ubiquitylation, which appears the 
strongest target as evidenced in this research project. Indeed, I provide evidence that ΔN-
HECTD1 causes polyubiquitylation of histone H3 in vitro, as well as a HECTD1 dependent 
histone H3 polyubiquitylation event in WI-38 cells. Also, of interest, is that NEDD4-mediated 
ubiquitylation of histone H3 at K23/K36/K37 reportedly has a role in transcription activation, 
stimulating the histone acetyltransferase GCN5. Furthermore, CUL4–DDB–ROC1 mediated 
ubiquitylation of both histone H3 and H4 has been implicated to have a role in NER. More 
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recently, UbiCRES, Ub-AQUA proteomics and in vitro autoubiquitylation assays have 
demonstrated that HECTD1 preferentially assembled K29 and K48 linked ubiquitin chains and 
that branching at K29/K48 was essential for the protein’s full ubiquitin ligase activity [346]. 
Therefore, given that none of the published cellular functions of HECTD1 have been 
attributed to K29 linked polyubiquitylation and for validation of this study, it is essential that 
chain dependence of HECTD1 substrates be defined. A key way in which histone H3 
polyubiquitylation by HECTD1 be validated is via identification of the type of ubiquitin chains 
modifying histone H3. For example, MS analysis of the HECTD1 dependent ubiquitylation 
sites of histone H3 may identify chain dependence which could then be validated by a SDM 
approach once a site is identified. Furthermore, if this ubiquitylation event was found to be 
K29 linked, exploring the regulatory role of TRABID, a DUB which cleaves K29 linked chains 
and HECTD1 is a known substrate of [346], may be a good next step to reveal the mechanism 
of opening chromatin to promote BER. Also, as histone H3 ubiquitylation has only been found 
to occur globally on 0.3 % of H3 histones [340]–[342], this may be suggestive of a specific 
role for histone H3 ubiquitylation in the DDR. Therefore, at least initially, the most productive 
use of time going forward may indeed be to focus attention on histone H3 ubiquitylation as 
a mode of action for HECTD1 in BER, and particularly in accumulating more data from 
cultured cell experiments supporting this process, as well as characterising the specific site 
within histone H3 that is targeted by HECTD1 for ACR activity.  
 
7.4 HECTD1 is required for efficient repair of DNA base damage and SSBs 
Following clear evidence that HECTD1 functions within BER in vitro, logically this role was 
further explored in cultured cells. Although HECTD1 was previously identified following 
purification from HeLa WCE, the focus of this project was to establish the role of HECTD1 in 
normal cell physiology, therefore normal lung fibroblast cell lines, namely AG06173, 
AG16409 and WI-38 were utilised for this purpose. A key approach in examining DNA repair 
kinetics in a cellular environment is via the comet assay, which assesses directly the levels of 
DNA strand breaks. Indeed, this technique has been previously adopted when establishing 
the role of Mdm2/USP7 in chromatin remodelling via H2B ubiquitylation. Using siRNA 
mediated depletion of USP7 in HeLa cells, it was demonstrated using alkaline comet assays 
that DNA damage induced by H2O2 resulted in a 2-fold delay of repair up to one hour post 
treatment. Furthermore, when HeLa cells overexpressed USP7, a 2-fold increase in the rate 
of repair of H2O2 induced DNA damage was observed. These key findings aided development 
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of the proposed model, whereby the stabilised Mdm2/USP7 complex allows for 
ubiquitylation of histone H2B by Mdm2 when DNA damage is detected, promoting open 
chromatin and therefore repair [253]. More recently, ALC1, a member of the SNF2 
superfamily, was defined to play a role in BER in chicken DT40 and human TK6 cell lines. ALC1 
knockout DT40 and TK6 cells were found to be sensitive to both H2O2 and MMS, displaying 
deficient SSB repair through alkaline comet assay analysis [264]. This comet assay data, 
coupled with alkaline-elusion assays, demonstrated that ALC1 promotes BER after SSB 
formation in both chicken DT40 and human TK6 cells, consistent with previously suggested 
roles of ALC1 in DNA repair [263], [344]. 
Similarly, in this project I also utilised alkaline comet assays coupled with an siRNA mediated 
depletion of the cellular levels of the HECTD1 protein to determine the contribution of 
HECTD1 in DNA repair in normal lung fibroblasts. Specifically, I investigated the repair of DNA 
damage known to be processed by BER, including IR and H2O2 that generate alkali-labile sites, 
SSBs and oxidative DNA damage, and MMS that mediates DNA base alkylation. The data 
presented in this thesis clearly demonstrates a significant delay in the repair in DNA damage 
induced by these DNA damaging agents, as analysed by the alkaline comet assay, in HECTD1 
depleted cells. Cumulatively, this shows the importance of HECTD1 in normal cells in the 
efficient processing of a variety of DNA damage processed by the BER pathway. Furthermore, 
as I have shown that HECTD1 promotes BER in chromatin by targeting histones for 
ubiquitylation in vitro, it is possible that this role of HECTD1 does not only have functionality 
within BER. However, assessing the DNA DSB repair kinetics through neutral comet assay 
analysis, I observed that there was no significant delay in the repair of DNA DSBs induced via 
IR and H2O2 associated with HECTD1 deficiency. This suggests that HECTD1 does not appear 
to have a major role within DSB repair pathways, however, this is a preliminary conclusion 
and further evidence would be essential to confirm this observation.  
Investigations have utilised the enzyme-modified neutral comet assay, previously described 
here [353] and successfully used in the Parsons laboratory [80], where treatment of the DNA 
with recombinant DNA repair enzymes post cell lysis incises residual DNA damage, therefore 
revealing additional strand breaks which can be analysed following electrophoresis. This 
technique has been used to assess the repair kinetics of complex DNA damage (also referred 
to as clustered/complex DNA damage), which is defined as two or more lesions induced 
within one to two DNA helical turns. Alternatively, and of particular relevance, would be 
adopting a similar approach as recently used in the Parsons laboratory, which examined 
unrepaired OGG1-dependent sites using enzyme modification in alkaline comet assays [345]. 
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A natural extension of the comet assay studies conducted as part of this research project 
would therefore be to assess NTH1 and OGG1-dependent unrepaired DNA base damage. 
Predictably, and in the absence of HECTD1, there would be delayed or unrepaired oxidised 
pyrimidines processed by NTH1 (and possibly 8-oxoguanine residues recognised by OGG1), 
whereas overexpression of HECTD1 should stimulate repair. In addition to comet assays, 
further extensions of these experiments could include examination by immunofluorescence 
microscopy as to whether HECTD1 co-localises with either γH2A.X or XRCC1 foci, commonly 
used as markers of DSB and SSB, respectively. This technique has similarly been used to 
assess the effect of cellular localisation on HSP90, a known ubiquitylation target of HECTD1. 
However, cellular localisation of HECTD1 was not reported, leading to queries as to the 
suitability of HECTD1 antibodies for immunofluorescence [303]. Additionally, further in vitro 
mononucleosome studies described earlier in this chapter would too be vital in designing 
other experiments to be performed in cultured cells and therefore to generate more 
concrete conclusions on HECTD1’s precise role in DNA repair, which may be beyond the roles 
in BER described in this thesis. 
Also of interest, is that this is the first reporting of a role of HECTD1 within DNA repair. 
Previously, HECTD1 has been shown to target a range of distinct signalling pathways, 
implicating HECTD1 in several biological processes [301], [302]. In relation to cellular 
localisation and secretion, HECTD1 has been characterised to target HSP90 for K63-linked 
polyubiquitylation [301], [303] and ubiquitylation of PIPKIγ90 at K97 [304]–[306]. In the 
context of Wnt/β-catenin signalling, HECTD1 has been identified as a negative regulator of 
the pathway, via K63 linked polyubiquitylation of APC [308]–[311]. HECTD1 has also been 
well characterised to have a role within EMT, implicated in the mediation of a range of target 
proteins. For example, through a ubiquitylation triggered degradation of the EMT 
transcription factor SNAIL [299] and by regulation of K48 polyubiquitylation of ACF7 [312]. 
Of interest, these previously defined roles of HECTD1 have identified the ability of the protein 
to modify K48 and K63 linked chains, the most extensively studied form of polyubiquitylation 
modification. However, more recently, HECTD1 has been identified as a substrate of the DUB 
TRABID, which recognises and cleaves K29 and K33 linked chains. Through analysis of this 
interaction, it was shown that upon cellular depletion of TRABID, HECTD1 is readily degraded, 
suggesting that TRABID controls HECTD1 stability [346]. As stated previously, it would be of 
interest to identify the specific chain linkage of the histone H3 polyubiquitylation event 
reported here, as none of the previously published cellular functions of HECTD1 have been 
attributed to K29 linked polyubiquitylation. Therefore, if indeed HECTD1 is assembling K29 
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linked ubiquitin chains on histone H3, further investigations into whether TRABID is involved 
in controlling HECTD1 stability, required for promoting DNA repair, would be of significant 
interest. 
 
7.5 Future directions 
The data presented in this thesis provides strong evidence that HECTD1 is a histone modifier 
which functions within BER at occluded sites of base damage. This has been characterised in 
mononucleosome substrates with occluded THF and TG sites. However, a more extensive 
validation of this general role of HECTD1 within BER, which I have proposed, is essential. 
Primarily this would involve extending current in vitro investigations to include GAP and NICK 
mononucleosome substrates incorporating the end processing mechanisms of BER. In the 
first instance, an assessment of GAP-IN vs OUT mononucleosome processing by Pol β would 
be of interest, perhaps providing more clarity as to the ability of Pol β to function as a DNA 
polymerase through single nucleotide insertion in a chromatin environment. However, I 
believe it to also be essential to expand into translational positioning variants for a more 
extensive assessment, using for example THF, uracil and TG substrates and the respective 
enzymes (APE1, UDG and NTH1) which will generate a more natural SSB flanked by 5’-dRP 
ends which also require Pol β end processing. This would naturally follow with an assessment 
of the ability of HECTD1 to promote Pol β polymerase and dRP lyase activity where either 
rotational or translational positioning is potentially limiting repair. Of course, the impact of 
chromatin on DNA ligation would similarly be assessed, realistically in parallel to 
investigations with GAP mononucleosome substrates. Furthermore, in addition to measuring 
the impact of chromatin on the individual enzymes, and of HECTD1 in stimulating these, it is 
also vital to consider the efficiency of the complete repair process. Therefore, for example, 
examining processing of TG substrates in different locations and/or orientations when 
supplemented with NTH1, APE1, Pol β and XRCC1-LigIIIα and analysing the final product. 
Thus, further elucidation of HECTD1’s mode of action may be gained through these in vitro 
studies. Further avenues to extend in vitro studies could also incorporate dinucleosomes, 
incorporating linker DNA and histones (H1), or nucleosomal arrays into the in vitro BER 
investigations [242], [351], providing a more accurate representation of the chromatin 
environment which should be taken into consideration for future work. In addition to this, it 
would also be useful to validate these in vitro mononucleosome studies with human HECTD1. 
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Therefore, efforts should be taken to clone and purify human HECTD1 and confirm the data 
generated using the mouse protein described here.  
This thesis also provides evidence that HECTD1 acts via histone H2B/H3 ubiquitylation at 
least in vitro. However, a precise site-specific target of ubiquitylation is still lacking. 
Attentions might be best spent on histone H3 given the in vitro evidence and that HECTD1 
dependent ubiquitylation of histone H3 is preliminarily observed in WI-38 cells. Furthermore, 
although ubiquitylation of the core histones is common (10-15 %), only <0.3 % of histone H3 
are found to be ubiquitylated, therefore this may be indicative of histone H3 ubiquitylation 
playing a precise and specific role in the DDR [340]. Therefore, this may be worth further 
attention, assessing in vitro ubiquitylation using antibodies against the histone H3 
ubiquitylation sites (K14, K23, K36 and K37 [340], [354]). Beyond this, an examination of 
ubiquitylation sites of histone H3 by MS analysis following in vitro incubation of histone 
octamer, or histone H3 alone, in combination with HECTD1 would also aid identification. This 
could be confirmed using a SDM approach to mutate the predicted ubiquitylation site and 
use the mutant histone in mononucleosome reconstitutions and subsequent in vitro assays 
to verify the specific target of HECTD1. Predictably, mutation of the histone ubiquitylation 
site targeted by HECTD1 would prevent chromatin remodelling and therefore DNA damage 
accessibility, leading to deficient BER of the DNA damage site. These in vitro studies could be 
complemented by MS analysis of histones extracted from cells following HECTD1 
overexpression and induction of DNA damage by IR, H2O2 and MMS.  Although to maximise 
the utility of this approach, the histone proteins and HECTD1 may need to be overexpressed 
in cells to provide optimal ubiquitylation. Consequently, rather than analysing the 
endogenous histones, the exogenously expressed histone H3 could be purified using pull-
downs before analysis by MS. A further approach, although not currently within the reach of 
this laboratory, would be to utilise a structural biology approach, using nuclear magnetic 
resonance (NMR) spectroscopy to analyse the interactions between the histones and 
HECTD1. However, given this size of the protein (289 kDa) and that currently the crystal 
structure of HECTD1 has not been defined, this may not be feasible in the near future.  
In addition to the expansion of in vitro investigations, more extensive work in cells would be 
a logical continuation of this project. One area to highlight would be to extend the 
examination of sensitivity to DNA damaging agents, incorporating agents known to induce 
DSB, such as bleomycin/phelomycin or crosslinking agents such as cisplatin, to define 
whether HECTD1 is specific to BER, or also functional in other DNA repair pathways. A more 
detailed characterisation of HECTD1 would also be aided by the generation of a CRISPR 
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HECTD1 knock out cell line, to complement experiments conducted using an siRNA mediated 
and transient depletion of HECTD1. HECTD1, via regulation of its known target proteins, has 
been implicated in cancer development, for example, dysregulation of HECTD1 has been 
linked to ER-α-negative breast cancer cell invasion [304] and aberrant gene expression, 
triggered by elevated HECTD1 expression, possibly underlies human cancer development 
[316]. Indeed, HECTD1 has also been implicated in fibroblast migration/proliferation 
expression of breast cancer patients [317]. Furthermore, the reported links between HECTD1 
and reduced survival in multiple cancer types, including breast, lung and brain [312], [319]–
[321] heavily suggest that investigations in cancer cell models to examine tumour-specific 
expression and roles of HECTD1, particularly related to regulation of the cellular DDR 
identified in this thesis, would be a vital extension of the work given the current focus on  
normal lung fibroblasts.  
 
7.6 Concluding remarks 
The findings presented in this thesis have clearly demonstrated:  
• HECTD1 promotes DNA glycosylase and AP endonuclease stages of BER in chromatin 
in vitro 
• HECTD1 ubiquitylates histones H2B and H3 in vitro 
• HECTD1 is essential for efficient SSB DNA repair and the promotion of cellular 
survival following exposure to X-ray IR, H2O2 and MMS in normal lung fibroblasts 
• A novel role for HECTD1 within DNA repair where it acts to promote BER in occluded 
regions of chromatin 
The work described in this research project is important as it has elucidated a novel role for 
the E3 ubiquitin ligase HECTD1 within DNA repair. Furthermore, this research project has 
focused on a relatively understudied area within the DNA repair field, strengthening 
evidence for chromatin remodelling events in BER, and having identified HECTD1 that 
functions in this capacity.  This has increased our knowledge and understanding of the 
cellular response to DNA damage and further validation of the underlying regulatory 
mechanism of HECTD1 within BER will undoubtedly aid in our understanding of how defects 
in DNA repair leads to genomic instability and pathogenesis. This solid foundation provides 
hope for the long-term goal of potentially utilising HECTD1 as a novel therapeutic target 
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given that HECTD1 is frequently mutated in breast, brain and lung cancers, and therefore 
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